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ABSTRACT 
Colorectal cancer (CRC) is one of the most common malignancies in the US 
and Western Europe and metastatic dissemination after CRC is a leading cause of 
mortality. New markers predictive of cancer cell behaviour are actively sought both as 
targets and as a means of predicting patient prognosis. The lectin from the Roman snail 
Helix pomatia (HPA) has attracted interest as tool for the detection of metastatic 
colorectal cancer but the HPA binding partners have remained poorly characterised. 
We established an in vitro model using human colorectal cancer cell lines 
ranging from HPA negative, non metastatic, to HPA positive and metastatic. Confocal 
microscopy was used to assess the HPA binding pattern in the cell lines and the 
monosaccharides N-acetylgalactosamine, N-acetylglucosamine, and sialic acid were 
used to inhibit the interaction between the lectin and the cancer cells. 
A proteomic approach based on cell membrane isolation, pre-fractionation using 
lectin affinity chromatography, followed by 2-dimensional electrophoresis and 
MALDI-TOF-MS enabled the identification of the HPA binding proteins in the 
metastatic cancer cell line HT29. The proteins that eluted in the HPA binding fraction 
were present either by virtue of their ability to bind directly to HPA or as protein 
complexes of HPA binding partners and included molecules involved in cell adhesion / 
migration (integrin a6, integrin aV, annexins) re-modeling (filament proteins including 
oc tubulin, Ptubulin, cytokeratins, actin) and anti-apoptotic pathways (Hsp-70, Hsp-90, 
Hsp-96 and TNFR-1). Although many of these proteins have previously been described 
as altered in cancer, we are not aware of a single reagent like HPA which will 
concurrently bind all of these molecules. 
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Cancer is a leading cause of death in the developing world with 1 in 3 people 
affected in their lifetime. The worldwide incidence is dramatic with about 10 million 
new cases every year. In the UK 276,678 persons were diagnosed with cancer in 2003 
with four types of cancer accounting for more than half of the cases. The pie chart 
Figure 1.1 shows the proportion of breast, lung, bowel and prostate cancers recorded in 
the UK population. 
Breast 16% 
Others 46% Lung 13% 
13% 
Figure 1.1: Proportion of the four major cancers, breast, lung, prostate and bowel in the UK, Office for 
National Statistics 2005. 
1.1.2 Hallmarks of cancer 
The critical event for many patients with solid tumours is the spread of tumour 
cells from their primary site, through the circulatory system (blood and lymph) to form 
secondary tumours in a distant organ, this process is known as metastasis. Although 
treatment and diagnosis of cancers has improved in the past two decades with 
corresponding increases in survival rates of patients, the prognosis remains poor for 
patients with distant metastases. 
Cancers develop from a single cell, which undergoes genetic changes in three 
types of genes: oncogenes, tumour-suppressor, and stability genes, this leads to a 
characteristic disregulation in cell growth. The transformation of the normal cells 
commonly occurs via a process which favours clones of cancer cells in response to 
natural selection pressure, thereby paralleling the process of evolution described by 
Darwin. The cells with genetic alterations conferring a substantial growth advantage are 
selected eventually leading to a cancerous phenotype. Over 100 histological types of 
cancer have been classified and those often differ by their tissue of origin. Carcinomas 
2 
Prostate 12% 
occurring in epithelial cells, such as the colon, represent 85% of all cancers. Cancers of 
different tissue may have distinct features and different molecular mechanisms may be 
responsible for their development, nevertheless, the general progression in development 
of the cancer is similar and is composed of six essential steps described by Hanahan and 
Weinberg (2000). Transformed cells first acquire the ability to grow in the absence of 
mitogenic growth signal yet required for the proliferation of normal cells. Several 
strategies are used by the cancer cells to achieve that goal. They may synthesise their 
own growth factor such as PDGF/TGFa (Fedi et al., 1997), overexpress growth factor 
receptors such as EGF-R/erbB (Slamon et al., 1987) or synthesise constitutively 
activated receptors. Next the cancer cells escape regulation of the cell cycle via 
disruption of TGFP pathways responsible for arresting the cells in the G1 phase of the 
cell cycle (Weinberg, 1995; Moses et al., 1990). The following step in the development 
of cancer is the evasion of the programmed cell death. Here the importance of the P53 
protein that normally blocks apoptotic effectors is recognised with an observation that 
greater than 50% of human cancers show mutations in this gene (Harris, 1996). Also 
survival factors such as IGF-1/2 and IL3 are activated during tumour progression ( Evan 
and Littlewood, 1998) Although cancer cells exhibit deregulated growth, studies have 
shown that mammalian cells carry independent mechanisms of senescence that limit the 
potential of the cells to divide by progressive shortening of the telomeres through cell 
replication cycle eventually causing cell death. The neoplastic cells maintain the length 
of their chromosomes by expressing telomerase enzymes (Shay and Bacchetti, 1997) or 
by interchromosomal sequence exchange (Bryan et al., 1995) therefore acquiring 
unlimited replication potential. The fast-growing abnormal cells require an increasing 
need for oxygen and nutrients, these are supplied by vascularisation induced by the 
neoplasia (Folkman, 1997; Bouck et al., 1996; Hanahan and Folkman, 1996). Genetic 
alterations of angiogenic activators and inhibitors occur during neoplasia. For example, 
the angiogenic activator VEGF and FGF are often increased and the angiogenic 
inhibitors such as thrombospondin-1 or f3-interferon are decreased in developing 
tumours (Singh et al., 1995; Volpert et al., 1997). The final step in the development of 
cancer development is an invasion of surrounding tissues and settlement of cells that 
form metastatic deposits, metastases are responsible for approximately 90% of cancer- 


























Figure 1.2: The six hallmarks of cancer development. 
1.1.3 Angiogenesis and metastasis 
1.1.3.1 Angiogenesis 
As discussed in the previous paragraph, the mutation of oncogenes and tumour 
suppressor genes leads to uncontrolled proliferation of cancer cells, a corresponding 
increase in size correlated with an increased demand for oxygen and nutrients (Folkman, 
1986). It has been shown that an adequate supply of oxygen, nutrients and the removal 
of toxic molecules is necessary for the survival and growth of tumour cells. Moreover 
oxygen diffusion from capillaries extends to only 150 µm-200 µm, therefore beyond 
this distance oxygen has to be supplied by new blood vessels. Expansion of tumour 
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larger than 1 mm of diameter depends on the formation of new blood vessels via the 
process of angiogenesis (Fidler, 1994; Folkman and Klagsbrun, 1987). The 
establishment of a neocapillary network from the host tissue not only provides the 
appropriate supply to allow the tumour to grow, it constitutes an entry into the 
circulation for metastasing cells. 
1.1.3.2 Metastasis 
The metastatic spread of tumour cells is a selective process which consists of a 
series of interrelated steps that leads to the establishment of micrometastasis in a host 
organ, these steps were reviewed by Fidler (1991) and summarised in Figure 1.3. 
Tumour cells invade the surrounding tissue and penetrate into newly formed blood 
vessel or lymphatic channels in a step named intravasation. The tumour cells circulate 
as a single cell or as clumps in order to escape the immune system and survive before 
arrest of circulating cells and extravasation (Fidler and Bucana, 1977). Metastatic cells 
eventually proliferate with the target organ parenchyma and form a secondary tumour. 
The metastatic spread of tumour cell follows the theory of "seed" and "soil" first 
established by Paget (1889). Based on post mortem observations, Paget suggested that 
certain tumours cells with metastatic ability, "seed", would develop on the right "soil", 
organ that provides a growth advantage to the seeds, these ancestral observations were 
recently supported by studies showing site-specific metastasis of solid tumours (Fidler, 
1995). 
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Figure 1.3: Schematic diagram illustrating the steps involved in the distant spread of cancer cells 
Tumour cells are composed of a heterogeneous population of cancer cells, 
exhibiting a wide range of genetic, biochemical, immunological and biological 
characteristics (Poste and Fidler, 1979; Fidler and Hat, 1982; Nicolson, 1987; Fidler and 
Balch, 1987). During metastasis, specific subpopulations of cells present in the parent 
tumour appear to be selected for their ability to invade and grow to a distant secondary 
tumour by interacting with host factors (Fidler, 1995). Adhesion molecules play a 
central role in this process as they are involved at each step by attaching to 
neighbouring cells or matrix molecules and the ability of tumour cells to form transient 
attachments is necessary. Tumour cells involved in metastasis show alteration in their 
cell adhesion receptors and ligands (Nicolson, 1988; Yeatman and Nicolson, 1993). 
The first step in the metastatic process is the invasion of the surrounding tissues 
by cancer cells. The invasion through the ECM is achieved by the combined action of 
degradative enzymes and by the mechanical pressure exerted by the expanding mass of 
cells. It is a common feature of tumours to find higher level of lytic enzymes such as 
cathepsin B2, plasminogen activator and matrix metalloproteases in malignant cells 
(Jones and Declerck, 1980; Ray and Stetler-Stevenson, 1994). The migration of cells 
through the matrix is a dynamic process, the leading edge must express activated 
proteinases in order to give rise to a proteolytic zone. Transient attachment mediated by 
integrins such as a5131, a6131, a4(31, a2(31 at the attachment site, along with other cell 
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adhesion molecules (CAM), occurs at the leading edge and rear of the cell therefore 
enabling the metastatic cell to crawl through the ECM (Lauffenburger and Horwitz, 
1996) eventually heading towards original or angiogenic blood vessels or lymph 
channels. By this process cancer cells enter the circulation as a single cell or more often 
as clumps of cells in order to improve their survival within the blood stream. The 
cancerous cell may also form complexes with blood-borne cells (Gasic, 1984), this step 
appears to be essential to allow cells to survive both mechanical pressure and immune 
system surveillance until they attach to the endothelial cells at the site of metastasis, 
extravasate and colonise the organ of metastasis. 
The arrest of circulating cancer cells occurs by attachment of cancer cells to 
endothelium, in particular at the endothelial cell junctions (Kramer et al., 1982) or sub- 
endothelial matrix (Nicholson, 1982a). The attachment of cancer cells involves the 
binding of sialyl Lewis x and sialyl Lewis a sugars expressed by the cancer cells, to P- 
selectin and E-selectin expressed by the activated endothelial cells (Miller et al., 1996; 
Takada et al., 1993; Dejana et al., 1992, Lauri et al., 1991). After attachment to 
endothelial cells, cancer cells break through the basement membrane and invade the 
tissue in a process named extravasation in a similar manner to the intravasation process 
described earlier. The tumour grows and in doing so may induce the formation of new 
blood vessel (neoangiogenesis) allowing the metastatic cancer to develop further. 
1.2. Colorectal cancer 
1.2.1 Colon Anatomy and histopathology of CRC 
development 
The colon starts on the right hand side of the body at the Caecum and ends at the 
rectum on the left hand side of the body. It consists of the ascending colon, transverse 
colon, descending colon and sigmoid colon. 
The colon wall is composed of several layers from the inside to the lumen, the serosa, 
muscle, submucosa and mucosa. The colonic epithelium is characterised by a 
monolayer (mucosa) of specialised cells forming invaginations known as crypts. The 
epithelial layer is renewed every 3-8 days in a dynamic process (Altman and Enesco, 
1967; Wright and Irwin, 1982; Schmidt et al., 1965) and is composed of four cell types; 
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columnar absorptive cells, mucus secreting cells, neuro epithelial cells and the paneth 
cells (Le Blond and Cheng, 1976). They all originate from intestinal stem cells located 
at the base of the crypt which proliferate and become fully differentiated as they move 
toward the upper crypt region (Gordon et al., 1992). 
Colorectal cancer begins to develop as hyperplastic or dysplastic growth named 
aberrant crypt foci (ACF). The accumulation of epithelial cells is the result of a 
deregulation of the crucial birth/loss balance. It may result in formation of a protrusion 
in the epithelial cells, called benign polyps. There are mainly two types of polyps which 
predispose to variable outcome with respect to CRC development. Dysplastic or 
adenomatous polyps, similar to those found in people with the genetic disorder familial 
adenomatous polyposis, are characterised by abnormal cells organised in several layers 
on the lamina propria. These lesions are also called carcinoma in situ and are confined 
to the epithelial layer but may eventually progress through the muscularis mucosae and 
invade the surrounding tissue forming a malignant carcinoma. 
1.2.2 CRC staging 
CRC staging characterises the extent of the primary tumour lesion in order to 
facilitate prognostication and is a key element in helping to determine appropriate 
patient management strategies. The Dukes classification system was the first to 
establish categories of tumour stages and these were termed Dukes A, B and C (Dukes, 
1932). This system was subsequently modified by Astler-Coller (1954) to include a 
fourth stage (Stage D). These staging systems were based entirely on the extent to 
which the primary tumour had spread locally as well as regionally to the lymph nodes 
and was based on histo-pathological examination of tissues from resected specimens 
taken from the bowel. Although Dukes staging was originally described for rectal 
cancer, it has also subsequently been shown to be of value in staging colon cancer. 
Dukes stages A, B and C correlate with the disease-free (and overall) patient survival. 
Subsequently, the American Joint Committee on Cancer introduced the TNM (Tumour, 
Node, Metastasis) staging system, which sought to classify all cancer patients into one 
of four stages (Stage I-IV) (AJCC, 2002). The TNM system combined a variety of 
staging systems and is now the method that is most often used to describe the extent of a 
primary cancerous lesion and metastases at the time of diagnosis. The TNM system 
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describes the size of the primary tumour (T), metastases to regional lymph nodes (N) 
and distant metastases (M) and is shown in detail in Appendix 1. Figure 1.4 depicts the 
steps in CRC progression. At TNM stage 0, also known as tumour in situ (T is), the 
tumour is confined to the mucosa and represents the earliest stage of CRC cancer. At 
TNM stage I the cancer has infiltrated the submucosa and may also have invaded the 
muscle layer (TI-2). Cancer at TNM stage II has migrated through the colon wall and 
invaded nearby tissues (T3-4). At stage 0, I and II there is neither lymph node 
involvement (NO) nor metastases in distant organs, also known as secondary spread of 
the tumour (MO). At stage III, the cancer cells have spread to nearby lymph nodes (N1- 
N2) but distant metastases are not observed (MO) whilst at stage IV the cancer cells 
have spread to secondary organs (Ml) and represent the most advanced stage of CRC. 
Patients presenting at stage IV have the poorest 5 year survival rate. 
Lymph nodes 


























Figure 1.4: Schematic representation of the cancer progression through the colon wall and invasion of the 
surrounding tissues associated with each stage (0-4) of the disease. (adapted form NCI, 
httl: //www cancer gov/cancertopics/pdg/treattnent/colon/Patient) 
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The different TNM stages from I to IV and the correlation with the Dukes and Astler- 
Coller staging system are described in Table 1.1 
Stages TNM status Dukes stage Astler-Coller 
0 T is, NO, MO 
I T1-2, N0, MO A A5 BI 
IIA T3, NO, MO B B2 
IIB T4, NO, MO B B3 
IIIA TI-2, N1, MO C Cl 
IIIB T3-4, Ni, MO C C2, C3 
IIIC T 1-4, N2, MO C Cl, C2, C3 
IV T l-45 NO-25 Ml D 
Table 1.1: Relation between the three types of classification used to characterise colorectal tumours. 
1.2.3 Incidence and mortality 
Colorectal cancer is the second leading cause of cancer-related death in Europe 
and was the cause of more than 16000 deaths in the UK in 2005. In the UK around 100 
new cases are diagnosed each day and CRC is ranked as the third most common cancer 
after breast and lung. In 2003,35000 new cases of CRC were registered in the UK, with 
the men (around 19000) being more affected than women (around 16000). Colon 
cancers are distributed with 2/3 in the colon and 1/3 in the rectum and reports suggest 
that the left side of the bowel is more often affected than the right side. In particular the 
sigmoid colon, rectosigmold junction and the rectum represent more than 50% of all 
cases. 
There have been important improvements in the diagnosis and treatment of CRC 
which has resulted in an increase of the five-year survival rate in men and women, 
between the 1970's and 1990's the average five-year survival has doubled from 22% 
and 23% to 47% and 48% for men and women respectively. The average five-year 
survival rate has increased further and is currently 51 % and 52% for men and women. 
These rates are average values but the five-year survival rate is very dependent of the 
Dukes stage at the time at which the cancer was diagnosed and therefore important 
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variations in survival are observed. The Table 1.2 shows the average five-year survival 
rate of people diagnosed with CRC. 
Dukes stage of the Frequency at Five year survival 
CRC diagnosis rate 
A <10% 93% 
B 30% 82% 
C 30% 55-60% 
D 20% 5-8% 
Table 1.2: Frequency and five-year survival rate of Duke's stage A, B, C and D CRC. Adapted from 
Nicholson et al. 2005. 
1.2.4 Risk factors 
The impact of the environment and lifestyle on the development of CRC was 
first proposed by Burkitt in the 1960's who suspected a relation between diet and bowel 
disease. Burkitt's hypothesis was that the colonic transit is slower in low fiber-diet and 
thatthis would facilitate the action of carcinogens on colon cells. In the mid 1970's the 
first large multicentre studies showed that lower fat intake reduced the incidence of 
human cancers (Walker and Burkitt, 1976). Studies based on population migrating from 
low risk to high risk areas showed a dramatic increase in incidence (Parkin et al., 1992) 
and it has since been estimated that environmental and lifestyle factors contribute to 
approximately 70-80% of all CRC (Doll and Peto, 1981; Willett, 1995). 
The diet is one of the most important lifestyle factors linked to the incidence of 
CRC. For instance dietary fat and meat intake have been linked to CRC and studies 
have postulated that a correlation between high fat intake and CRC was via bile salts. 
Bile salts produced by the liver to facilitate the absorption of fat in the small intestine 
are eventually reabsorbed and redirected to the liver but 1-2% of residual bile salt are 
metabolised by the colonic microflora into mutagenic secondary bile salts (Van Munster 
and Nagengast, 1993). Although early studies linked dietary fat intake with CRC 
incidence (Walter and Burkitt, 1976; Pwynder, 1975), more recent studies failed to find 
an association between fat intake with risk of CRC (Giovannucci et al., 1992; Howe et 
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al., 1997; Stemmermann et al., 1984). Red meat intake has been linked to CRC risk, 
several studies have shown an increased risk of CRC with high intake of red meat 
(Giovannucci et al., 1992, Willett et al., 1990) and an even higher risk with processed 
meats (Chao et al., 2005; LeMarchand, 2002). More over there is evidence that there is 
a reduced incidence of CRC in populations that consume a high-fibre diet. A large 
European study, European Prospective Investigation into Cancer and Nutrition (EPIC), 
is currently being conducted. This is the largest prospective study yet involving more 
than half million people in 10 countries, and the first results of this study found a dose 
dependent protective effect of a high-fibre diet on CRC development (Bingham et al., 
2003), and a dose dependent association between red meat intake and colorectal cancer 
incidence was observed (Norat et al., 2005). The sedentary lifestyle of the Western 
countries, where the energy balance is displaced (more energy intake than energy 
consumption), is characterised by an increase of obesity which has been identified as a 
risk factor for CRC in human and animal models. Indeed people with active lifestyles 
have increased five-year survival as compared to inactive people (Haydon et al., 2006). 
Cigarette smoke has been linked to lung cancer development however cigarette smoke 
has also been consistently linked to CRC in several epidemiological studies (Reviewed 
in Franco et al., 2005; IARC, 2004). 
Age is a major risk factor as the chance of developing CRC dramatically 
increases after the age of 50 (Quinn et al., 2001). In the UK there is also a geographic 
component as London and south east England have lower incidence and mortality than 
the rest of the UK and Ireland (Office for National Statistics, 2005). 
Other factors linked to CRC formation include personal or familial history of 
CRC, personal history of adenomatous polyps and history of inflammatory bowel 
disease. Inherited genetic predisposition also increases the chance of developing CRC 
and the two major factors are Familial Adenomatous Polyposis (FAP) and Hereditary 
Non Polyposis Colorectal Cancer (HNPCC). FAP is a genetic disorder where people 
develop hundreds of polyps in their colon and rectum throughout their life. Virtually all 
the people with this disorder develop a colorectal cancer by the age of 40 but they 
represent only 1% of all the CRC cases. HNPCC is another genetic predisposition that 
increases the chance of young people developing CRC, together these syndromes 
account for no more than 2-6% of all CRC (Kemp et al., 2004). 
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1.2.5 CRC screening and treatments 
1.2.5.1 Screening 
Colorectal cancer has a high incidence (see section 1.2.3), and the mortality rate 
is elevated in Europe but when detected at early stage (Dukes A) the five year survival 
is greater than 93% (Nicholson et al., 2005). The problems with early detection are that 
colorectal cancers remain asymptomatic and when the symptoms appear the cancer cells 
have already invaded the neighbouring tissues with a corresponding drop in the five 
year survival. For an individual without a family history of CRC the life time incidence 
for CRC is 6% and the risk doubles every ten years after the age of 40 (Nicholson et al., 
2005), therefore the population screening is likely to reduce the mortality but the best 
screening tool has yet to be identified. 
The double contrast barium enema has good sensitivity of 83% (Winawer et al., 
2000) for colorectal cancer but it is only used if colonoscopy has failed. Sigmoidoscopy 
is a quick, sedation-free approach. A long-term follow-up study over a 13 year period 
has shown a reduction in incidence of CRC of 80% and a reduction in mortality of 50% 
however studies show that missed CRC lesions in the right colon occur when 
sigmoidoscopy is used as a diagnostic tool (Lewis et al., 2003; Harewood and 
Lieberman, 2003). Colonoscopy is an invasive but sensitive method for the detection of 
neoplastic lesions in the colon. A large multi centre study over a follow-up period of 10 
years was conducted in the italian population (Citarda et al., 2001). 1693 patients, male 
and female of 40-69 years old which had undergone colonoscopic polypectomy of at 
least one adenoma >5mm were studied and the incidence ratio for CRC was compared 
to the expected age/sex-specific incidence of the general population. Six cases of CRC 
were obsreved in the screened population over a period of 10 years whereas 17.7 cases 
would have been expected in the general population. This results are in accordance with 
the results of the National US Polyp Study (NPS) and confirm that the removal of 
adenomatous polyps is associated with a decrease in incidence of CRC. Flexible 
sigmoidoscopy and colonoscopy are both invasive screening tools which are not popular 
with an asymptomatic patient. Moreover there are risks associated with these two 
procedures such as perforation, bleeding for sigmoidoscopy or complication and risk of 
death with colonoscopy. The Faecal occult blood test (FOBT) is a non invasive 
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technique which consists in detecting traces of blood in stools. The sensitivity is not as 
high as colonoscopy but the acceptance of asymptomatic patients is much higher and 
this enables repeated testing currently recommended at 1-2 yearly intervals, this 
increases the sensitivity for CRC detection to 90% (Mandel et al., 1993). Also a new 
immunochemichal FOBT has shown better sensitivity (66%-90%) than the original 
Guaiac-based FOBT. However it seems that endoscopy is becoming the method of 
choice as it can be used to take a tissue sample in order to evaluate the stage of the 
cancerous lesion and hence plan treatment. New imaging techniques such as computed 
tomography scans and magnetic resonance imaging are now used to stage a tumour at 
the time of diagnosis and to plan the optimum treatment. 
1.2.5.2 Treatments 
CRC is highly treatable and curable when diagnosed at early stage when the 
tumour has not penetrated through the bowel wall. The characteristic of the cancer is 
defined by TNM staging, described in section 1.2.5, and taken together with the serum 
levels of carcinoembryogenic antigen (CEA) have an impact on the treatment decisions. 
About 50% of CRC are cured by surgery but recurrence of the tumour at loco-regional 
or distant sites occur and are a major cause of patient mortality. 
Surgery remains the main treatment and about 80% of patient with CRC 
undergo surgery, 50% of which have cancer recurrence within 24 months. This rate may 
be lowered in rectal cancer by using total mesorectal excision (TME). However 
chemotherapeutic drugs such as 5-FU and folinic acid are often used after surgery and 
reduce cancer recurrence therefore increasing the 5 years survival rate by 5-6% (Dube et 
al., 1997). In particular patients diagnosed with stage III cancer (see 1.2.5.2) are treated 
by chemotherapy and stage IV patients require palliative chemotherapy and/or 
radiotherapy. New approaches are also being investigated such as the use of monoclonal 
antibody (Bevacizumab and Cetuximab) for first and second line treatment (NICE, 
2005). 
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1.2.5.3 CRC biomarkers 
Over the past few decades the early detection of cancers has become a focus. An 
ideal tumour marker would be a protein or peptide that can be detected in blood or urine 
of cancer patients but not in healthy persons. The first biomarker to be used was the 
carcinoembryonic antigen (CEA), which was found in the blood of patients with colon 
cancers (Gold and Freedman, 1965). Later serum tests have been developed for a 
variety of of cancers such as the detection of CA 19-9 for colorectal and pancreatic 
cancers, CA15-3 for breast cancers, CA-125 for ovarian cancer and Protate Serum 
Antigen (PSA) for prostate cancers (reviewed by Chatterjee and Zetter, 2005). However 
most cancer clinical diagnosis still rely on a pathological tissue examination and 
biomarkers such as CEA are used to monitor cancer reccurence or evaluate treatment 
efficacy rather than for the detection of early stage cancers. There is still a need for 
highly sensitive and specific biomarkers in CRC and other cancers. In more recent years 
several markers have been identified for their ability to predict the tumour outcome 
which would improve the therapeutic approach for each patients. In CRC, mutations in 
mismatch-repair genes are associated with poor prognosis and their detection could be 
useful to predict the outcome of several colon tumour (Bubb et al., 1996; Halling et al., 
1999). Also increases in level of D-dimer has been proposed as a prognostic biomarkers 
for invasive CRC (Blackwell et al., 2004). However the discovery of sensitive and 
specific biomarkers remain a challenge and new technologies such as gene microarray 
or mass spectrometry-based proteomics could enable the identification of such 
molecules. 
1.2.6 Genetic factors in CRC development 
The majority of CRC are sporadic (85%) whilst hereditary factors account for 
the minority (15%) of CRC cases. FAP is an autosomal dominant condition which 
affects both men and women, it is characterised by the development of thousands of 
adenomatous polyps in the colon. Most cases of FAP carry a germ line mutation of the 
APC gene located on chromosome 5g21. HNPCC, also named Lynch syndrome (Lynch 
et al., 1993) accounts for approximately 3% to 5% of all CRC and is an autosomal 
dominant condition caused by mutation of one of the DNA mismatch repair genes 
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(MLH1, MSH2, PMS2, MSH6). The average age for developing sporadic CRC is 64 
years whereas it is 55-57 years for individuals with a mutation in MSH6 and individuals 
with HNPCC have an 80% chance of developing CRC in their lifetime (Vasen et al., 
1996). 
The most common genetic event in CRC is a mutation in the APC gene, this 
occurs in approximately 80% of CRC cases. APC is a tumour suppressor gene whose 
mutation is necessary and occurs at very early stage of the development of CRC. Fearon 
and Vogelstein (1990) have described a model of CRC tumour progression which is a 
multistep process involving genetic alterations leading to the progressive transformation 
of normal colonic epithelial cells into malignant carcinoma (Kinzler and Vogelstein, 
1996; Fearon and Vogelstein, 1990). This multistep process is illustrated in Figure 1.5. 
The earliest alteration described in this model is the mutation of APC. The genetic 
instability observed in CRC is necessary for the malignant progression of such lesions, 
two main mechanisms are observed, chromosomal instability or loss of heterozygosity 
in 85% of CRC and microsatellite instability in 15% of CRC. 
Chromosomal instability or loss of heterozygosity (LOH) ensures a fast and 
efficient accumulation of other cancerous mutations. A recent study has linked the loss 
of function of APC with chromosomal instability (Fodde et al., 2001). In HNPCC and 
15% of sporadic CRC's chromosomal instability does not occur, instead these tumours 
present a hypermutable phenotype (microsatellite instability) to facilitate the 
accumulation of mutations necessary to progress to a malignant phenotype. 
Microsatellite instability occurs by loss of DNA repair mechanisms and the mismatch 
repair genes mentioned earlier play a crucial role in microsatellite instability. The genes 
mutated during the progression from adenoma to invasive carcinoma mainly belong to 
four signalling pathways: Wnt signalling pathway, KRas pathway, P53 pathway and 
TGF(3 pathway. APC mutations appear to be the rate-limiting genetic event in CRC 
initiation (Powell et al., 1992). The tumour suppressor activity of APC resides in its 
capacity to regulate intracellular levels of (3catenin, a key member of the Wnt pathway. 
Other members of this pathway such as (3catenin, axin-1 and axin-2 have also been 
shown to be mutated during CRC progression. The activation of KRas represents the 
second step in the cancer progression model proposed by Fearon and Vogelstein. KRas 
mutations are found in at least 50% of CRC larger than l cm (Vogelstein et al., 1988). 
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The mutation of KRas often affects the guanine triphosphate activity leading to a 
constitutive activation of Ras, Raf, MEK and ERK signal transduction pathway, 
therefore it induces proliferation and inhibition of apoptosis and thus malignant 
transformation. On the way to malignancy tumours undergo two other genetics events. 
LOH occurs on the long arm of chromosome 18 (18q) (Vogelstein et al., 1988, 
Vogelstein et al., 1989) involving the possible alteration of the "deleted in colorectal 
cancer" (DCC) genes, SMAD2 and SMAD4 (TGFý pathway). Mutated SMAD2 and 
SMAD4 prevent cellular functions such as growth inhibition, apoptosis, differentiation 
and matrix production (Heldin et al., 1997; Duff and Clarke, 1998). Mutations in TGF(3 
are also frequent in microsatellite unstable tumours and are observed on chromosome 
17 (17p) were the p53 gene is located. p53 is known as the "guardian of the genome" 
and blocks cell proliferation to allow DNA repair or induce apoptosis (Lane, 1992; 
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Figure 1.5: Adenoma-carcinoma sequence. This diagram depicts the major genetic alterations occurring 
at each step of colorectal cancer development. Adapted from Fearon and Vogelstein 1990. 
The model described by Vogelstein and Fearon had a major impact on CRC 
research as it provided new insights into understanding the genetic modifications 
associated with colorectal cancer progression. However, several studies have proposed a 
more complicated system in the development of CRC. The existence of two categories 
of CRC according to their location in the proximal or distal colon was proposed by 
several research groups (Bufill, 1990; Knudson, 1989; Rothberg et al., 1985; Distler and 
Holt, 1997; Gervaz et al., 2001). The two main hereditary CRC, FAP and HNPCC, are 
characterised by different changes in signal transduction pathways and arise at different 
sites in the colon. Almost all FAP develop in the distal colon and rectum and 
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approximately 70% of HNPCC develop in the proximal colon (Lynch et al., 1988). The 
anatomic differences in the right and left colon and clinical differences of CRC 
development in the proximal and distal colon have led to the idea that the formation of a 
CRC may follow different molecular pathways (lacopetta, 2002). 
1.3. Glycosylation and cancer 
1.3.1 Functions of oligosaccharides on glycoproteins 
Glycoconjugates are essential in a vast number of biological functions including 
blood clotting, lubrication, structural support, immunological protection, hormone 
activation and recognition, storage of bioactive molecules, cell-cell and cell-matrix 
interactions and adhesion (reviewed in Varki, 1993). In contrast to peptides and 
oligonucleotides which form linear polymers, oligosaccharides are arranged as branched 
macromolecules and can exhibit a large number of structures. This potentially vast 
variation in oligosaccharide structures confers considerable opportunity for 
carbohydrate-protein recognition and adhesion. 
The carbohydrate-protein and carbohydrate-carbohydrate interactions which are 
known to occur during cell-cell, cell-matrix and cell-pathogen interaction (Liotta, 1992), 
(for example sialylated-Le" and -Lea) are important in the recognition of, for example, 
endothelial cells by leukocytes. Oligosaccharides are involved in compaction of the 
embryo at the 16-cell stage of development and this occurs via Le"-Le" interactions 
(Eggens et al., 1989). At the protein level, oligosaccharides have diverse functions such 
as protection of proteins from enzymatic degradation (Homans et al., 1987) or as cell 
adhesion molecules (Lasky, 1992, Springer, 1990). Plasma membrane proteins have 
three main roles, as enzymes, channels or cell / protein receptors and most of these 
proteins undergo glycosylation as they traffic through the secretory pathway. The 
glycans confer additional properties such as shape, hydrophobicity, charge and may 
interact with carbohydrate binding proteins. 
Carbohydrates have been shown to play an important role in cancer and 
metastasis. Lectins, plant or animal carbohydrate binding proteins, provided the first 
evidence of aberrant glycosylation in cancer. The changes in carbohydrate composition 
of cancer cells have since been shown to play a critical role in the cell-cell and cell- 
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matrix interactions necessary for cancer cell survival, invasion and metastasis. When 
cells are oncogenically transformed they often express foetal carbohydrates called 
oncofoetal antigens. A variety of oncofoetal changes in cancer glycosylation have been 
described, these include increased N-linked carbohydrate size due to extensive 
branching, truncated carbohydrates as observed on mucin-type glycoconjugates, 
exposing structures such as the T and Tn antigens and increased expression of the Lewis 
sugars Lewis x and Lewis x. 
In normal human cells there are four main groups of glycoconjugates: 
glycoproteins, glycolipids, glycoaminoglycans (GAGs) and glycophosphoinositol (GPI) 
anchors. GPI anchors are exclusively membrane bound and are implicated in cell 
signalling (Low et al., 1986; Merida et al., 1990). Glycolipids are mainly located on cell 
membranes (Hakomori, 1986) and glycoproteins are found in various cellular locations 
such as the intracellular compartment, plasma membrane (integral or membrane- 
associated glycoproteins) or in the sera (Lis and Sharon, 1993). Finally GAGs play a 
structural role in the extracellular matrix. 
In humans seven monosaccharides are commonly found attached to 
glycoproteins or glycolipids, these entities are shown in Figure 1.6. The potential 
diversity of structures, for example in the formation of a simple disaccharide from two 
monosaccharides, is shown in Figure 1.7. Two types of oligosaccharides are most 
commonly found attached to the protein backbone. These are classified by the nature of 
their linkage to the proteins: N-linked glycans by the attachment of an N- 
acetylglucosamine (GlcNAc) residue on the nitrogen atom of an asparagine residue and 
O-linked glycans are mainly characterised by a GaINAc residue attached to an oxygen 
atom of the hydroxyl group of serine or threonine on the protein. The importance of 
glycosylation in human biology is evidenced by the number of gene products involved 
in the biosynthesis of glycans with about 1% of the translated genome being implicated 
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Figure 1.6: Monosaccharides associated with human glycoproteins and glycolipids 
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1.3.2 N-linked oligosaccharides 
Biosynthesis of all N-linked oligosaccharides begins in the rough ER and can be 
viewed as four distinct phases associated with different compartments of the secretory 
pathway. Firstly glycosyltransferases specifically and sequentially add monosaccharides 
to a dolichol molecule anchored in the ER membrane eventually generating the large 
lipid-bound oligosaccharide intermediate of general formula G1c3Man4GlcNAc2- 
dolichol presented in Figure 1.8 (Hubbard and Ivatt, 1981; Kobata and Takasaki, 1992). 
The oligosaccharide is eventually transferred by the enzyme dolichyl- 
pyrophosphoryloligosaccharide-polypeptideoligosaccharyltransferase (Das and Heath, 
1980) to an accessible asparagine residue within the sequence Asn-X-Ser/Thr, where X 
can be any amino acid except proline. After attachment of the oligosaccharide 
intermediate to the nascent polypeptide chain in the ER the glycan structure is 
recognised by the calreticulin and calnexin system and if the protein is correctly folded 
it is transported via vesicles to the Golgi apparatus where the oligosaccharide is 
trimmed and processed by a series of glycosidase and transferase enzymes (Kornfeld 
and Kornfeld, 1985). The structural variation in glycans is due to tissue-specific 
variations in expression of glycosyltransferases genes, sugar nucleotide availability in 
the Golgi apparatus and competition between enzymes during glycan elongation. In the 
Golgi apparatus further residues are added to the oligosaccharide, these most commonly 
include galactose, sialic acid and fucose and these residues form extensions and 
"branches" eventually generating a diverse range of mature N-glycans. N-linked 
oligosaccharides possess a common feature, Man3GlcNAc2 (Kobata and Takasaki, 1992) 
but the wide range of variability in branches results in structural heterogeneity. 
Furthermore these glycoproteins often undergo 0-glycosylation within the Golgi 
apparatus (Kornfeld and Kornfeld, 1985) and are then transported via vesicles to the cell 
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Figure 1.8: The glycosylated oligosaccharide lipid intermediate. 
1.3.3 0-linked oligosaccharides 
O-linked oligosaccharides are typically characterised by the addition of N- 
acetylgalactosamine (Ga1NAc) to serine or threonine of a polypeptide backbone, this 
occurs in the cis Golgi. Ga1NAc is transferred to the serine or threonine from the 
nucleotide donor substrate UDP-Ga1NAc by the action of one of several UDP-Ga1NAc- 
polypeptide a-N-acetylgalactosaminyl transferase (ppGalNAc-T) enzymes. The 
presence of proline residues in the region surrounding the glycosylation site is 
necessary for effective transfer of a Ga1NAc by ppGalNAc-T. The attachment of the 
a Ga1NAc glycan to the glycosylation site of the polypeptide gives rise to the Tn 
antigen, this is then processed by glycosyltransferases to generate O-linked glycan 
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motifs termed "core" structures which can be further modified to create 0-linked 
glycans (Brockhausen, 2000). 
The oligosaccharides attached to Ser/Thr vary widely in size from a single 
Ga1NAc (Tn antigen) up to greater than 18 sugar residues. The structure of large 0- 
glycans may include: 
-A core unit linked to the Ser/Thr of a polypeptide 
-A backbone, not always present 
- Peripheral structures 
Eight core O-linked structures have been identified (core 1-8) but cores 1 and 2 are the 
most common in normal breast and colorectal tissues whilst core 3 and 4 have a lower 
occurrence, cores 5-8 occur rarely. Figure 1.9 depicts the biosynthetic pathways of core 
1-4 O-linked glycans and their extensions. The type of core has a direct influence on the 
final structure of the O-glycans. The peripheral structures decorating the core and 
backbone units are responsible for the huge variation in O-glycan structures. O-linked 
glycans play a variety of biological roles, for example as cell adhesion molecules (sialyl 
Le"/sialyl Lea) and as blood group antigens. The three parts of the 0 glycans, mentioned 
earlier are shown in Table 1.3, the structure of the Tn antigen, cores 1-8 and the 
backbone units and selected peripheral branches are presented. 
Glycosidases and glycosyltransferases (GTases) enzymes are responsible for the 
elaboration of the glycan extensions on the newly synthesised protein. Their sequential 
and ordered action leads to the addition of defined glycans to proteins. The GTases are 
found in the organelles of the secretory pathway and in particular in the ER and Golgi. 
The GTases are themselves glycoproteins attached to the ER/Golgi membrane via a 
transmembrane domain (Paulson and Colley, 1989). The diversity of protein 
glycosylation relies on the specificity of GTases and recent developments in molecular 
biology have shown that there is a great diversity of enzymes with, potentially, several 
hundreds of genes coding for enzymes involved in glycosylation reactions. In humans, 
more than 200 glycosyltransferase (GTase) sequences have been reported. The various 
GTases compete with each other to react with polypeptides and monosaccharides to 
form glycopeptide or oligosaccharide structures. Factors such as the level and activity of 
an enzyme and the presence of appropriate nucleotide donors influence the final glycan 
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G1cNAc: N-acetylglucosamine, Fuc: fucose 
Figure 1.9: Biosynthesis pathways of the most represented cores 1-4 and their extensions. The addition of 
an al linked Ga1NAc to Ser/Thr constitute the Tn antigen. The addition of Gal to the Tn antigen in aP 1- 
3 linkage form the Core 1 structure. Ga1NAc in a p1-6 linkage added to Core 1 constitute the Core 2 
structure. The formation of Core 3 consists of the addition of a G1cNAc residue to the Tn antigen. A 
G1cNAc residue added to Core 3 in a p1-6 linkage form the Core 4 structure. Cores 1-4 can be extended 
by peripheral structures as shown. From Corfield, 2005 (Encyclopaedia of genetics, genomics, 
proteomics and bioinformatics). 
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Core classes Structures 
core Galß 1-3 Ga1NAca-O-Ser/Thr 
Core 2 Gal(31-3Gar1NAca-O-Ser/Thr 
G1cNAc(31-6 
Core 3 G1cNAc(31-3Ga1NAca-O-Ser/Thr 
Core 4 GIcNAc(31-3I Ga1NAca-O-Ser/Thr 
G1cNAc(31-6 
Core 5 Ga1NAca1-3Ga1NAca-O-Ser/Thr 
Core 6 G1cNAcß l -6 Ga1NAca-O-Ser/Thr Core 7 GalNAcal-6GalNAca-O-Ser/Thr 
Core 8 Galal-3Ga1NAca-O-Ser/Thr 
Backbone units 
Type 1 Gal(31-3 G1cNAc 
Type 2 Gal(31-4G1cNAc 
Poly N-acetyl lactosamine (Gal(31-4G1cNAc(31-3)n 
type 2 
Branched N-acetyl Gal(31-4G1cNAc(31-6Galß 1- 
lactosamine 2 Gal(31-4G1cNAý131-3 
Peripheral Structures 
Blood Group H Fucal -2Gal f 31-3G1cNAc(31- 
Blood Group A Ga1NAca 1-3Gal 31-4G1cNAc(31- 
B Fuca l -2 
Blood group B Gala l -3 Galj31-3 GlcNAc(31- 
Fuca 1-2 
Sialyl Lewis a Neu5Aca2-3 Galj31-3 GlcNAc(31- 
Fuca l -4 
Sialyl Lewis' Neu5Aca2-3Gal(3l -4G1cNAc(3l - 
Fuca l -3 
Sialyl Tn Neu5Aca2-6GalNAca-O-Ser/Thr 
Sialyl T antigen Neu5Aca2-3Gal(31-3GalNAca-O-Ser/Thr 
Table 1.3: Types of 0-linked oligosaccharides found on glycoproteins and mucins. Adapted from 
Brockhausen, 1999. 
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1.3.4 Important extensions of N- and O-linked glycans- 
blood group sugars and Lewis antigens 
The complexity of glycan structures on glycoproteins relies on the ability of 
GTases to form the various branched extensions of oligosaccharides. The classical core 
structures of N- and O-linked glycans often comprise a G1cNAc residue at the non- 
terminal end; this is usually extended with a Gal residue in either a (31-3 or ß 1-4 linkage 
resulting in type 1 or 2 chains respectively. 
The blood group ABO system was first described by Landsteiner in 1902. ABH 
determinants (Table 1.3) are attached to type 1 or type 2 O-linked glycan chains of 
glycolipids of erythrocytes, on glycoproteins and in secretions such as mucus (reviewed 
by King, 1994). The Lewis blood group antigens are fucosylated antigens found mainly 
in glycolipids but also glycoproteins. Lewis a and Lewis b are based on the type 1 chain 
and Lewis x and Lewis y are based on the type 2 chains, shown in Table 1.3. Sialylation 
of these antigens can also occur conferring a negative charge to the glycan chain. 
Modification of the Lewis determinants has been shown in cancer and will be described 
further. The type 2 chain can contain repeating units known as polylactosamine repeats 
and these have been found to occur on both N- and O-linked carbohydrates. 
1.3.5 Altered glycosylation in cancer 
There is a considerable body of evidence detailing abnormal glycosylation of 
glycoproteins in cancer development. There are four main types of glycosylation 
changes in solid tumours (reviewed by Dwek and Brooks, 2004); synthesis of truncated 
glycans, inappropriate synthesis of blood group determinants, changes in 
polylactosamine synthesis and increased (31-6 branching and finally alterations in 
sialylation. 
1.3.5.1 Altered 0-glycans 
Mucin glycoproteins are highly glycosylated in specific domains termed variable 
number tandem repeats (VNTR), these regions are rich in the serine and threonine 
residues to which O-linked oligosaccharides are attached. Mature mucins typically 
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comprise between 50% and 90% carbohydrate (Kim, 1992). Mucins also contain N- 
linked oligosaccharides but these are a minor constituent although they have been 
reported to play an important role in the oligomerisation of these glycoproteins (Dekker 
and Strous, 1990). The first gene sequence for a mucin was obtained for MUC 1. Many 
other genes coding for mucins have since been identified and these have been named 
MUC 1 to MUC17. Mucins are classified into two main groups according to their 
structural and functional charateristics: secreted mucins (MUC2, MUC5AC, MUC5B, 
MUC6), transmembrane mucins (MUC 1, MUC3A, MUC3B, MUC4, MUC 11, MUC 12, 
MUC 17) and mucins that belong to neither of these groups, for example MUC7, MUC8, 
MUC9, MUC 13, MUC 15 and MUC 16 (reviewed in Byrd and Bresalier, 2004). Initial 
studies suggested that mucin expression was organ-specific (Yonezawa et al., 1991) but 
it now seems that most organs express more than one type of mucin although there are 
predominant mucin types in a particular organ. The loss of organ specific expression of 
mucins is a common feature of gastrointestinal tumours. 
In CRC MUC1 expression is an independent prognostic factor (Baldus et al., 
2002) and an indicator of high risk of death in Caucasians, (Manne et al., 2000). Early 
studies used an immuno-histochemical approach to evaluate MUC1 expression in 
normal colon and CRC (Nakamori et al., 1994) but it was suggested that differences in 
binding between normal and cancerous cells observed with antibodies directed towards 
MUC 1 were not due to differences in the level of the mucin but due to differences in 
glycosylation, affecting antibody interaction with the mucin protein backbone. mRNA 
based studies showed that there is stable expression of the MUC 1 gene product in 
normal and cancerous colon and further work showed that in CRC there is a decrease in 
glycosylation which leads to unmasking of the MUCI protein backbone (Ajioka et al., 
1996; Cao et al., 1997). MUC1 with abnormal glycosylation becomes antigenically 
distinct from its normal form and this may render it a favourable target for immuno- 
therapy of CRC (Singh and Bandyopadhyay, 2007; Tarp and Clausen, 2007). 
It has been reported that, in cancer, the oligosaccharides on mucins and other 
glycoproteins are truncated or show structural differences compared with the glycans of 
mucins and proteins derived from matched normal tissues (Kim et al., 1974). 
Alterations in the enzymes active in glycosylation pathways (Boland and Deshmukh, 
1990; Yang et al., 1994) leads to the altered glycan structures. In colon cancer there is 
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an increase in Lea and Le" sugars and exposure of the Tn (GalNAcal-3-O-Ser/Thr), 
sialyl Tn and T antigens (Springer, 1984; Itzkowitz et al., 1986b; Itzkowitz et al., 1989; 
Kim, 1992). 
Increased expression of T antigen is partially due to an increase in core 1 (33 
galactosyl transferase and decrease in core 3 ß3 G1cNAc transferase (Yang et al., 1994) 
and correlates with an increased risk of liver metastases (Cao et al., 1995). The presence 
of T antigen has also been correlated with the presence of lymph node metastases in 
patients with breast and gastric cancer (Mustac et al., 1996, Yamashita et al., 1995). 
Leathern and Brooks (1987) reported a correlation between an increased ratio of Tn/T 
and the degree of differentiation of breast tumour cells, malignancy and survival. Over- 
expression of a2,6-sialyltransferase-I, responsible for addition of a2,6 linked sialic acid 
residues, has been shown to lead to the abnormal sialylation of the Tn antigen (STn) 
(Yang et al., 1994). Increased levels of STn have been reported at an early stage of CRC 
formation and STn expression correlates with the formation of metastases and poor 
prognosis (Itzkowitz et al., 1989). 
Sialyl Lewis", sialyl Lewisa and sialyl-dimeric Lewis" have all been shown to be 
elevated in metastatic cancer cells as compared to primary tumours (Hanski et al., 1996; 
Ito et al., 1997; Nishihara et al., 1999; Petretti et al., 2000). Elevated levels of sialyl 
Lewis" can be attributed to an increase in the activity of a3-sialyltransferase and 
correlates with lymph node invasion by colorectal cancer cells. The enzyme 0- 
fucosyltransferase which controls the formation of sialyl-dimeric Lewis" is increased in 
colorectal cancer and is related to poor prognosis (Kudo et al., 1998). 
In summary, the incomplete glycosylation of O-linked glycans observed in 
cancer results in exposure of glycan structures normally masked by further 
glycosylation. Some of the most commonly reported cancer associated glycan motifs 
are shown in Table 1.4 
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Cancer-associated glycans Increased/decreased in cancer 
Tn antigen 
STn antigen 





Type 1 chain 




Table 1.4: O-glycans associated with cancer. Adapted from Brockhausen, 2006 
1.3.5.2 Alteration of Lewis sugars and blood group antigens 
The role of ABH determinants in normal epithelia or neoplasia is unknown 
although it has been suggested that blood group A antigen may be involved in 
regulation of cell proliferation (Feizi and Childs, 1987). It is now widely recognised that 
the normal pattern of tissue-associated blood group antigens are modified in cancerous 
lesions (Bloom et al., 1990). Aberrant expression of antigens and/or deletion of antigens 
normally expressed often occurs during cancer formation. The loss of the blood A and B 
antigens by removal of Ga1NAc and Gal residues respectively is a common feature of 
carcinoma development (Hakomori, 1999; LePendu et al., 2001). This uncovers the 
common precursor of blood A and B determinants termed the blood group H antigen 
which is often seen to be increased in carcinomas such those of the breast, colon and 
stomach (Marionneau et al., 2001; Idikio and Manickavel, 1992). Decreased ABH 
expression in lung and bladder cancer is associated with metastatic potential and poor 
prognosis (Matsumoto et al., 1993; Orntoft et al., 1996) and patients with gastric 
carcinoma and increased blood group A antigen / GaINAc containing oligosaccharides 
(as detected using the lectin HPA) exhibit a lower survival rate (Kakeji et al., 1991). 
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The changes in glycosylation of blood group antigen may occur at the invasive front of 
the tumour and may be associated with the degree of differentiation of the tumour. The 
Lewis A and Lewis B (Leb) and the sialylated form of the Lewis antigens have been 
shown to be altered during cancer formation with decreased levels in cancer cells as 
compared to the normal surrounding tissues. The loss of Leb correlates with the grade of 
the lesion (Idikio and Manickavel, 1991). Le" is an oncofetal antigen (Feizi, 1985) 
found in higher quantities in breast, colon and renal carcinomas and Le'" is elevated in 
various carcinomas such as colon and liver cancer (reviewed by Dwek and Brooks, 
2004). In a manner similar to the ABH antigen, the abnormal occurrence of Lewis 
antigens is a marker of de-differentiation and therefore a marker of malignancy. 
Sialylated forms of Lewis antigens have attracted much interest as they are 
binding partners for selectins and are implicated in metastatic mechanisms. Hoff et al. 
(1989) showed that elevated levels of SLe" are found on the surface of liver metastases 
confirming a significant role of this antigen in the metastatic spread of the cancer cells. 
SLe" and SLea on cell surface glycoconjugates assists in the attachment of cells to E-, P- 
and L-selectins present on activated endothelia, leukocytes and platelets. This ability of 
cancer cells to bind to blood-borne cells and endothelia is an important factor in 
enabling the metastatic spread of tumour cells. Expression of SLex is an early marker 
of metastasis and has been inversely correlated with survival in CRC and other 
carcinomas (Nakamori et al., 1997, Baldus et al., 1998). A recent study conducted 
using cell lines and a murine model by Fuster et al. (2003) established that a 
disaccharide which inhibits the synthesis of SLex results in a decrease in the metastatic 
potential of colon and lung cancer cell lines and cancer cells treated with this 
disaccharide showed a reduction in binding to Selectin, thrombin-activated platelets and 
TNFa-activated endothelium and a reduced ability of the colon cancer cell lines to 
metastasise to the lung in SCID mice. 
1.3.5.3 Altered N-glycans 
It is a common feature that malignant cells display increased glycosylation in 
particular the acquisition of large N-linked glycans as a result of the presence of 
polylactosamine extensions (Gal(31-4G1cNAc(31-3),,. The presence of polylactosamine 
repeats has been associated with malignant transformation and metastatic competence 
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(Dennis, 1986; Pierce and Arango, 1986; Yamashita et al., 1984). Polylactosamine 
repeats may form on N-glycans but also on 0-glycans to a lesser extent. Studies have 
demonstrated that polylactosamine extensions are preferentially added to the 
GlcNAcP 1-6Manal -6(3 branch of N -linked oligosaccharides as a result of an increased 
activity of 31-3GnT which is responsible for the synthesis of polylactosamine (van den 
Eijnden et al., 1988). For instance in colon cancer (31-3GnT activity is increased and 
this results in an increased synthesis of the polylactosamine structures. These structures 
may bear blood group determinants which may be functionally involved in malignancy. 
For example SLe' on polylactosamine extensions of colon cancer cells exhibits a more 
invasive phenotype when implanted in nude mice (Saitoh et al., 1992). 
The acquisition of large N-glycan structures in cancer development due to 
polylactosamine extensions is the result of increased (31-6 branching and increased 
levels of polylactosamine extensions in rodent cells have been correlated with increased 
levels of the enzyme responsible for the synthesis of ß 1-6 branching structures, G1cNAc 
transferase V (GnTV, Yousefi et al., 1991). Several studies have reported increased f 31- 
6 branching in human carcinomas of the breast and colon (Dennis and Laferte 1989; 
Fernandes et al. 1985) and the overexpression of GnTV was associated with increased 
invasion and metastasis in various tumour types (Yagel et al., 1989). 
The lectin L-PHA recognises (31-6 branched structures and has been used to 
study the involvement of 131-6 branched structures in cancer development and 
metastasis. The mutant lymphoma cell line MDA-D2 which displays large amounts of 
polylactosamine and (31-6 branches (as recognised by L-PHA lectin) was highly 
metastatic in nude mice whereas mutant cells without GntV activity which did not 
synthesise these glycan structures were resistant to L-PHA-mediated cell killing. 
Moreover the L-PHA resistant cells were no longer metastatic and this provided the first 
evidence of the importance of polylactosamine extensions and (31-6 branching in 
metastasis (Dennis et al., 1987). 
Inhibitors of N-linked glycans synthesis which result in abrogation of 
biosynthesis of polylactosamine extensions and 131-6 branching have been used in 
numerous studies. For instance melanoma cells treated with swainsonine display a 
decreased metastatic potential in the nude mouse model (Dennis et al., 1987). Changes 
in N-linked glycosylation play a key role in cancer progression and could be used as 
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biological markers, for example the N-linked oligosaccharide on prostate specific 
antigen (PSA) is altered in the serum from patients with prostate cancer (Tajiri et al., 
2007). This alteration in glycosylation may allow discrimination between patients with 
benign prostatic hyperplasia and prostate cancer both of who may present clinically with 
elevated levels of PSA. 
1.3.5.4 Sialylation 
The negative charge conferred to the polypeptide by sialic acid residues may 
modulate cell-cell and cell-environment interactions. Alterations in quantity, 
distribution, the type of sialic acid and bonding to neighbouring sugars have been 
reported in cancer (Bhavanadan and Furukawa, 1995). The use of the lectin SNA to 
detect sialic acid on colorectal cancer cells has shown an increase in N-acetylneuraminic 
acid containing glycans in this type of cancer (Dall'olio and Trere, 1993) and a study 
using an immunodefficient murine model has shown the role of N-acetylneuraminic 
acid in metastasis (Saitoh et al., 1992). 
The extent of sialylation appears to be an important factor in cancer formation 
(and metastasis) and a loss of cancer cell adhesion has been attributed to the cells 
expressing increased levels of sialic acid (Dennis et al., 1989; Dennis, 1986). 
The observations of several studies, taken together with the importance of 
sialylation on the Lewis determinants in tumourigenesis, suggests that sialylation may 
play an important role in malignancy. 
1.4. Glycoproteins and cancer 
Cell-cell and cell-substratum interaction have long been established as essential 
for the survival of the human cells. During development and cell migration, the contacts 
established by epithelial cells with their surroundings, such as the ECM or neighbouring 
cells, plays an essential role in cellular behaviour. The integrity of the epithelia relies on 
the connections established between cells and between cells and the ECM, these 
interactions are mediated by glycoproteins and proteoglycans. Cell adhesion molecules 
(CAMs) are cell surface glycoproteins with a large extracellular domain, a membrane 
spanning region and a cytoplasmic domain. Although their primary function is to 
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maintain tissue structure via cell-cell and cell-substratum interactions, they are also 
involved in cell migration, differentiation cell signalling and gene transcription 
(Goodison et al., 1999). CAMs involved in cell-cell and cell-matrix interactions are 
altered during progression to tumour malignancy. Alterations in CAMs modify adhesion 
processes and may modulate intracellular signalling (reviewed by Christofori, 2003). 
More than 50 CAMs have been identified and can be organised in superfamilies. The 
largest superfamilies will be treated in this chapter; mucins, cadherins, 
immunoglobulin-like CAMs, selectins, integrins and proteoglycans. 
1.4.1 Cell adhesion molecules 
1.4.1.1 Cadherins 
Many human cancers originate in epithelial cells which are, in normal conditions, 
tightly organised and maintained by a number of specific junctions such as tight 
junctions, adherens-type junctions and desmosomes. These are connected to actin and 
intermediate filaments of the cytoskeleton and constitute a tightly bound structure. 
Cell-cell adhesion is often mediated by cadherins, a family of Ca 2+ dependent 
glycoproteins and in epithelia, they mediate cell-cell adhesion at adherens junctions via 
homophilic protein-protein interactions. 
E-cadherin expression is lost during tumourigenesis. Birchmeier and Behrens 
(1994) suggested that loss of E-cadherin function is a prerequisite for tumour cell 
invasion and several other studies have shown that loss of E-cadherin expression is 
accompanied by the acquisition of an invasive phenotype. Further studies on cell lines 
have demonstrated that re-expression of E-cadherin by invasive cell lines (which had 
previously lost E-cadherin) resulted in a reversion from an invasive to benign cellular 
phenotype (Vleminckx et al., 1991). 
1.4.1.2 Selectins 
The selectin family is composed of E-selectin, L-selectin and P-selectin. E- 
selectin is expressed soley on endothelial cells, P-selectin is expressed on platelets and 
endothelia and finally L-selectin is present on leukocytes. Selectins are calcium- 
dependent type 1 transmembrane glycoproteins. Structurally, they consist of a short 
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intracellular C-terminal domain and a single transmembrane domain. The extracellular 
domain is composed of varying numbers of short consensus repeats (SCRs) which act as 
spacers between the N terminal domain and the plasma membrane. In humans L-, E-, 
P-selectins possess respectively 2,6 and 9 SCRs. The N terminal domain of selectins is 
aC type (Ca 2+ dependent) lectin-like domain which mediates interaction with small 
sialylated, fucosylated carbohydrate ligands such as SLe" and SLea (Bresalier et al., 
1998). In normal conditions monocytes and neutrophils express SLea- and SLe'- 
containing carbohydrates and their binding to selectins has been shown to participate in 
the recruitement of leukocytes to sites of tissue damage binding to the selectins on 
activated endothelial cells (reviewed in Nangia-Makker et al., 2002). SLe" is an 
oncofetal antigen that has been shown to be expressed in various cancers including 
colon cancer (Itzkowitz et al., 1986). The amount of SLe" expressed by cancer cells has 
been linked to metastasis and patient survival (Ono et al., 1996; Nakamori et al., 1993). 
SLe" plays a role in metastasis via its ability to interact with selectins. Selectins have 
been involved in several aspects of carcinogenesis. E and P selectins have been shown 
to be related to angiogenesis by inducing neovascularisation (Koch et al., 1995). L 
selectin binding to tumour cells may facilitate metastasis in a murine model (Qian et al., 
2001). Moreover when colorectal cancer cells were implanted into P-selectin deficient 
mice, a reduced number of lung metastases was observed and this correlated with a 
decrease in the number of tumour cell-platelet aggregates (Kim et al., 1998). It has been 
suggested that the tumour cell-platelet complex occurs via adhesion to P- selectins and 
this is one of the mechanisms by which tumour cells escape the host immune system 
during the metastatic process (Honn et al., 1992). The selectins mainly bind to mucin- 
type glycoproteins or O-linked glycoproteins that exhibit glycan structures SLea, SLe". 
Such glycans are often the result of altered glycosylation in cancer cells (described 
earlier) and their overexpression has been linked to increased metastatic potential and 
poor patient prognosis. 
1.4.1.3 Immunoglobulin-like CAMs 
The Immunoglobulin-like CAMs (Ig-CAMs) possess Ig-like folds in their 
extracellular domain and are involved in homophilic interaction (Tang and Honn, 1995). 
Carcinoembryonic antigen (CEA) is an Ig-CAM and has been used as a marker of 
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malignancy and for measuring response to treatment in colorectal cancer (Fearon et al., 
1991; Benchimol et al., 1989). 
1.4.1.4 Hyaluronate receptor CD44 
CD44 is a cell surface proteoglycan and is a member of the hyaluronate receptor 
family. There are multiple CD44 isoforms that originate from splice variants of a single 
CD44 gene (Goodison et al., 1999). CD44 is a single polypeptide chain oriented with its 
large N terminus domain on the outside of the cell, and C terminal domain in the cytosol. 
Its major ligand is hyaluronic acid (HA) an extracellular polysaccharide component of 
the ECM. CD44 is the most commonly expressed isoform in mammalian cells although 
some epithelial cells express the larger isoform CD44E. CD44 is involved in a variety 
of functions such as maintenance of the structure of organs and tissues, cell movement 
and cell aggregation of macrophages, lymphocytes and fibroblasts via its HA binding 
site. CD44 exists as several isoforms which enables binding to a variety of ligands, for 
example, osteopontin, serglycin, collagen, fibronectin and laminin. All CD44 isoforms 
contain the HA binding site and it has been shown that loss of CD44 N-glycosylation 
abrogates HA binding (Lesley et at, 1995). CD44 molecules which bind to HA may 
play a role in cancer development and invasion (Sy et al., 1991). Tumour cells express 
multiple unusual isoforms of CD44 as compared to normal tissues and this abnormal 
expression may result in changes in HA binding and may influence tumour growth 
(Stamenkovic et al., 1989). Studies in animal models have shown that increased 
expression levels of CD44 proteins results in a more invasive phenotype (Birch et al., 
1991). Gunthert et al. (1991) first investigated the impact of increased expression of 
CD44 in non-metastatic rat pancreatic cancer cells with respect to cancer progression 
and invasion. Over expression of CD44v conferred metastatic potentiality to the cells 
whereas CD44s did not. Variant v6 and v7 modulated the invasive behaviour of cancer 
cells independently of their ability to bind HA (Gunthert et al., 1991; Seiter et al., 1993). 
More recent studies have used the metastatic colorectal cancer cell line HT29 and 
silenced CD44v6 by an antisense approach. Down-regulation of CD44v6 did not 
abrogate the capacity of HT29 cells to bind to hyaluronan but did diminish their ability 
to form liver metastases in nude mice (Reeder et al., 1998). 
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1.4.1.5 Integrins 
The integrin superfamily is a family of extensively glycosylated glycoproteins 
which emerged in metazoa over 600 million years ago (Hynes, 1992; Hynes and Zhao, 
2000). It is a large family of at least 24 ocß heterodimeric type I transmembrane 
glycoproteins. Integrins are composed of two subunit a and (3 noncovalently attached 
together. To date there have been 18 a and 8 (3 chains characterised and these have been 
shown to form 24 different heterodimers. The 24 c43 combinations are presented in 
Figure 1.10, the a subunit has one (3 subunit partner with the exception of a6, a4 and 
ccV which form heterodimers with several 1 subunits. 
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Figure 1.10: Integrin family members. 
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The a and ß subunits possess an extracellular domain and, by noncovalent 
interaction, these form the ligand binding site (Figure 1.11). The a and (3 subunits also 
have a small hydrophobic transmembrane region and a cytoplasmic domain (Loftus et 
al., 1990, Vogel et al., 1990). The extracellular domain of the integrins plays a central 
role in cell-cell, cell-ECM recognition and adhesion. An inserted domain of - 200 
residues, termed the I domain is present in several a subunits (ul, a2, alO, all, 
aE, aL, aM, (xX and aD). The I domain and the ß subunit of the integrins have a ligand 
binding activity via the metal-ion dependent adhesions site (MIDAS). Integrins are 
essential for cell migration, cell differentiation, proliferation and survival. 
These 
functions also confer important roles for the integrins in the development of an adult 
organism (Hynes 1992). Integrins function as receptors 
for ECM but also as cell surface 
counter receptor and as receptors for some soluble plasma proteins. 
The expression of 
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integrins is cell type dependent, for example aII03 is platelet-specific and recognises 
fibrinogen and fibronectin, similarly in leukocytes all (32 integrins and aE(37 are 
involved in cell-cell interactions. Epithelials cells express mainly integrins that bind to 
the ECM and include the followings, al(31, a2(31, a3(31, a5ß1, a6J31, a9(31, a604, 
(Wp5and aVß6. a1131 and a2131 recognise principally collagen, in particular collagen I 
and collagen IV. a901 is a receptor for tenascin C and osteopontin, a3131 and a6ß1 
recognise laminin isoforms. a6ß4 is laminin receptor with a specificity for laminin-5 as 
well as a component of hemidesmosomes. W(31, aV J36 and a501 are vitronectin 
receptor which are expressed in response to injury (reviewed in Gilcrease, 2007). 
Alterations in integrin structure and expression are associated with cancer and 
metastasis (Ruoslahti and Giancotti, 1989). The loss of polarized integrin expression is 
a common feature of malignant cells, for instance integrin a6J34, is mainly localised in 
the hemidesmosome of the basal surface of epithelial cells and sustains changes in 
expression in cancer. Here a6ß4 becomes more localized at the leading edge of the 
invading carcinoma cells (Rabinovitz et al., 1999; Chao et al., 1996; Rabinovitz and 
Mercurio, 1996; Mercurio et al., 2001). Loss of polarisation of a6 subunit has also been 
shown in ovarian cancer (Bottini et al., 1993) and in breast carcinoma an up regulation 
of a6 has been correlated with reduced survival (Friedrichs et al., 1995) although other 
studies have found a6j34 to be down regulated in aggressive breast cancer (Natali et al., 
1992; D'ardenne et al., 1991). Integrin a2ß1 has been associated with malignant 
transformation and its down regulation is the most common type of alteration in integrin 
expression that has been associated with malignant transformation (Pignatelli and 
Stamp, 1995). Integrin a2(3l has been shown to be down-regulated in several types of 
cancer for example colon, breast, pancreatic and lung carcinoma (reviewed in Gilcrease, 
2007). 
he integrins are important molecules in CRC and it has been suggested that 
a6(31 and 0604 play a role in invasion and migration through the ECM via adhesion to 
laminin. It seems that although there is a tendency towards decreased integrin levels 
during tumour progression, numerous reports suggest a great heterogeneity of integrin 



























Figure 1.11: The two types of Integrin structures: The a and (3 subunit of an integrin 
associate by noncovalent interaction to form a ligand binding site via the metal-ion 
dependent adhesion binding site (MIDAS) as shown on the left-hand side of the 
diagram. Several a subunits possess an inserted domain (I domain) which comprise the 
MIDAS domain and form a ligand binding site when associated with the appropriate (3 
subunit (right-hand side of the diagram). All f3 subunits posses four EGF-like cysteine 
rich repeats and a subunits comprise Ca 2+ binding sites. 
1.5. Lectins and cancer 
1.5.1 History of lectins 
Lectins are sugar-binding proteins of non-immune origin that agglutinate cells or 
precipitate glycoconjugates and were first identified in the 19th century by Peter Herman 
Stillmark (1888) who described a protein extract from the seeds of the castor tree 
(Ricinus communis) which had the ability to agglutinate erythrocytes and this was 
termed a haemagglutinin (Reviewed in Franz, 1988). The first lectins to be described 
were plant lectins although Mitchell observed agglutination activity in snake venom 
before 1860 but this was described as an "antibody-like factor". In the 1940's the ability 
38 
of plant lectins to specifically agglutinate A, B and 0 erythrocytes was discovered and 
later, specificity towards other blood group substances and antigens such as T and Tn 
were also described. The lectin HPA was one of the first blood group A specific lectins 
of animal origin to be described (Uhlenbruck and Prokop, 1966; Hammarstrom and 
Kabat 1969) and HPA remains one of the most specific blood group A lectins described. 
Lectins have played a crucial role in determining the sugar composition of antigens 
associated with the ABO blood group system. Their use also led to the observation that 
cells possess glycans on their surfaces (reviewed in Morgan and Watkins, 2000). The 
discovery of the first mammalian lectin occurred in 1974 with the isolation of the 
galactose specific hepatic asialoglycoprotein receptor from rabbit liver (Stockert et al., 
1974). 
In animals the main function of lectins are the recognition of molecules in the 
immune system. In invertebrates lectins are thought to act as primitive immune 
molecules directed against pathogens by virtue of their ability to recognise the 
extracellular oligosaccharides of microorganisms. In humans several lectins such as the 
mannan-binding lectin, ficolins and the membrane-bound macrophage mannose 
receptor mediate elimination of pathogens (reviewed in Kilpatrick, 2002). Several cell 
adhesion molecules with lectin activity, for example selectins and CD44 have been 
identified in humans and these are involved in cell recognition and cell trafficking. 
Galectins-1 have immuno-regulatory properties in animals (Levi et al., 1983; Offner et 
al., 1990; Santucci et al., 2000) and cytokines play a role in immune-regulation via 
lectin-like interactions (Fukushima and Yamashita, 2001). 
Several findings have led to an interest in lectins in cancer research, in particular 
the ability of some lectins to bind preferentially to malignant cells. The first observation 
concerning recognition of malignant cells by lectins was by Aub et al. (1965) who 
discovered that wheat germ agglutinin (WGA) recognised cells with a malignant 
phenotype. Since that time many lectins have been tested to evaluate their ability to bind 
differentially to normal and cancerous cells. The differential binding of lectins to 
normal and cancer cells has shown that alterations in glycosylation occur during 
malignant transformation. For instance in colon cancer the lectins from Erythrina 
cristagalli (ECA) and Enythrina corallodendron (EcorA) display altered binding as 
compared to normal colonic epithelia (Baldus et al., 1996). Other lectins such as 
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Dolichos biflorus agglutinin (DBA), Ulex europaeus agglutinin-1 (UEA-1) and WGA 
have shown differential binding between normal and cancerous colorectal cells 
(Iwakawa et al., 1996; Sams et al., 1990). The lectin HPA extracted from the Roman 
snail Helix pomatia has attracted interest as its binding has been associated with poor 
patient prognosis and the lectin has been suggested to be a useful tool for identifying 
aggressive cancer including colorectal cancer (Ikeda et al., 1994; Schumacher et al., 
1994a, 1994b). 
1.5.2 HPA 
Helix pomatia agglutinin (HPA) is a lectin extracted from the albumen gland of 
the Roman snail. The lectin is thought to function in the innate immune system of the 
snails by conferring protection for the fertilized eggs. The lectin has been shown to be 
capable of aggregating bacterial pathogens and Herpes virus (Kholer et al., 1973; 
Patchett et al., 1991; Slifkin and Cumbie, 1989). HPA has a binding specificity for the 
Forssman antigen (aGalNAc l -3 Ga1NAc-R), the blood group A antigen (aGa1NAc l- 
3 [aFuc 1-2]Gal), Cad antigens (Baker et al., 1983), the Tn antigen ((xGa1NAc-Ser/Thr) 
(Springer, 1989), Ga1NAc, G1cNAc (Hammarstrom and Kabat, 1969) and also sialic 
acid (Saint-Guirons et al., 2007). HPA is a 79kDa hexamer which contains 7% 
carbohydrate and is composed of identical monomers present in at least 12 glycoforms 
(Vretlab et al., 1979), the lectin is a trimer of covalently-bound dimers (Hammarstrom 
and Kabat, 1969; Hammarstrom et al., 1972 Vretlab et al., 1979). Mass spectrometry 
data indicate that the HPA monomer, dimer and hexamer are 12.7 kDa, 24.6 kDa and 76 
kDa respectively. The crystal structure of HPA has been recently solved by Sanchez et 
al. (2006). The HPA monomer is formed of six anti-parallel (3-sheets connected by 
short loops, which form a ß-sandwich structure stabilised by a disulphide bridge 
between cysteine 9 and 80. The dimers then associate together to form trimers. There is 
one Ga1NAc and Zn 2+ binding site in each monomer at the opposite side of the 
dimerisation site, as shown on Figure 1.16. The sugar binding site is formed in the 















Figure 1.12: HPA structure. Panel A shows the structure of HPA alone obtained with a resolution of 2.5 





In addition to the ability of HPA to specifically agglutinate human blood-group 
A erythrocytes, it has been demonstrated that HPA binds preferentially to cancer cells 
with a metastatic phenotype. Leathem et al. (1983) first observed the preferential 
binding of HPA to breast cancer cells as compared to normal breast cells. These 
findings were later corroborated by Leathem and Brooks (1987a) who reported an 
association between the expression of HPA-binding glycans in breast cancer cells and 
metastatic phenotype. Numerous studies (Fenlon et al., 1987, Fukutomi et al., 1989, 
1991; Alam et al., 1990; Noguchi et al., 1993 a, b; Thomas et al., 1993) have confirmed 
the prognostic significance of the lectin including a large study carried out by Leathem 
and Brooks (1991) using 373 primary breast cancers with 24-year patient follow-up. 
They demonstrated that the HPA staining of primary tumours and the presence of lymph 
node metastases were significantly related although no correlation was made with 
tumour size, histological grade or age at diagnosis. The prognostic significance of HPA 
has also been demonstrated in other types of cancers such as oesophageal (Yoshida et 
al., 1994; Takahashi et al., 1994), gastric (Kakeji et al., 1991,1994), prostatic (Shiraishi 
et al., 1992), lung (Kawai et al., 1991) and colorectal (Ikeda et al., 1994; Schumacher et 
al., 1994 a, b) cancers. Ikeda et al. (1994) have studied the HPA staining pattern in 117 
CRC tissue samples and showed a positive correlation between HPA-staining and the 
occurrence of lymph-node metastases. This was confirmed by Schumacher et al. (1994a) 
in a study of 130 CRC tissue samples. In this study they found that the binding of HPA 
to primary CRC cells was associated with poor prognosis, with similar outcome of 
patients with HPA positive tumours as those of Dukes stage C. The observations made 
on cell lines and tumours from SLID mice with respect to HPA binding corroborate the 
previous statement about the prognostic utility of the lectin. However it has been shown 
that the local environment modulates the expression of carbohydrates associated with 
metastasis (Schumacher et al., 1994b; Schumacher and Adams, 1997). 
Several groups have failed to establish a relationship between HPA binding and 
poor cancer prognosis (Galea et al., 1991; Taylor et al., 1991; Gusterson et al., 1993). It 
has been argued that the reasons for the differences in the results were methodological, 
in particular that an indirect method of detection for histochemistry-based studies is 
preferred (Brooks et al., 1996). 
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HPA has the ability to preferentially bind to metastatic cancer cells and may be useful 
as a prognostic marker in a range of solid tumours. Approximately 80% of metastatic 
tumours contain HPA binding epitopes (Brooks and Leathern 1998-1999) and an 
association between HPA binding to cancer cells and metastasis in vivo has been 
described (Schumacher et al., 2005). Despite the evidence of its utility HPA does not 
yet have a role in clinical decision-making for any tumour type, and the glycoproteins of 
HPA binding cancer cells have similarly never been defined. It was initially 
hypothesized that HPA simply detects cancer cells over-expressing blood group A 
substance but this was discounted (Brooks and Leathern, 1995). Extraction of cancer- 
associated HPA-binding glycans revealed that they contain both N-acetylgalactosamine 
(Ga1NAc) as well as sialic acid and the predictive power of HPA was lost when cancer 
tissue sections were pretreated with neuraminidase (Fenlon et al., 1987). A seemingly 
diverse range of glycan structures bind to HPA including GalNAcal-3Ga1NAc, 
Ga1NAca-Ser/Thr (Tn antigen) and the Forssman antigen. With the exception of the Tn 
antigen (Chen et al., 1995; Piller et al., 1990), the relevance to cancer of these antigens 
and the proteins to which they are attached has not been established. However the HPA 
binding partners found on the cancer cells have been incompletely characterised. Their 
further characterisation (elucidation) will provide new insights into the understanding of 
the role of HPA binding partners in cancer progression. 
The aim of this research project were to establish a robust, reproducible in vitro 
model of HPA binding to CRC cells and, using a proteomic approach, to identify the 
cell surface glycoproteins recognized by HPA in the metastatic CRC cell lines. The 
secondary aim of the project was to evaluate whether the proteins identified in the 
metastatic CRC cell lines were also present in tissue specimens collected from patients 
with CRC. 
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1.6. The work described in this thesis 
The work described here is in four parts: 
1) The development of an approach using confocal microscopy and fluorescently 
labelled HPA was undertaken in order to localise with precision the HPA-binding 
glycoproteins on the membrane of HT29. A new type of microtitre plate assay was 
developed to evaluate the binding of HPA on a large population of cell (>100000 cells) 
and hence provide statistically significant data. This new method aimed to evaluate the 
intensity of the HPA binding to the three cell lines HT29, SW620 and SW480 as well as 
providing insights into the sugar composition of the glycotope recognised by the lectin 
(Chapter 3). 
2) A method to prepare a membrane-enriched fraction from HT29 was developed 
in order to concentrate the HPA-binding proteins, which are mainly localised in the 
membrane of HT29. The conditions of solubilisation and separation of these proteins 
were also optimised in order to obtain a robust 2-DE based method suitable to analyse 
the composition of the HPA-binding proteins as well as their changes of expression 
(Chapter 4). 
3) The characterisation of the HPA binding glycoproteins of the metastatic cell line 
HT29 was undertaken using western blotting with HPA. The proteins were separated by 
1-DE to obtain an overview of the HPA binding glycoproteins, which are localised in 
two main bands, GP130 and GP80.2-DE was used to provide insights into the 
composition of the main HPA binding protein band GP 130. A strategy using affinity 
chromatography and 2-DE was developed to concentrate and separate the HPA-binding 
proteins into single polypeptide in order to be identified by MS MALDI-TOF and hence 
understand the clinical significance of HPA (Chapter 5). 
4) Finally a preliminary study was undertaken on human tissue samples in order to 







2.1. Cell lines 
The three cell lines, HT29, SW620 and SW480 have been extensively studied as 
models of metastasis in relation with HPA binding. In particular HT29 and SW480 have 
been studied in vitro and in animal model and proved to be consistently metastatic and 
non-metastatic respectively when implanted in SCID mice (Schumacher et al., 1994a; 
Schumacher and Adams, 1997). An other interesting feature resides in the common 
origin of SW480 and SW620, which constitute a unique model for studying the later 
stage of CRC progression ( Zhao et al., 2007; Liang et al., 2007; Kim et al., 2004). 
SW480 was derived from a Duke's B primary tumour of the colon and SW620 was 
derived from mesenteric lymph node metastases of the same patient six months later 
and has been shown to be more metastatic than SW480 in vitro (Hewitt et al., 2000). 
Also shared marker chromosomes were seen (Gagos et al., 1995) and confirmed a 
monoclonal origin of the two cell lines. The model used in our study is hence composed 
of a highly metastatic cell line (HT29), a moderately metastatic cell line (SW620) and a 
non-metastatic cell line (SW480). More over the phenotypic difference of SW620 and 
SW480 are likely to be associated with malignant progression and hence confirm the 
suitability of our model to study the process of metastasis. An interesting feature of this 
model is the clonal origin of SW480 and SW620 which confer important similarities 
and the phenotypic differences of SW620 and SW480 are likely to be associated with 
malignant progression and constitute a suitable model to study the process of metastasis. 
However this remains an in vitro model and it does not reflect the heterogeneity of an in 
vivo tumour and the importance of the cellular environment in the complex phenomenon 
of metastasis. 
Human colorectal cancer cell lines HT29, SW480 and SW620 were kindly 
provided by Dr M Loizidou (Department of Surgery Royal Free and University College 
Medical School). The details of the three cell lines are given in Table 2.1. All the cell 
lines were grown in either 75 cm3 or 175 cm3 flasks (Falcon) maintained in Dulbecco's 
Modified Eagle's Medium, DMEM (Cambrex, Berkshire, UK) supplemented with 10% 
v/v foetal calf serum (Biosera) and 0.1% v/v gentamycin (Cambrex). All the cell lines 
were grown at 37°C with 5% CO2 (Hera Cell incubator 240), maintained by changing 
the media every two days and passaging every 5 to 6 days using standard trypsinisation 
protocols as follows: Briefly, cells were grown to approximately 80% confluence and 
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washed once with phosphate buffered saline, PBS (Sigma). Cells were then incubated 
for 3 to 5 min at 37°C with 0.5 g/l trypsin, 0.2 g/l EDTA (Sigma) made up in PBS until 
they rounded up and were then removed by gentle agitation and pipetting. Cells were 
pelleted at 400 g for 5 min, resuspended in media and diluted at a ratio of 1: 6 in a new 
flask. 
Cells used for protein extraction were grown to near confluence, washed in PBS, 
mechanically detached in PBS (Sigma) using a sterile plastic cell scraper, centrifuged at 
400 g in Centaur I MSE centrifuge and stored at -80°C until cell membrane preparation 
(Lehner et al., 2003) and protein extraction were performed. 
Cell ATCC Derived from Dukes 
lines number stage 
Reference 
HT29 HTB-38 Moderately differentiated N/A 
primary colon cancer. 44 year 
old female 
SW620 CCL-227 Lymph-node metastasis from C 
colon adenocarcinoma. 51 year 
old male 
SW480 CCL-228 Poorly differentiated primary B 






Table 2.1: The characteristics of the three cell lines HT29, SW620 and SW480 used in this study. 
2.2. Confocal microscopy 
Cells were grown in 6 well plates for 24 hours after passaging and fixed for 30 
minutes in 10% formalin in PBS (pH 7.4). After washing away the formalin with PBS, 
the fixed cells were incubated for 20 min at 37° C with 1 mg/ml trypsin (type II from 
porcine pancreas; Sigma). Trypsinisation was used as an antigen retrieval technique. For 
fluorescent lectin staining, cells were fixed and washed as above, and blocked in 5% 
w/v BSA for 30 minutes. Fluorescein isothiocyanide (FITC) and tetramethylrhodamine 
isothiocyanide (TRITC) conjugated lectins encompassing a range of binding sugars 
were used to stain the cells (Table 2.2). Cells were incubated in the 
dark after washing 3 
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times for 5 min in PBS and each lectin was used at 10µg/ml for one hour in lectin buffer 
(0.05 M TBS, 1 mM CaC12,1 mM MgC12 pH 7.6). All lectins (except HPA which was 
obtained from Sigma), were purchased from Vector Laboratories, Burlingame, CA. The 
nuclei were counterstained using To-Pro-3 (Molecular Probes, Eugene, USA) at 1 µM 
in PBS for 20 min after treatment with 100 gg/ml Ribonuclease A (Sigma) for 20 min at 
37°C in PBS. A DNAse free Ribonuclease A stock solution was prepared by boiling for 
10 min in 10 mM Sodium Acetate buffer (pH 5.2). As a negative control for lectin 
staining cells were incubated with buffer alone. 
Lectins Abbreviations Nominal Fluorophores 
binding 
sugars 
Concanavalin A Con A a-mannose FITC 
Wheat germ agglutinin WGA G1cNAc FITC 
Soybean agglutinin SBA cc/(3 Ga1NAc FITC 
Ulex europeaus UEA-1 a fucose FITC 
agglutinin 1 
Ricinus communis RCA-1 Gal/Ga1NAc FITC 
agglutinin 1 
Helix pomatia agglutinin HPA Ga1NAc/G1cNAc TRITC 
Dolichos b florus DBA a Ga1NAc FITC 
agglutinin 
Peanut agglutinin PNA Galactose FITC 
Table 2.2: The lectins used in this study and their putative binding sugars. 
2.3 Specificity of HPA binding assessed by confocal 
microscopy 
HPA-positive HT29 cells were grown in 6 well plates, fixed and blocked with 
BSA as described in section 2.2. The specificity of the lectin binding to HT29 was 
evaluated by assessing the intensity of the HPA staining (10µg/ml) after pre-incubation 
for 30 min with increasing concentrations of Ga1NAc (25mM, 50 mM and 150 mM). 
D-mannose (50 mM) was included in the experiment as a negative control. The cells 
were incubated in the dark with the HPA/sugar mixture for lh and counterstained with 
To-Pro-3. The intensity of the HPA staining was evaluated in 10 cells for each condition. 
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The average and standardised value for fluorescence intensity (representing the intensity 
of the HPA binding) were used to evaluate the specificity of interaction between HPA 
and its cellular binding partners in HT29. 
2.4 Confocal microscopy image capture 
Images were acquired by sequential scanning using a Leica TCS SP2 confocal 
system (Leica Microsystems, Milton Keynes, UK) and a X63 ceramic dipping objective 
at 1024x1024 format and scanning speed of 400 Hz with a line average of 2. A 488 nm 
(Intensity 25%) laser was used for the excitation of FITC, a 543 nm laser (Intensity 
100%) was used for TRITC, and a 633 nm laser (Intensity 35%) was used for To-Pro-3. 
Emission was recorded over the bandwidth of 500-550 nm (FITC), 553-630 nm (TRITC) 
and 650-720 nm (To-Pro-3). These parameters are summarised in Table 2.3. the 
background was compensated by adjusting the Gain and Offset commands in order to 
minimise the noise. For 3D images, Z-stacks with increments of 1 µm were scanned. 
Excitation Emission Laser 
Fluorophore 
Wavelength (nm) Bandpass (nm) Intensity (%) 
FITC 488 500-550 25 
TRITC 543 550-630 100 
To-Pro-3 633 650-720 35 
Table 2.3: Spectra parameters of fluorophores and the intensity of lasers used for confocal imaging. 
2.5 Image 3D reconstructions and 2D models 
3D reconstructions were produced using the Imaris® 4.0 software from 
Bitplane®-AG to combine the Z-stacks obtained by confocal microscopy. 2D models 
were made using the Imaris Surpass® tool from Imans® 4.0 after baseline correction. 
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2.6 Data analysis of images from confocal microscope 
Relative quantification of lectin binding was performed using the Confocal 
Analysis Package (Leica Microsystems, Milton Keynes, UK). The method developed 
previously by Kerrigan and Hall, (2005) was used as follows. For repeatable and 
unbiased analysis, two linear profiles through the centre of each cell were drawn 
avoiding regions of cell-cell contact, where possible. The fluorescence along each line 
was determined using the Leica software. The mean data acquired every 0.0125 gm for 
22 cells (per cell line) was calculated using Microsoft Excel®. The background 
fluorescence signal was determined by drawing and averaging at least 10 individual 
linear profiles from areas with no cells and was used to subtract from each value 
calculated from the linear cell profile. 
The data was expressed as mean maximal fluorescence ± standard error of the 
mean using SigmaPlot® (Jandel Scientific, Ekrath, Germany). 
2.7 HPA binding assay using microtitre plate format 
HT29, SW620 and SW480 cells were harvested and pelleted by centrifugation at 
400g as before and resuspended in lml PBS. 100 µl of the cell solution was mixed with 
100 µl of 0.2% Trypan blue (Cambrex) and a cell count was performed using a 
haemocytometer and a light microscope. 100 000 cells were seeded into each well of a 
96 well microplate (Falcon) and allowed to settle for 12 hours. The lectin staining 
procedure is similar to the one described earlier. Briefly, cells were fixed for 30 min in 
10 % formalin prepared in PBS. Cells were washed 3 times each for 5 min in PBS to 
remove the formalin solution and incubated for 20 min at 37°C with 1 mg/ml trypsin. 
The cells were washed again and incubated for 30 min in 5% w/v BSA as a blocking 
step. The cells were then incubated with 10 µg/ml biotinylated-HPA for 2h and 4 µg/ml 
FITC-conjugated streptavidin for 1 h. As a negative control cells were incubated only 
with FITC-conjugated streptavidin. Fluorescence readings were acquired using a 
fluorescent microplate reader (Fluostar Optima, BMG Labtech). The fluorescence 
emission was read from the bottom of each well at 544 nm after excitation at 485 nm. 
The fluorescence intensity was calculated from an average of 81 readings taken from 
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each well. A negative control without lectin was included in each experiment and the 
resulting average fluorescence was used to normalise the data. The experiments were 
performed in six replicates. The experimental layout is presented in the Figure 2.1. 
Replicates 
HT29 + HPA + Streptavidin 
HT29 + Streptavidin (negative control) 
SW620 + HPA + Streptavidin 
SW620 + Streptavidin (negative control) 
SW480 + HPA + Streptavidin 
SW480 + Streptavidin (negative control) 
ooaoao 
000000 000000 000000 000000 000000 
Figure 2.1: HPA binding to HT29, SW620 and SW480. Experiment layout 
2.8 Assessing the specificity of HPA binding using the 
microtitre plate assay 
For each of the three cell lines used, the specificity of HPA binding was 
evaluated using four sugars: G1cNAc, Ga1NAc, SA and mannose. One separate 96-well 
microplate was used for each sugar tested. As shown on the experimental layout in 
Figure 2.2, the cells were incubated with HPA alone or HPA preincubated with 20 mM, 
50 mM and 250 mM of appropriate sugar as before and finally with streptavidin alone 
as a negative control. The cells were incubated with the HPA/sugar mixture for 2 hours 
followed by streptavidin-FITC (Figure 2.2). A negative control (without lectin) was 
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Figure 2.2: Experimental layout for inhibition experiments of HPA binding to HT29, SW620 and SW480. 
2.9 Cell lysate preparation 
Colorectal cancer cells were grown to confluence in 175 cm3 tissue culture 
flasks (Falcon) and harvested using a sterile cell scraper (Falcon) into 20 ml PBS as 
described in section 2.1. Cells in suspension were centrifuged for 5 min at 400 g in a 
bench top Centaur I MSE centrifuge before being stored as a dry cell pellet at -80°C. 
Cell pellets were resuspended and proteins solubilised in 3 ml of lysis solution 
U7M/T2 containing urea 7M, CHAPS 4% w/v, DTT 1% w/v, ampholytes 2% v/v and 
thiourea 2M (added after protein assay), by sonication using an ultrasonic probe (MS73 
Status 200) at 40% power, 5 times for 10 seconds with intermittent cooling on ice cold 
water. Cellular debris were removed by centrifuging the cell lysate in a Sorvall Super 
T21 centrifuge with SL50T rotor for 30 min at 11,000 g before the protein concentration 
was determined. 
2.10 Preparation of a membrane-enriched fraction 
Microsomes were prepared from frozen cell pellets by ultracentrifugation using 
a modified version of the procedure described by Lehner et al. 
(2003). The preparation 
process is summarised in Figure 2.3. 
Briefly, the colorectal cancer cell lines were disrupted using an ultrasonic probe 
MS73 Status 200 at 40% power, 5 times for 10 seconds in 3 ml of 150 mM KCI. The 
homogenate was centrifuged at 11,000 g for 30 min at 4°C to pellet the cell 
debris and 
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nucleic acids. The supernatant was subsequently centrifuged for lh at 170,000 g at 4°C 
(Sorvall Discovery 90SE ultracentrifuge with rotor T-865). At this stage soluble 
proteins in the supernatant were separated from the pellet containing microsomes. The 
pellet was re-suspended in 150 mM KC1, and sonicated as before and centrifuged for a 
further lh at 170,000 g at 4°C to pellet the microsomes. The membrane-enriched 
proteins were then solubilised using 1 ml of the lysis buffer U7M/T2 described in 
section 2.9, prior to protein assay. Several preparations were performed to evaluate the 
reproducibility of the method and its efficiency to concentrate the HPA-binding protein 
in the membrane-enriched fraction. No charaterisation of the purity of the membrane 






Spin at 11,000 g 30 min 4°C 
DNA Supernatant 
pellet 




Spin 1h at 170,000 g, 4°C 
supernatant Microsome 
pellet 
Solubilise proteins in 
Figure 2.3: Schematic diagram showing the preparation of a membrane enriched fraction. Cells 
were disrupted by sonication in 150 mM KC1. The cell lysate was then centrifuged at 11,000 g 
in 
order to remove the cell debris and the nucleic acids from the cellular solution. The supernatant 
was centrifuged at high speed (170,000 g) in order to pellet the cellular membranes prior to protein 
extraction. 
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2.11 Protein solubilisation 
A total of four solubilisation buffers were investigated for their suitability as 2- 
DE solubilisation buffers (Görg et al., 1999). The compositions of the complete 2-DE 




U Urea 9M, CHAPS 4%, DTT 1 %, Ampholytes 1% 
T Urea 7M, Thiourea 2M, CHAPS 4% w/v, DTT 1% w/v, 
Ampholytes 1% v/v 
U7M/T Urea 7M, Thiourea 2M, CHAPS 4% w/v, DTT 1% w/v, 
Ampholytes 1% v/v (Thiourea added after protein assay was 
performed) 
U7M/T2 Urea 7M, Thiourea 2M, CHAPS 4% w/v, DTT 1% w/v, 
Ampholytes 2% v/v (Thiourea added after protein assay was 
performed) 
Table 2.4: The solubilisation buffers used in this study and their composition. 
2.12 Protein assay 
Three protein assay kits were tested for compatibility with the chemicals used to 
make the solubilisation buffers; (i) Bradford reagent (Sigma) based on the original 
method developed by Bradford (Bradford, 1976), (ii) DC protein assay kit (Bio-Rad) 
and (iii) RCDC protein assay kit (Bio-Rad), both based on the original method 
developed by Lowry (Lowry et al., 1951). 
Bovine serum albumin, BSA (Sigma) was used as the protein for the generation 
of standard calibration curves. BSA solutions were prepared in lysis buffers 1 to 4 
(Table 2.5) at a concentration ranging from 0.25 mg/ml to 2 mg/ml and were assayed 
using the Bradford, DC and RCDC protein assay according to the manufacturer's 
recommendations. The protocols are shown in Appendix 2. 
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The concentration of protein in the cell lysates, membrane protein preparations and 
tissue sample lysates were determined using the Bradford reagent (Sigma) which was 
found to be the most suitable system to allow compatibility with the buffers used. 
Buffers Composition 
1 Urea 7M, CHAPS 4% 
2 Urea 7M, CHAPS 4%, DTT 1% 
3 Urea 7M, CHAPS 4%, Ampholytes 2% 
4 Urea 7M, CHAPS 4%, DTT 1%, Ampholytes 2% 
Table 2.5: Buffer composition used for protein assay 
2.13 1-D electrophoresis (1-DE) 
Whole cell lysate or cell membrane proteins prepared and assayed as described 
earlier, were separated by SDS-PAGE according to the method developed by Laemmli 
(1975). Briefly, a suitable volume of cell lysate or enriched cell membrane proteins to 
obtain between 5 and 20 µg of protein in a maximal volume of 10 µ1 were mixed with 
an equal volume of two times Laemmli reducing buffer (125 mM Tris-HC1 pH 6.8,5% 
glycerol (v/v), 4% SDS (w/v), trace of bromophenol blue, 10% (3mercaptoethanol). The 
samples were boiled for 5 min to achieve complete denaturation of the proteins and 
were allowed to cool to room temperature before being loaded on the SDS-PAGE gel as 
detailed below. 
2.14 SDS-PAGE 
Protein samples along with protein molecular weight markers (Bio-Rad or GE 
Healthcare) were loaded on either 10 % or 12% SDS PAGE gels and electrophoretically 
separated in running buffer (25 mM Tris, 192 mM Glycine, 0.1% SDS pH 8.3) at 150 V 
for Ih to 1hl5min in the Mini Protean 3 gel system (Bio-Rad). A stacking gel (4%) was 
poured over the resolving gel in order to ensure better separation by concentrating the 
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proteins into a thin zone (the stack) prior to separation in the separating gel. All the 
buffers and recipes are summarised in Appendix 3. 
2.15 Data analysis 
Digital images of I DE separations and Western blots were obtained using 
transillumination with white light and a UVP Biochemi Image Capture System. The 
Labworks software (UVP) enabled the analysis of electrophoretically separated proteins 
by calibration of protein gels and Western blot membranes using molecular weight 
marker proteins. A lane profile and intensity histogram was obtained with relative 
intensity values for each of the bands detected. 
2.16 2-D electrophoresis (2-DE): Sample preparation 
The appropriate volume of cell lysate or membrane protein preparation 
equivalent to between 50 and 100 gg of protein was mixed with rehydration buffer (T 
buffer) containing 7M Urea, 2M Thiourea, CHAPS 4% w/v, DTT 1% w/v, Ampholytes 
2% v/v, to a final volume of 125 µl prior to loading onto an IPG strip followed by in-gel 
rehydration. DTT was added fresh to the T buffer prior to use in order prevent 
denaturation of the DTT . 
2.17 In-gel rehydration 
The protein samples were loaded onto 7 cm Immobiline Drystrips (GE 
Healthcare) of pH3-10, pH5-8, and pH4-7 depending on the experiment. The protocol 
used for rehydration was identical regardless of the pH gradient used. Briefly, 125 µl of 
sample containing 50 to 100 pg of proteins prepared in T buffer was pipetted into a 
groove of the reswelling tray. The dry IPG strip was inserted into the groove, gel face 
down, to cover the sample previously loaded. Silicone oil was layered on top of the strip 
to prevent the strip drying out and rehydration was allowed to proceed overnight at 
20°C. 
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2.18 Isoelectric focussing 
Rehydrated IPG strips were rinsed in distilled water, placed on the 
isoelectrofocussing unit (Multiphor, GE Healthcare), gel facing up with wet filter paper 
between the gel and the electrodes to trap the fast moving ions that may cause an 
increase in current intensity and unwanted heating. 
The isoelectrofocussing was performed under the conditions summarised in 
Table 2.6. The two parts of the focussing proceeds at low voltage (300 V and 600 V) to 
enable the removal of fast moving ions, being eventually trapped in the filter paper 
placed at the electrode. In the second part of the focussing step at 3500 V, 
isoelectrofocussing of the protein takes place. The charged proteins move toward the 
anode/cathode depending on their charge. They eventually come to rest at the pH zone 
equal to their pKa. 
Gel length: 7 cm 
Temperature: 20°C 
Current max: 2 mA 
Voltage max: 3500 V 
IEF Volts Time 
Initial steps 300 V 30 min 
600 V 30 min 
Focussing step 3500 V 2h 30 min 
Total Volt hours 9200 Vhour 
Table 2.6: The isoelectrofocussing of the proteins loaded onto a7 cm IPG strips are shown. The IEF 
consists of three steps. The two first steps at 300V and 600V remove ions. At 3500V the charged proteins 
move within the pH gradient of the IPG strip until they reach a zone of pH corresponding to their pKa 
where the proteins precipitate. 
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2.19 Equilibration of IPG strip 
Focussed strips were equilibrated for 15 min in 50 mM Tris-HCI, pH 8.8,6 M 
urea, 30% v/v glycerol, 2% w/v sodium dodecyl sulphate (SDS), 1% w/v DTT and then 
for 15 min in 50 mM Tris-HCI, pH 8.8,6M urea, 30% glycerol, 2% w/v SDS, 2.5% w/v 
iodoacetamide. These steps are included with the aim of reducing the disulfide bonds 
and unfolding the proteins in order to facilitate their exit from the IPG strip as well as to 
reduce electroendosmotic effects which may result in poor transfer of protein from IPG 
strip to SDS-PAGE gel. 
2.20 Second dimension: SDS-PAGE 
Focussed and equilibrated strips were gently applied on top of a vertical lmm 
thick, 8x7 cm, 10% SDS-PAGE gel prepared according to the procedure described 
earlier. Molecular weight standards were loaded on a small piece of filter paper inserted 
next to the low pH side of the IPG strip. An agarose containing solution (0.5% w/v 
agarose, 25 mM Tris, 192 mM glycine, 0.1% SDS, trace of bromophenol blue, pH 8.3) 
was poured over the strip to seal the system in order to prevent the IPG strip from 
moving during protein separation. Gels were run for 1h 15 min at 150 V prior to protein 
staining or Western blotting. 
2.21 Protein staining using Coomassie Brilliant Blue 
The solutions used to fix, stain and destain the protein gels, were freshly 
prepared and are shown in Table 2.7. All three steps of the staining protocol were 
performed under gentle agitation on a rocking tray. First the gels were fixed for 30 min 
in methanol/acetic acid; the gels were then stained in Coomassie Brilliant Blue solution 
for one hour and destained for two hours. Complete destaining was achieved by leaving 
gels overnight in water until the protein bands were stained deep 
blue against a 
transparent background. Gel images were then captured using the UVP Bioimaging 
Autochemi System as before. 
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Solutions Composition Time 
Fixing solution 50% methanol, 10% Acetic acid, dH2O 30 min 
Staining solution 10% acetic acid, 0.025% Coomassie lh 
Brilliant Blue, dH2O 
Destaining solution 10% Acetic acid, dH2O 2h 
Table 2.7: Coomassie blue staining 
The solutions to fix, stain and destain, the proteins separated on SDS-PAGE, are reported in this table 
along with the time used for each step. 
2.22 Fluorescent staining of proteins separated by 2- 
DE 
2-DE protein minigels were stained with the fluorescent dye, Sypro Ruby 
(Molecular Probes) according to the manufacturers recommendations. Sypro Ruby 
enables the detection of protein at a concentration as low as 0.25 ng hence increasing 
the sensitivity of detection (up to 10 times more sensitive than Coomassie Brilliant 
Blue). Briefly, gels were fixed in methanol/acetic acid solution, stained overnight with 
the undiluted dye and washed with a methanol/acetic acid containing solution. The 
complete composition of the solutions and protocol are given in Table 2.8. 
The Sypro Ruby stained gels were visualised using a laser scanner (Typhoon 
8610, GE Healthcare) at an excitation wavelength of 450 nm and emission wavelength 
of 610 nm. 
Solutions Composition 
Fixing solution 50% methanol, 7% Acetic acid, dH2O 
Staining solution Undiluted Sypro Ruby gel stain 
Destaining 10% Methanol, 7% Acetic acid, dH2O 
solution 
Time 
2x 30 min 
Overnight 
30 min 
Table 2.8: The composition of the solutions and the duration of each step of the fluorescent staining with 
Sypro Ruby, are shown. 
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2.23 Data analysis from 2-DE experiments 
The 2-DE gel images were obtained using either, for Sypro Ruby stained gels, a 
dual-laser Typhoon scanner (GE Healthcare) or, for Western blot membranes, 
transillumination with white light and UVP Biochemi Image Capture System. Images 
in TIFF format were imported into two 2D analysis softwares: Progenesis Samespots 
(Nonlinear Dynamics) and Image Master 2D Platinum (GE Healthcare) and processed 
by background subtraction, spot detection, landmarking, overlay analysis and 3D 
reconstruction of the proteins separated by 2-DE. 
2.24 Protein transfer by Western blotting 
The electrophoretically (1-DE or 2-DE) separated proteins were transferred onto 
nitrocellulose membranes (GE Healthcare) by wet transfer using a Mini Trans Blot 
transfer cell (Bio-Rad). The proteins were electrophoretically transferred from the gel to 
the nitrocellulose membrane at 100 V for Ih 30 min in transfer buffer (25 mM Tris, 192 
mM glycine and 20% v/v methanol pH 8.3). The system was cooled throughout the 
experiment. 
2.25 Ponceau S staining of Western blots 
The membranes were stained with the reversible protein dye, Ponceau S (Sigma) 
to check the efficiency of the transfer and also to localise the lanes and molecular 
weight markers prior to immunodetection. 0.1% w/v Ponceau S in 5% acetic acid was 
used for this purpose. The stain was subsequently removed in water. 
2.26 Immuno/Lectin detection on Western blots 
Prior to immunodetection, the nitrocellulose membrane was blocked with 2% 
w/v BSA in Tris buffered saline/Tween 0.05% v/v, pH 7.6 (TBS/T) overnight at 4°C 
and washed 3 times for five minutes in TBS/T. Lectin/antibody steps and washing steps 
were carried out in TBS/T. The incubation steps with antibodies, lectin or streptavidin 
were all performed at room temperature under gentle agitation. 
60 
2.27 Lectin blotting with HPA 
After blocking, the blots were incubated for 2 hours with 5µg/ml biotinylated 
HPA (Sigma). The protein blots were subsequently incubated with 2µg/ml HRP- 
conjugated streptavidin (Pierce, UK) for 1 h. The blots were washed 3 times for 5 min in 
TBS/T between each step. The detection was performed by addition of the chromogenic 
substrate diaminobenzidine (DAB) prepared in TBS/ H202 (6mg of DAB prepared in 
9m1 of TBS and 60 µl of 30 volume H202). The reaction was stopped by addition of 
excess water. 
2.28 Probing Western blots with anti-blood group A 
antibody 
After blocking, the proteins were probed with a murine monoclonal antibody 
directed against blood group A antigen (anti-blood A) from Ortho-Diagnostics, Johnson 
and Johnson, kindly provided by Dr P Greenwell (University of Westminster) using the 
anti-blood A antibody at a dilution of 1/5 for 2 hours. After washing 3 times for 5 min 
in TBS/T the membrane was incubated for one hour with a goat anti-mouse antibody 
(Sigma) conjugated with HRP, prepared at a dilution of 1/10000 in TBS/T. The 
detection was performed using the chemiluminescent reagent, Super Signal West Dura 
(Pierce), according to manufacturer's instructions. The detection was performed by 
exposure of an X-ray film for 10 sec to 1 min. 
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2.29 Probing Western blots with anti-integrin a6 (anti- 
CD49f) antibody 
Proteins separated by SDS-PAGE and transferred to nitrocellulose were blocked 
in BSA as before and probed with a rat monoclonal biotinylated anti-integrin a6 
antibody (Anti-CD49f, AbD Serotec) prepared in TBS/T to a concentration of 4µg/ml. 
The membrane was incubated with the antibody anti-CD49f for 2 hours and washed 3 
times for 5 min followed by one hour incubation with 2 gg/ml streptavidin-HRP. The 
detection was performed using the chemiluminescent reagent Super Signal West Dura 
(Pierce) as before. Visualisation of the results was achieved by exposure of a X-ray film 
to the blot for 10 sec to 1 min. 
2.30 Inhibition of HPA binding to HT29 proteins 
HT29 membrane proteins separated by 1-DE or 2-DE and transferred to 
nitrocellulose membranes were blocked with BSA and incubated for 2h with 5µg/ml 
biotinylated HPA in TBS/T preincubated for 30 min with either 250 mM G1cNAc, 
Ga1NAc or SA. The membrane was washed in TBS/T and incubated with 2µg/ml of 
HRP-conjugated streptavidin before detection with DAB as before. 
2.31 HPA affinity chromatography 
AI ml lectin affinity chromatography column (0.7 cm diameter x 2.5 cm length) 
was prepared and used to purify the HPA binding membrane proteins from HT29, 
SW480 and SW620.1 mg HPA (Sigma) was coupled to a HiTrap NHS-activated 
Sepharose prepacked column (GE Healthcare) according to the manufacturer's 
recommendations. The packing matrix contains activated N-hydroxysuccinimide (NHS) 
functional groups capable of forming covalent bonds with the primary amino groups of 
proteins. During the preparation of the column the flow rate was maintained below 
1 ml/min. The column was first washed with 6ml ice cold 1 mM HCI. 1 ml of lmg/ml 
HPA was prepared in standard coupling buffer (0.2M NaHCO3,0.5M NaCl, pH8.3), 
injected onto the column and allowed to interact at room temperature to enable the 
formation of covalent bonds between the matrix and the lectin. The unbound ligand was 
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washed away and unbound active NHS groups were inactivated with 18 ml of 0.5M 
ethanolamine, 0.5M NaCl, pH8.3 and 18 ml of 0.1M acetate, 0.5M NaCl, pH 4. 
The column was fitted to an AKTA prime semi-automated system with in-line 
UV detector and fraction collector (GE Healthcare). The column was washed and 
equilibrated with 10 column volumes of binding buffer (20 mM Tris, 0.5M NaCl, pH 
7.4) at a flow rate of 0.5 ml/min. Cell pellets from HT29, SW480, and SW620 were 
prepared in the binding buffer, solubilised using an ultrasonic probe as before and 
centrifuged at 11,000g. 0.5mg of each cell line protein preparation was injected onto the 
column using a 500µ1 injection loop. The column was washed with 15 column volumes 
of binding buffer to remove any unbound proteins. The bound proteins were eluted with 
a gradient of binding buffer supplemented with IM G1cNAc. G1cNAc has been shown 
previously to bind to HPA (Vretblad et al., 1979). Finally the column was extensively 
washed and re-equilibrated with 10 column volumes of binding buffer. Fractions of l ml 
were collected and the eluted material pooled, dialysed against distilled water overnight 
at 4°C and freeze dried (Super Modulyo D, Thermo Electron). The bound fractions were 
resuspended in buffer before separation by 1-DE or 2-DE. 
2.32 Improved method for the purification of the HPA 
binding partners from HT29 
The method described above was further refined using proteins from the cell 
line HT29. A1 ml HiTrap NHS-activated Sepharose column (GE Healthcare) was used 
to prepare the HPA affinity column as before according to the manufacturer's 
recommendations with the exception that 5 mg of lectin was coupled to the NHS- 
Sepharose matrix rather than l mg. The column was first washed and equilibrated with 
10 column volumes of lectin buffer containing 0.1 % w/v CHAPS. 0.5 mg of membrane 
proteins were loaded onto the column in the lectin CHAPS buffer using a 500 µl 
injection loop as before, the column was washed with 5 column volumes of lectin buffer 
containing 0.1 % CHAPS to remove unbound proteins and bound proteins were eluted 
with freshly prepared lectin buffer containing 0.1 % CHAPS and 250mM G1cNAc in a 
step gradient of 10 column volumes. The flow rate was maintained at 0.5 ml/min 
throughout the experiment. 
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Protein peaks detected at 280 nm were integrated using the Prime Evaluation 
software (GE Healthcare) and this enabled evaluation of the relative amount of unbound 
and bound proteins. 
2.33 Spot picking from 2-DE separated HPA binding 
proteins 
The HPA binding proteins of HT29 above were dialysed, freeze dried and 
resuspended in T buffer prior to 2-DE. Approximately 100µg of HPA binding proteins 
were loaded onto an IPG strip of pH 3-10, the proteins were focussed, separated on a 
10% SDS-PAGE and stained with Coomassie Brilliant Blue as before. Proteins spots 
were excised from the gel using a clean scalpel and stored at -80°C in 0.5 ml sterile 
Eppendorf tubes. 
2.34 Protein identification by MALDI-TOF Mass 
spectrometry 
Protein identification was carried out by commercial arrangement with Dr Jerry 
Thomas at the University of York. A MALDI-TOF/TOF 4700 analyser from Applied 
Biosystems was used. The 2-DE protein spots stained with Coomassie Brilliant Blue 
excised from the gel were provided to the Thomas laboratory. The proteins were 
reduced using DTT and S-carbamidomethylation was performed using iodoacetamide 
prior to the tryptic digest. The gels pieces were washed three times in 50% v/v 
acetonitrile / 25mM ammonium bicarbonate and air dried before rehydration in 10 µl of 
0.02µg/µl sequencing-grade, modified porcine trypsin (Promega). Digestion was 
performed over night at 37°C. A 0.5 µl aliquot of each tryptic digest and 0.5 µl of a 
solution of 4-hydroxy-a-cyano-cinnamic acid (Sigma, Poole, UK) in 50% aqueous (v/v) 
acetonitrile containing 0.1% TFA (v/v), was applied to the MALDI target plate. Mass 
spectra were obtained in reflection mode with an accelerating voltage of 20kV. The 
peptide mass fingerprint generated was compared to the masses of all theoretical tryptic 
peptides generated in silico by the MASCOT search program. MASCOT produces a 
statistically based Mowse score that evaluates the significance of the matches. A 
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significant event would be expected to occur at random with a frequency less than 5% 
(Pappin et al., 1993). The Mowse score generated by the search depends on parameters 
such as the sequence database used, the protein studied and hence there is no absolute 
threshold value for MASCOT (Perkins et al., 1999). Collision induced dissociation 
(CID) MS/MS was also performed to corroborate the significant matches from the 
MALDI/MS. The results are shown as mass spectra as well as a list of peptides detected 
and the sequence coverage. 
2.35 Selection of colorectal tissue samples for 
evaluation of HPA binding glycoproteins 
Tissue samples were used to determine whether the differential expression of 
HPA binding proteins observed between the metastatic cell line HT29 and the non- 
metastatic cell line are also found in human colorectal cancer. 
The human colorectal tissue samples were collected following informed consent and 
subject to local ethics committee approval at the University Hospital of Martinique and 
were provided by Dr Smith-Ravin (University of Guadeloupe). We selected eight 
samples which were categorised into two cohorts. Four samples (1-4) showed no 
regional lymph node involvement at the time of tumour resection and were described as 
the "early stage" group termed C I. Four other tissue samples (5-8) with more advanced 
tumour stage and lymph node involvement were selected and were described as the 
"advanced" group termed C2. For each patient a piece of healthy tissue was also 
surgically removed. The healthy tissue from patients 1 to 4 and 5 to 8 were used to 
prepare the healthy counterpart of Cl and C2 termed Ni and N2. The characteristics of 
the samples are shown in Table 2.9. The samples were evaluated by cutting frozen 
sections and H+E staining prior to use. 
Samples were pooled into two groups "early stage" and "advanced" cancers in 
order to facilitate the analysis and the correlation with the findings made in vitro in the 
metastatic and non-metastatic cell lines. The use of pooled samples of human tissues 
does not provide information on the HPA binding glycoproteins of a given 
individual, 
rather, it provides a quick overview of HPA binding to the glycoproteins 
in an entire 
pool. Proteomic studies based on pooling samples are a relatively quick method 
for 
identifying fold-changes in protein levels in individuals from different clinical groups. 
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Such changes may be subject to bias as, in the extreme situation; the altered protein 
levels may simply represent a change in protein level from a single individual of the 
group. It is widely accepted that proteomic studies with pooled samples require further 
verification and validation with proteins from the individuals in the group run separately. 
Patients Age Gender TNM status 
1 44 Female T2NO 
2 62 Female T2NO 
3 54 Female T2NO 
4 70 Male T3NO 
5 64 Female T4N1 
6 70 Male T4N2 
7 49 Female T3N2 
8 57 Female T3N2 
Table 2.9: Characteristics of the patient samples used in this study. 
2.36 Protein preparation 
2 mm2 tissue pieces from each patient were individually disrupted in U7M/T2 
buffer using a "rotor stator type" hand-held homogeniser. The protein mixture was then 
centrifuged at 11,000g for 10 min in order to remove cellular debris and nucleic acids 
and the protein solution was eventually assayed. 
100 µg of the protein mixture extracted from cancerous and healthy tissue of 
patient 1 to 4 were pooled to prepare respectively the "early stage" cancer protein 
mixture (Cl) and its healthy counterpart (N 1). The "advanced" cancer protein mixture 
(C2) and its healthy counterpart (N2) were prepared identically. 
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2.37 Protein separation 
90 gg of proteins from Cl, C2, Ni and N2 were individually separated by 2-DE. 
IPG strips of pH3-10 were used to separate the proteins in the first dimension, and 10% 
SDS-PAGE was used for the second dimension. The running conditions were the same 
as those described earlier. The gels were stained by Coomassie Brilliant Blue and 
images acquired via the Autochemi Bioimaging system. 
2.38 Analysis of HPA binding proteins separated by 1- 
DE 
20 µg of the two cancerous and corresponding healthy protein mixtures (Cl, C2 
Ni and N2) were separated by 10% SDS-PAGE and transferred onto nitrocellulose 
membrane before being probed with biotinylated lectin (HPA) as before 
2.39 Analysis of HPA binding proteins separated by 2- 
DE 
90 µg of proteins from Cl, C2, NI and N2 were separated by 2-DE and 
transferred onto nitrocellulose membranes and probed with HPA as before. 
2.40 Probing Western 
antibody to integrin a6 
blots of CRC samples with 
The presence of integrin a6 in Cl, C2, NI and N2 protein mixtures was 
evaluated by separating 20µg of proteins on 10% SDS-PAGE and transferring to 
nitrocellulose membrane. The membrane was then probed with the monoclonal rat anti- 
integrin a6 antibody (anti-CD49f) using conditions identical to those described in 
section 2.29, detection was performed using chemiluminescence and exposure of X-ray 
film as described earlier. 
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CHAPTER THREE 
Lectin binding to colorectal 
cancer cells: A focus on Helme 
pomatia agglutinin (HPA) 
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3.1 Introduction 
The carbohydrate moieties of glycoconjugates on the outside of cells are known 
to play an important role in maintaining cellular integrity by controlling cell-cell, cell- 
matrix interactions and correlate with cell differentiation. Over the past two decades a 
large range of glycoconjugates including glycoproteins and glycolipids have been 
shown to be modified during differentiation and malignant transformation (Aoki et al., 
1993; Iwakawa et al., 1996; Remani et al., 2000). Observations have strongly suggested 
that the post-translational modification of proteins, particularly glycosylation is altered 
in relation to cancer progression to a metastatic phenotype (Smets and Van Beek, 1984; 
Altevogt et al., 1983). 
The study of the modified carbohydrate structures occurring during malignant 
transformation has often been achieved using lectins. Carbohydrate binding proteins 
including lectins have attracted interest in cancer research applications. In the 1960's 
researchers discovered that some lectins bound specifically to particular cancer cells 
(Aub et al. 1963,1965; Burger 1969). Over the past thirty years lectins have been used 
to study changes in glycoconjugates involved in pathophysiological events including 
cancer development as well as cancer prognosis. A study by Rhodes et al. (1986) 
investigated the binding properties of various peroxidase-labelled lectins including PNA, 
WGA, SBA, DBA and UEA-1 to nineteen colorectal carcinoma (CRC) and twenty 
normal mucosa specimens. They found an association between PNA/UEA-1 binding 
and poor patient prognosis. Iwakawa et al. (1996) studied the binding of two lectins, 
UEA-1 and DBA, on colorectal tissues and highlighted changes in the N-acetyl- 
galactosamine, L-fucose and O-acetylated-sialic acid expression in cancer. These 
authors also unravelled the differential binding of these lectins to normal tissue, 
adenoma and adenocarcinoma. A study by Sams and co-workers reported a decreased 
reactivity of FITC- labelled WGA towards colorectal cancer tissue specimens (Sams et 
al., 1990) whereas a recent study by Garcia De Albuquerque Garcia Redondo et al. 
(2004) reported increased binding of WGA on invasive colorectal cancer cell lines. 
These two studies contradict the findings of Rhodes et al. (1986) discussed earlier who 
failed to identify any significant difference in binding of peroxidase-labelled WGA in 
normal colon and carcinoma tissue samples. This non-exhaustive list of studies 
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highlights the usefulness of lectins as tools for detecting changes in the carbohydrates 
found on the surfaces of malignant cells but illustrates the problem of reproducibility 
amongst the systems and methodologies used. The lectin HPA, which binds to N- 
acetylgalactosamine residues, has been studied for over twenty years. Retrospective 
studies have shown HPA to bind to tumours and correlate with poor patient prognosis in 
breast (Leathern, 1983; Leathern and Brooks, 1987; Thomas et al., 1993; Brooks and 
Leathern, 1991), gastric (Kakeji et al., 1991), oesophageal (Yoshida et al., 1993), 
prostate (Shiraishi et al., 1992) and colorectal cancer (Ikeda et al., 1994; Schumacher et 
al., 1994; Mitchell and Schumacher; 1999; Brooks, 2000). A correlation between HPA 
staining and poor prognosis colorectal cancer was first established by Ikeda et al. in 
1994 and has since been reported by several research groups and found to correlate with 
a metastatic phenotype. In later studies the Schumacher group established an animal 
model to study the role of HPA binding cancer cells in the metastatic process. 
Colorectal cancer cell lines (HT29, SW480) were implanted subcutaneously in SCID 
mice and the development of lung metastases showed a positive correlation with the 
HPA staining pattern of the cell lines (Schumacher et al. 1994b, 1996; Schumacher and 
Adams 1997). The use of appropriate methodology is important when studying lectin 
binding as argued by Brooks et al. in 1996. Earlier studies of HPA binding to colorectal 
tumours that were contradictory were probably due to differences in the lectin binding 
methods used (Kim and Isaacs, 1975; Hakamori, 1989; Kemmer et al., 1992). 
The choice of cellular model and methodology is an important consideration 
when using lectins as a tool to study the glycoconjugates potentially involved in the 
metastatic process. For this study we have chosen a well-characterised metastatic and 
non-metastatic colorectal cancer cell line model. HT29 and SW480 are two cell lines 
derived from human colorectal adenocarcinomas. SW480 was established from a Dukes 
type B colorectal adenocarcinoma of a 50 year old Caucasian male; HT29 was 
established from a colorectal adenocarcinoma of a 44 year old female. The cells lines 
have been extensively used to study the binding of HPA directly on cells or in tumours 
grown in immuno-deficient mice and HT29 has been shown to be HPA positive whilst 
SW480 has been shown to be HPA negative (Schumacher and Adam, 1997). Each of 
the cell lines has been studied in SCID mice in an attempt to evaluate their metastatic 
potential and it appears that their HPA-binding properties correlate with their ability to 
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metastasise. SW480 did not form metastases after growing a tumour when implanted in 
SCID mice, whereas HT29 did grow a tumour and form lung metastases (Schumacher 
et al., 1994a, 1996; Schumacher and Adam, 1997). 
Earlier studies of HPA binding to breast and CRC cancer tissues and/or cells 
have mainly used light microscopy-based methods of detection. These systems do not 
allow absolute quantification of HPA binding; they are rather subjective qualitative 
assessments potentially subject to variation. In a study by Brooks et al. 2001, 
fluorescent HPA (FITC) was used in conjunction with confocal microscopy and a range 
of breast cancer cell lines. This approach allowed localisation of the binding 
(perinuclear or surface/cytoplasm) but the quantification used a scale ranging from "-" 
for low binding to "+++" for intense binding, in a similar approach to the scoring 
system used in light microscopy. Although the results gathered in their study were of 
interest in terms of their qualitative observations, there remained an opportunity to 
improve the methods to allow semi-quantification. De Albuquerque Garcia Redondo et 
al. (2004) used gold-labelled lectin in an attempt to quantify binding of HPA to CRC 
cells but most of the studies with HPA over the past 15 years relied on colorimetric 
detection systems with light microscopy or, alternatively, fluorescence-based methods. 
In this study an effort was made to standardise the analysis of HPA binding and 
minimise reporter variation particularly to improve the scoring systems. For this we 
used a confocal microscopy-based and a microtitre plate-based approach. We also used 
simple sugars (mannose, G1cNAc, Ga1NAc, SA) to inhibit the binding of HPA to 
determine the specificity of binding. A combination of 2D reconstruction and 3D views 
generated from the confocal microscopy-based method enabled visualisation of the 
binding of HPA to HT29 and SW480. This approach offered an insight into localisation 
of HPA binding. This method also enabled us to visualise the inhibition of HPA binding 
to HT29 cells by Ga1NAc. The confocal microscopy was a useful tool to evaluate the 
extent of HPA binding but used a relatively small number of cells. 
The development of a microplate-based assay allowed evaluation of HPA 
binding on a larger population of cells and enabled inhibition experiments using a 
variety of simple sugars and provided an insight into the binding partners of HPA. 
71 
3.2 Lectin binding to HT29 and SW480 
In the first part of the evaluation of lectin binding to the CRC cell lines, we used 
several fluorescently-labelled lectins, including HPA and confocal microscopy. We 
sought to confirm using the HT29 and SW480 cell lines, previous findings in which 
HPA was reported to bind more strongly to the cells with metastatic capability (HT29) 
compared to other lectins. 
HT29 and SW480 cells were grown to near confluence in Petri dishes, the cells 
were fixed in formalin to mimic the tissue processing methods used in Histopathology 
Departments and the binding of eight fluorescently-labelled lectins was evaluated. 
The total fluorescence intensity of the 8 lectins mentioned above was measured 
for each cell line and the results are shown in Figure 3.1. In this system, no significant 
differences in binding to HT29 and SW480 cells were observed for RCA, ConA and 
PNA, however the binding pattern were not identical for the three lectins. PNA bound 
weakly (<25 Au) to both HT29 and SW480 suggesting that low expression of T antigen 
whereas the binding of RCA and Con A was about 6 times more intense than PNA but 
was not significantly different between HT29 and SW480. All three lectins failed to 
bind differentially to our cell line model and therefore were not considered relevant for 
the study glycoconjugates changes associated with metastatic tumour cells. On the 
contrary, HPA, UEA-1, DBA and SBA all bound more intensely to HT29 than to 
SW480. UEA-1 and DBA were previously reported to detect changes in glycosylation 
occurring during development from adenoma to adenocarcinoma and behaved similarly 
in this system (Iwakawa et al. 1996), Here UEA-1 bound 7 times and DBA bound 4 
times more intensely to the metastatic cell line, HT29 as compared to the non-metastatic 
cell line, SW480. Similarly, SBA bound 5 times more intensely to HT29 than SW480. 
In our system HPA bound 9 times more intensely to the metastatic cell line HT29 than 
to the non-metastatic cell line SW480 and was the lectin that showed the most 
differential binding to glycoconjugates of HT29 compared to SW480, confirming 
previous studies that suggest HPA has the ability to detect changes in glycosylation 
associated with a metastatic colorectal cancer phenotype. The lectin WGA bound in a 
very intense manner (233 Au) to HT29 but bound also intensely to the non metastatic 
cell line SW480 (152 Au), the difference of binding was not found to be significant and 
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hence we failed to confirm the observation by De Albuquerque Garcia Redondo et al. 
(2004) that WGA staining increases in malignancy (IEC-6, CaCo-2 and HCT-116). This 
apparent dichotomy may be due to variations in the methodology and the cell line used. 
CaCo-2 used by De Albuquerque Garcia Redondo et al. is a cell line with low 
metastatic potential and may be one of the causes of the ambiguous results. The CaCo-2 
cell line has been studied by many other groups including Mitchell et al. (1998) who 
reported that it metastasised in only 25% of the cases when implanted in SCID mice. In 
the study by De Albuquerque Garcia Redondo et al. using gold labelled HPA, the lectin 
was found to bind similarly to the CRC cell lines irrespective of their invasive potential 
whereas several studies, including our own, concluded that HPA is a useful tool for 
identifying cancer cells with a metastatic phenotype (Ikeda et al. 1994; Schumacher et 
al. 1994; Mitchell et al. 1998). 
This experiment confirmed the validity of HPA as a tool for detecting colorectal 
cancer cells with metastatic potential. 






















Figure 3.1: Lectin binding to HT29 (blue) and SW480 (red) cell lines observed and evaluated using a 
confocal microscope. The mean values of the global 
binding intensity evaluated for 22 cells +/- SE are 
presented. 
73 
HPA DBA SBA UEA-1 PNA W GA 
RCA UUNA 
3.3 Localisation of HPA binding in HT29 and SW480 
In order to obtain a clear overview of the localisation of HPA binding in 
metastatic (HT29) and non-metastatic (SW480) cell lines HPA-TRITC was used and the 
staining analysed by confocal microscopy. In this way we confirmed the observations of 
Schumacher et al. (1994b) who used an indirect colorimetric method and found HT29 
to be HPA positive whereas SW480 was HPA negative. We performed at least five 
reproducible experiments and Figure 3.2 shows a typical result. 
HPA bound intensely to the HT29 cell membrane with granular staining in the 
cytoplasm and in the perinuclear region. On the other hand, HPA showed very faint 
binding to SW480 in both membrane and cytoplasmic compartments. Brooks et al. 
(2001) used FITC-labelled HPA with confocal microscopy and breast cancer cell lines 
and reported perinuclear and membrane binding to the metastatic breast cancer cell lines. 
Although a direct detection system was used in these confocal experiments 
(TRITC-labelled HPA) the results were consistent with those obtained using an indirect 
method (Schumacher et al., 1994). The use of peroxidase-labelled HPA as a direct 
detection method may not be appropriate (Leathern, 1983) as the horseradish peroxidase 
molecule (MW: 40,000 Da) used to label HPA (MW: 76,000 Da) is relatively large and 
may interfere with HPA binding to cancer cell glycans. The indirect methods which use 
either native HPA (Brooks et al., 1996) or biotinylated HPA (Brooks and Wilkinson, 
2003) (biotin MW: 244 Da) are comparable to our fluorescent system. The TRITC 
fluorophore (MW: 443.5 Da) used to label HPA and used in our study is about 100 fold 
smaller than HRP (MW: 40,000 Da) used in colorimetric direct detection methods and 
our results suggest that it does not hinder HPA binding even though 
it is slightly larger 
than both biotin and FITC. In summary, this experiment validated the use of HPA- 
TRITC to study lectin interaction with HT29 and SW480 cells. 
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Figure 3.2: The binding of HPA -TRITC to HT29 and SW480 cells 
Confocal images showed the binding of TRITC-labelled HPA (red) to HT29 (panel A) and SW480 
(panel B). The nuclei were counterstained with ToPRO-3 (blue). Image A shows intense lectin 
binding on the surface of HT29 with some granular staining inside the cell. There is almost no HPA 
binding to SW480 on the surface or inside the cell. Scale bars 8, um 
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3.1 Quantification and localisation of HPA binding: 
In an attempt to localise the binding of the lectin HPA and obtain relative 
quantification of binding, the confocal images were used with data analysis using the 
Leica software analysis package. Briefly, two lines were drawn across either HT29 or 
SW480 cells. On the field shown in Figure 3.3, nine cells were evaluated and the 
intensity of fluorescence was calculated along the two lines drawn on each of the cells. 
An example of a linear profile taken across one of the cells (framed in Figure 3.3 panel 
A) is also presented (Figure 3.3, panel B). This approach enabled relative quantification 
values to be obtained and generated digitised data showing localisation of the binding of 
HPA via the measurement of the fluorescence intensity along the lines drawn across the 
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Figure 3.3: An example of linear profiling of HPA binding to HT29 using the Leica analysis software. 
Two lines were drawn across each of the nine HT29 cells chosen in this field in order to evaluate the 
intensity of the HPA binding in the different compartments of the cells (panel A). An example of the 
linear profile generated with this technique is shown in the framed region (panel B). 
3.2 2D and 3D reconstruction of confocal images 
The Leica software package was used to produce 2D and 3D models of HPA 
binding (Figure 3.4). Sections were taken of HPA-stained cells at increments of 1 µm. 
The sections were compiled to generate a 3D representation of HPA binding. Figure 3.4 
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shows nine HT29 cells stained with TRITC-labelled HPA and counterstained with the 
nuclei dye ToPRO-3. The 3D view offers an insight into the location of HPA binding 




Figure 3.4: 2D and 3D representation of HPA binding to HT29 cells. The Leica softwarein "Surpass 
view" shows a 2D representation of HPA binding to HT29 cells. The nuclei are displayed in blue and the 
lectin in red. As observed under the microscope the 2D reconstruction showed binding mainly located on 
the membrane with some staining within the cells at perinuclear sites consistent with the endoplasnic 
reticulum and Golgi apparatus (panel A). The Leica software Imans 4.0 was used to generate a 3D view 
of nine HT29 cells. The 3D image was reconstructed from Z stacks taken at 1µm increments. Blue nuclei 
are displayed and the HPA binding is shown in red (panel B). 
3.3 Evaluation of the specificity of HPA binding at the 
cellular level 
The experiments presented in this section were designed to evaluate the binding 
of HPA to HT29 and SW480 at the cellular level. HPA has a nominal specificity for 
glycans bearing Ga1NAc and G1cNAc residues (Vretlab et al. 1979). In this experiment 
GaINAc was used to competitively inhibit the binding of HPA. HT29 cells were used in 
binding experiments with HPA, pre-incubated with different concentrations of Ga1NAc 
(20 mM - 150 mM). Three experiments were performed and provided reproducible 
results, Figure 3.5 shows the typical inhibition observed across the experiments. 
Specific inhibition of HPA-binding by GaINAc was observed (Figure 3.5 panel A) and 
the detection of HPA-TRITC binding decreased with the addition of GaINAc, in a dose 
dependent manner. The intensity of fluorescence, as a measure of the HPA binding, was 
evaluated as described earlier and is displayed graphically in Figure 3.5 panel B. A 
decrease in fluorescence intensity with increasing concentration of inhibiting sugar was 
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detected and the presence of GaINAc at 25 mM and 50 mM resulted in inhibition of the 
binding by 50 % and 75 % respectively. Almost complete inhibition of binding was 
obtained when the lectin was preincubated with 150 mM GaINAc. This experiment 
confirmed that the lectin specifically binds to glycoconjugates via Ga1NAc residues on 
the surface of the malignant colorectal cancer cell line, HT29. 
By way of a negative control an experiment was performed in which HT29 cells 
were incubated either with HPA alone or with HPA preincubated with 50 mM of 
Ga1NAc or 50 mM of mannose. An inhibition of 75 % of binding was observed when 
HPA was preincubated with 50 mM GaINAc whereas only 17% inhibition was 
observed when HPA was preincubated with 50 mM mannose. These results support the 
observations of Hammerstrom and Kabat (1971) that the primary specificity of HPA is 
towards Ga1NAc-containing glycoconjugates. 
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Figure 3.5: Specificity of the binding of HPA to HT29 cells. The cells were incubated with 10 tg/ml 
HPA-TRITC alone or after preincubation with increasing concentrations of GaINAc at 25 mM, 50 mM or 
150 mM Ga1NAc (panel A). Substantial inhibition of HPA binding was observed at 50 mM Ga1NAc. 
Quantification of membrane binding was achieved by linear profiling using the Leica software (panel B). 
Error bars represent the Standard Error of the Mean (SEM) of 10 cells (single inhibition experiment). A 




3.7 The development of a microtitre plate assay to 
evaluate HPA binding to SW480, SW620 and 
HT29 cells 
A microtitre plate assay was designed to quantify the binding of HPA using a 
large population of cells in each well. This served as a higher throughput system for 
assessing the HPA binding than the confocal microscopy based system. It also allowed 
further evaluation of the monosaccharides that inhibit HPA interaction. For this assay 
100,000 cells were seeded into individual wells in a 96 well plate and fixed in formalin. 
The assay used an indirect method of detection, with biotinylated-HPA and a FITC- 
labelled streptavidin detection system thereby modelling the tissue based histochemistry 
methods of other researchers. The second step with streptavidin increased the 
background signal but this was normalised using a negative control of cells incubated 
with streptavidin-FITC alone. Brooks and co-workers (2001) used FITC-HPA to study 
binding to breast cancer cell lines but the methodology was different and, importantly, 
they used cells grown on a coverslip which hinders the study of a large population of 
cells. Five experiments were performed for the evaluation of the binding and the sugars 
specificities and reproducible results were observed. In this section one typical result of 
each experiment is presented. 
3.8 HPA binding using the microtitre plate assay 
system 
HPA binding was assessed by measuring the fluorescence in six wells per cell 
line and normalised by subtracting the background signal generated by the streptavidin- 
FITC alone. The results of the six wells for HT29 and SW480 are shown in Figure 3.6. 
In this experiment we included a third cell line. SW620 has been established from the 
lymph node metastases of the same patient from whom SW480 originated one year 
earlier. We evaluated this cell line in this system in an attempt to verify the 
binding of 
HPA to SW620 which may be regarded as an intermediate between the non metastatic 
SW480 and the highly metastatic HT29. 
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Figure 3.6: An assessment of the binding HPA using a microtitre plate assay. 
For each cell line, HT29, SW620 and SW480 the mean fluorescence from six wells and standard 
deviation are shown. This chart clearly showed the difference of HPA binding between HT29, 
SW620 and SW480. The average fluorescence for HT29, SW620 and SW480 was 7014,4985 and 
1216 respectively. 
A significant difference in HPA binding was observed between HT29 and 
SW480 and this data concurs with the results obtained previously with confocal 
microscopy. Whilst this system does not allow detailed localisation of the lectin binding 
it provided a reliable overview of binding of HPA using a larger population of cells. 
SW620 was described as HPA negative by Mitchell et al. (1998) but was consistently 
`HPA positive' in this system. 
3.9 Inhibition of the binding of HPA in the microtitre 
plate assay 
This experiment aimed to test a wider variety of inhibitory monosaccharides and 
to better characterise the binding properties of HPA to the colorectal cancer cell lines. 
Cells were prepared as before and were incubated with HPA alone or HPA preincubated 
with 20 mM, 50 mM or 250 mM competing sugar. 
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The binding of HPA to HT29 glycoproteins was inhibited in a dose dependent 
manner with G1cNAc, Ga1NAc and SA, as shown in Figure 3.7, panel A. Inhibition of 
HPA binding was achieved using 50 mM Ga1NAc, G1cNAc and SA with 77%, 87% and 
79% inhibition respectively. When 50 mM mannose was used in this system only 23% 
inhibition was achieved. The inhibition reached with GaINAc at 50 mM (87%) concurs 
with the observations made using the confocal microscopy-based approach (75%). 
Similar observation were made with the cell line SW620 (Figure 3.7 panel B) with 
specific inhibition observed with 50 mM of GlcNAc, GalNAc and SA whereas in the 
HPA negative cell line, SW480, the binding of HPA remained low and unchanged in 
presence or absence of sugars (not shown). Intriguingly, this experiment showed that 
sialic acid (SA) could inhibit HPA binding to HT29. SA has not previously been 
described as a specific sugar involved in HPA binding, although in this system it 
inhibited 79% and 80% of the HPA binding in HT29 and SW620 respectively. A study 
by Dwek et al. (2001) reported that HPA binding glycans were sialylated, and Fenlon et 
al. (1987) reported a loss of the predictive power for HPA when tissue sections were 
pretreated with neuraminidase. The results shown here reinforced these findings and 
suggest a role for sialic acid as part of the glycan epitopes recognised by HPA. Findings 
by A Markiv (unpublished data) suggest that one of the proteins in the HPA preparation 
(NCBI entry gi: 93209532) has 55% sequence similarity to a sialic acid binding protein 
from Cepaea hortensis and this data supports the idea that the HPA preparation 
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Figure 3.7: Inhibition of the binding of HPA to HT29, SW620 and SW480 colorectal cancer cells. 
Competitive inhibition of HPA using Ga1NAc, G1cNAc, SA and mannose was assessed using a microtitre 
plate assay. The monosaccharides were added to the HPA solution prior to incubation with the cells and the 
intensity of the binding was evaluated by reading the fluorescence emitted at 520 nm. Each sugar was used 
in an independent experiment including a positive control (biotinylated-HPA and Streptavidin-FITC). In 
HT29 (panel A) a high signal was detected with HPA alone and competitive inhibition was observed with 
the maximum inhibition reached at 50 mM of G1cNAc, Ga1NAc and SialAc and no significant inhibition 
was observed with mannose at 50 mM. The experiment using SW620 showed similar resuls although the 
binding of HPA alone was less intense than HT29 (panel B). 
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3.10 Discussion 
The development of a microtitre plate assay confirmed, using a large population 
of cells, that the lectin HPA binds to the metastatic cell lines HT29 and SW620 via 
carbohydrate-mediated interactions, in contrast, HPA did not bind to the non-metastatic 
cell line SW480. Immunohistochemistry using TRITC-labelled HPA combined with 
confocal microscopy enabled localisation of binding of HPA to HT29 both via classical 
images of the cells as well as using reconstructed 2D and 3D images. This method 
confirmed observations that had previously been made that HPA binds intensely to the 
metastatic cell line HT29 and weakly to the non-metastatic cell line SW480. HPA 
binding was located mainly to the surface of HT29 but also some granular intracellular 
staining was observed. This is consistent with binding of HPA to the Golgi apparatus 
that has been reported elsewhere (Virtanen, 1990) and is attributed to binding of 
glycoproteins in transit through the secretory pathways or to glycosyltransferase / 
glycosidase enzymes resident in this organelle as described in chapter 1. 
The development of the microtitre plate assay conferred a greater confidence in 
the inhibition experiments. The two methods developed in this study provided a reliable 
analysis of HPA binding to the two cell lines HT29 and SW480 and showed that HPA 
binding to these cells is via a lectin-glycan mediated interaction that can be inhibited 
using GaINAc, GlcNAc and SA. The experiments also showed that the HPA binding 
site encompasses glycoconjugates containing N-acetylgalactosamine as well as charged 
residues (SA) and N-acetylglucosaminylated structures. The development of this system 
also allowed us to establish the cell line SW620 as a model of moderate HPA binding. 
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CHAPTER FOUR: 
Method development for 
the separation of 
membrane-enriched 




In the previous chapter, we observed that HPA has the ability to detect changes 
in the glycoprotein composition on the cell membrane of two cell lines with different 
metastatic potential. Studying glycoproteins from cells which differ in their biological 
behaviour may provide new insights into the role of glycosylation of proteins in the 
metastatic spread of primary tumours. In this new aspect of the work we aimed to 
analyse HPA-binding glycoproteins of HT29 and SW480 cells using a proteomic 
approach. 2-DE was selected for this as it is capable of resolving thousands of proteins 
in a single experiment (O'Farrell, 1975). 
The solubilisation of proteins remains a critical step for high performance 2-DE 
and a wide range of protein solubilisation cocktails have been reported with the 
composition adapted to each analysis. Such a mixture needs to contain, as a minimum 
requirement, chaotropes to unfold proteins, non ionic detergents, reducing agent(s) and 
ampholytes (O'Farrell, 1975). However, it is also important to note that the accurate 
determination of protein concentration of the sample of interest is a prerequisite towards 
a comparative study of the protein expression in any two cell lines and the use of 
complex solubilisation mixtures may be incompatible with protein assay reagents and 
hence a source of misinterpretation of results. 
In this chapter we evaluated the compatibility of the chemicals contained in the 
solubilisation buffers using three commercially available protein assay kits. We aimed 
to determine the most suitable method to evaluate the protein concentration of our 
sample prior to analysis by 2-DE. Secondly we used a method developed by Lehner et 
al. (2003) to isolate cell membranes by ultracentrifugation in an attempt to prepare a 
protein fraction enriched in HPA-binding proteins. We then evaluated the efficiency of 
four home-made solubilisation buffers by comparing the quality of the protein 
separation on 2-D gels. Finally we analysed the robustness of our system by assessing 
the reproducibility of protein migration of two replicates of the same sample. We also 
evaluated the suitability of our 2D system to compare the protein composition of HT29 
and SW480. 
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4.2 Compatibility of solubilisation buffers with protein 
assay reagents 
HPA mainly binds to membrane proteins of the metastatic cell line HT29. These 
membrane proteins are present in relatively small quantities and possess hydrophobic 
domains and they therefore fall into the category of "biochemically challenging 
proteins". The method developed by Laemmli in 1970, based on the use of an SDS- 
containing buffer, has been successfully used as a standard method to solubilise a wide 
range of proteins, including hydrophobic proteins. The use of 2-DE does not, however, 
allow the use of the anionic detergent SDS (or only if followed with excess dilution in 
classical 2D buffer, Harder et al., 1999) since SDS imparts a negative charge to all the 
proteins in solution thereby causing problems in the isoelectric focussing step. 
To take advantage of the high resolution of 2-DE, proteins have to be denatured, 
disaggregated, reduced and solubilised to achieve complete disruption of molecular 
interactions and ensure that each spot represents, ideally, an individual polypeptide. In 
order to solubilise proteins prior to separation by 2-DE, high concentrations of 
chaotropes such as urea and thiourea are commonly used to unfold hydrophobic 
proteins (O'Farrell, 1975; Rabilloud et al., 1997) and are combined with zwitterionic 
detergents such as CHAPS or sulfobetaines (Santoni et al., 2000; Molloy, 2000). As a 
standard procedure, reducing agents such as DTT are used in lysis buffers to break 
disulfide bonds, along with carrier ampholytes to facilitate solubilisation with the aim 
that each spot contains a single polypeptide. The lysis buffer is a complex mixture of 
chemicals and compatibility with commercially available protein assay kits had to be 
tested in order to ensure an accurate evaluation of the concentration of solubilised 
proteins. Thiourea is known to not be compatible with commercially protein assays and 
can lead to inaccurate evaluation of the protein content of a solution. An accurate 
evaluation of the protein concentration of the cell lysate or membrane protein mixture is 
an essential step prior to separation by 2-DE or any other proteomics-based 
methodologies. 
We tested the effect of the classical components of a 2D buffer Urea, CHAPS, 
DTT and ampholytes (O'Farrell, 1975) on three protein assay kits, (i) DC protein assay, 
(ii) RC-DC protein assay and (iii) Bradford assay, in an attempt to select the most 
reliable method for evaluating the protein content of our cell 
line protein extracts. The 
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results obtained for the standard curve using BSA prepared in a range of buffers (Table 
4.1) and assay systems are shown in Figures 4.1,4.2, and 4.3. 
Buffer Composition 
1 Urea 7M, CHAPS 4% 
2 Urea 7M, CHAPS 4%, DTT 1% 
3 Urea 7M, CHAPS 4%, Ampholytes 2% 
4 Urea 7M, CHAPS 4%, DTT 1%, Ampholytes 2% 













Figure 4.1: Bio-Rad DC protein assay. 
An increasing concentration of BSA ranging from 0.25 to 2 mg/ml was prepared in four buffers. 
Theprotein assay was performed according to manufacturer recommendations. Buffers 1,2,3,4 appear in 
bleu, green, black and pink respectively, a positive control consisting of BSA prepared in water (grey) 
was added to the experiment and the absorbance was read at 655nm. 
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Figure 4.2: Bio-Rad RC/DC protein assay. 
A BSA solution ranging from 0.25 to 2 mg/ml was prepared in four buffers. A protein assay was 
performed according to manufacturer recommendations. Buffers 1,2,3,4 appear in blue, green, black and 
pink respectively. A control consisting of BSA prepared in water (grey) was included and the absorbance 
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Figure 4.3: Bio-Rad Bradford protein assay. Calibration curves using BSA prepared in buffers 1,2,3,4 
respectively in blue, green, black and pink, were drawn. A control consisting of BSA prepared in water 
(grey) was included and the absorbance was read at 595 nm. 
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When using the DC protein assay the absorbance read at 655 nm was rather 
inconsistent throughout the experiment and hence the DC protein assay does not appear 
to be suitable to accurately assess the protein content of protein mixtures prepared in 
buffers containing any of the following chemicals, urea, CHAPS, DTT, and ampholytes. 
In experiments using the RC/DC protein assay the absorbance read at 750 nm was also 
rather inconsistent and was not sufficiently reliable to allow accurate assessment of the 
protein content of the protein mixtures prepared in buffers containing urea, CHAPS, 
DTT, and ampholytes. However, when the Bradford assay was used the results showed 
a linear association between absorbance and protein concentration for BSA prepared in 
the buffers above. The consistency of the readings throughout the experiment showed 
that the Bradford reagent is a reliable assay to use in this system. 
4.3 Membrane preparation 
In chapter 3, studies using confocal microscopy demonstrated the predominant 
cell membrane binding of HPA to the metastatic cell line HT29 and hence the 
preparation of a cell membrane-enriched fraction was a focus of this work. Five cell 
membrane-enriched preparations were reproducibly carried out and the result a typical 
experiment is presented in this section. 
In this experiment the two cell lines SW480 and HT29 were used. The proteins 
from the three fractions generated during the membrane preparation, (i) cell debris and 
nuclei, (ii) soluble proteins and (iii) membrane-enriched proteins were extracted in 
Laemmli buffer and analysed to evaluate the HPA-binding proteins. Proteins (20 µg) 
from the three fractions were separated by SDS-PAGE, transferred onto nitrocellulose 
and probed with biotinylated-HPA. This experiment shows that most of the HPA 
binding protein were recovered in the membrane fraction of the metastatic cell line 
HT29 (including the two most intense protein bands shown by asterixes in Figure 4.4, 
lane 3) confirming our previous observations and suggesting a successful enrichment of 
the HPA binding proteins. Amongst the cytoplasmic proteins of SW480 (Figure 4.4, 
lane 5) a protein is intensely bound by HPA and shown with an asterix. A protein of 75 
kDa is consistently bound in the 6 protein fractions (indicated with a black arrow 
in 
Figure 4.4) and represent the non specific signal due to the streptavidin binding (Banks 
et al., 2003). 
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Figure 4.4: Evaluation of the HPA binding glycoproteins content of the three fractions from the 
membrane preparation. 20 µg of proteins extracted from the debris, cytosol and membrane of HT29 and 
SW480 were separated on a 12% SDS-PAGE and probed with the lectin HPA. The proteins extracted 
from the cell debris, the cytosol and the membrane-enriched fraction are shown in lane 1,2 and 3 for 
HT29 and 4,5 and 6 for SW480. The two main protein bands recognised by HPA in the membrane- 
enriched fraction of HT29 are shown by asterixes in lane 3. A protein band is intensely detected in the 
cytoslic fraction of SW480 and shown by an asterix in lane 5. A non specific protein band is detected in 
each lane and is indicated with an arrow. 
The results the Western blot data for the HPA binding proteins are shown in a 
illustrate the successful enrichment of HPA-binding proteins in the membrane fraction 
of HT29 cells. 
The binding of HPA to each of the three fractions from SW480 confirmed the 
observations of the confocal microscopy that HPA only binds weakly to this cell line. In 
HT29 the HPA binding varied between the fractions from low binding in the debris and 
soluble fractions to very intense binding in the membrane fraction. In HT29, most of the 
HPA binding was recovered in the membrane-enriched fraction. 
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4.4 Solubilisation of membrane-enriched proteins for 
separation by 2-DE 
The analysis of membrane proteins appeared crucial in our study because they 
comprise most of the HPA-binding epitopes which we intend identify. 2-DE offers one 
of the highest resolution available and enable the separation of post-translationally 
modified proteins. However the use non ionic/switterionic detergents do not guaranty a 
total recovery of membrane proteins, hence the solubilisation of membrane-enriched 
proteins and the choice of the solubilisation buffer remains a key element for proteomic 
analysis by 2-DE. The limitations of the use of 2-DE to study membrane-enriched 
proteins and possible improvements will be discussed in section 4.6. Four buffers were 
used to solubilise the proteins of the membrane-enriched fraction of HT29. U buffer 
(Urea 7M, CHAPS 4% w/v, DTT 1% w/v, Ampholytes 1% v/v), T buffer (Urea 7M, 
Thiourea 2M, CHAPS 4% w/v, DTT 1% w/v, Ampholytes 1% v/v), U7M/T buffer 
(Urea 7M, CHAPS 4% w/v, DTT 1% w/v, Ampholytes I% v/v with 2M Thiourea added 
after protein assay is performed) and U7M/T2 (Urea 7M, CHAPS 4%, DTT 1%, 
Ampholytes 2% with 2M Thiourea added after protein assay is performed). 
HT29 membrane-enriched protein samples were prepared in each buffer and 
reproducibly separated by 2-DE in duplicate. The gels stained with Sypro Ruby and one 
typical gel per condition is shown in Figure 4.6. 
The HT29 membrane-enriched proteins solubilised in T buffer (Figure 4.6, panel 
A), U buffer (Figure 4.6 panel B), U7M/T buffer (Figure 4.6 panel C) and U7M/T2 
buffer (Figure 4.6 panel D) presented a similar pattern of protein migration however 
proteins in U buffer showed distortion and poor resolution. The remaining three gels 
showed protein migration across the pI and MW range with slight variation in the 
quality of separation due to the yield of solubilisation achieved in each buffers. The T 
buffer (Thiourea 2M, Urea 7M, CHAPS 4% w/v, DTT 1% w/v, Ampholytes 1% v/v) 
seemed to offer the best solubilisation in this system. 
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Figure 4.5: Profile of HT29 membrane-enriched proteins solubilised in four different buffers and 
separated by 2-DE. HT29 membrane proteins were prepared and solubilised in T buffer (panel A), U 
buffer (panel B), U7MT buffer (panel C) and U7MT2 buffer (panel D). 70 µg of proteins were then 
loaded on a pH 3-10 IPG strip and subsequently on a 12% SDS-PAGE in order to achieve a 
bidimensional separation of the proteins. Similarities in the general pattern are observed in the four gels 
We have selected a region MW 30-70 kDa and pI 4.5- 6.5 (Figure 4.5, white box) 
subject to variation in resolution depending on the buffer used to solubilise the proteins. 
The framed region contains a large selection of proteins and was used to further 
compare the quality of the protein separation of the four gels using the 2-D analysis 
software Melanie Image Master 2D Platinum (GE Healthcare). 
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4.4.1 T buffer 
The framed region in Figure 4.5, panel A is presented in a zoom view (Figure 
4.6 panel A). In this system the proteins were all well separated. Two specific regions 
were investigated further (Figure 4.6, panel A, boxes Al, A2) as they contain 
challenging proteins that seemed to vary across the four gels. Zone Al contained two 
well separated protein spots, when presented in the 3D view this allows an assessment 
of the quality of the separation. The two peaks representing the two protein spots 
appeared sharp and well separated suggesting a good resolution, with one of the 
proteins being extracted in higher quantity and showing overloading in this detection 
system. The three proteins highlighted in box A2 were also well separated and again 
were somewhat overloaded as shown by the 3D view (Figure 4.6, panel A2). This 
detailed view confirmed that T buffer offers good extraction and separation of proteins 
including those with similar isoelectric points but unfortunately this buffer is not 
compatible with the protein assay and alternative buffers were tested. This gel was used 
as the reference gel for subsequent analyses. 
Figure 4.6: Evaluation of T buffer for membrane- 
enriched protein solubilisation and separation 
The zoom view of the framed area selected on the 
gel A (Figure 4.5) is shown in panel A and two 
particular areas (boxes Al and A2) were looked at in 
order to evaluate the solubilisation capability of T 
buffer. The proteins in region 1 appeared well 
separated as illustrated by the two sharp and well 
separated peaks in the 3D view (panel Al). The area 
A2 contained three proteins of similar MW and very 
close pI; these proteins were well separated as shown 




4.4.2 U buffer 
The framed region from Figure 4.6 is shown in a zoom view as for the T buffer 
(Figure 4.7), in this view it is clear that U buffer does not enable protein solubilisation 
and resolution at the level observed with the T buffer (Figure 4.6). 
BI 
Figure 4.7: Evaluation of U buffer for membrane- 
enriched protein solubilisation and separation 
A zoomed view of the framed region selected on gel 
B (Figure 4.6) representing a zone containing a large 
amount of protein is shown in panel B and two 
particular areas (boxes B1 and B2) were looked at to 
evaluate the solubilisation capability of U buffer. 
There is only one protein in zone BI whereas T 
buffer solubilised two. This protein was not well 
solubilised as shown on the corresponding 3D view 
(panel BI). The area B2 contained two proteins 
instead of three with T buffer and those proteins 
were not well separated (panel B2). 
B2 
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4.4.3 U7M/T buffer 
The U7M/T buffer contains the same components as T buffer with the difference 
that thiourea was added after protein assay. Thiourea in conjunction with urea has been 
shown to allow the solubilisation of hydrophobic proteins (Rabilloud, 1998). The framed 
region of gel C (Figure 4.5) was investigated with a particular interest in area C1 and C2 
(Figure 4.8). The area Cl contained only one protein rather than the two observed with T 
buffer. In region C2 three proteins were recovered with a good resolution but in lower 
quantity compared to the T buffer. Therefore it can be surmised that the addition of 
thiourea after the protein assay improved the solubilisation of proteins although 
improvements would be needed to achieve the solubilisation and separation that was 
obtained with the T buffer. 
Figure 4.8: Evaluation of U7M/T buffer for 
solubilisation and separation of membrane-enriched 
proteins from HT29. 
The HT29 membrane proteins were solubilised in 
U7M/T buffer and separated by 2-DE (Figure 4.5, 
panel Q. A zoomed view of the framed region 
representing a zone containing many proteins is 
shown (C). Zone Cl contains only one well 
resolved protein as shown on the 3D view. Region 
C2 displayed three proteins but only one (central) 




4.4.4 U7M/T2 buffer 
To try to obtain the separation of proteins observed with buffer "T" and retain 
compatibility with the protein assay we used a buffer similar to the previous buffer 
U7M/T but the concentration of ampholytes was increased from 1% to 2% as the 
addition of carrier ampholytes enhances the solubility of individual proteins as they 
approach their isoelectric points. Ampholytes also produce an approximately uniform 
conductivity across the pH gradient. The quality of resolution was assessed as before. 
Figure 4.9 shows the proteins were solubilised and well separated and the quality of the 
separation obtained with U7M/T2 was similar to that achieved with T buffer and in 
addition it offered the possibility to evaluate the protein concentration of the sample 
prior to loading onto IPG strip and therefore this buffer was used in subsequent 
experiments. 
. tr - 
Figure 4.9: Evaluation of U7MT2 buffer 
The HT29 membrane-enriched proteins were 
solubilised and separated by 2-DE and a zoomed 
view of the framed region in figure 4.5 D is shown 
on panel D. Two areas (D 1 and D2) were 
evaluated. Two proteins were recovered in the 
zone D1. In region D2 three proteins were 
solubilised and well resolved. Overall the quality 
of the solubilisation and the resolution achieved 









4.5 Reproducibility of the 2-DE system 
In this section the reproducibility of the 2-DE separation was assessed using two 
analytical replicates of the same sample (HT29 membrane-enriched proteins). Next two 
gels from different samples were compared, one from HT29 and one from SW480. 
Overall we aimed to determine whether the 2-DE system was suitable for the 
study of changes in protein expression in two cancer cell lines originating from the 
same organ and hence having organ/cell type specific protein composition but also 
having different malignant potential. 
4.5.1 Analytical reproducibility using two replicates of HT29 
membrane-enriched proteins 
HT29 membrane-enriched proteins from the same membrane preparation were 
run on two separate gels in parallel and the reproducibility was assessed. An overview 
of the separation is shown in Figure 4.10. To evaluate the reproducibility between the 
two gels, three regions were chosen, these contained proteins which were low to high 
abundance and from low to high molecular mass. The three regions were numbered 1,2, 
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Figure 4.10: HT29 membrane-enriched proteins separated by 2-DE on a pH 3-10 IPG strip. 
90 µg of protein were loaded and proteins were stained with Sypro Ruby. Three regions numbered 
1,2,3 
were analysed in two replicates of the same gel. 
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For region 1 we observed similar protein separation in both gels with some 
slight differences due to gel-to-gel variation. The zone is located from pH 5.5 to 7 and 
MW from 100 to 250 kDa and contained 4 groups of proteins (Figure 4.11, "a", "b", "c", 
"d") each containing several isoforms of very low abundance proteins as suggested by 
their faint Sypro Ruby staining (Figure 4.11, area 1). Some differences were observed in 
terms of intensity, for example protein "c" was less intense in replicate B as compared 
to replicate A. On the contrary protein "b" was less intense in replicate A. Overall, the 
pattern of migration was reproducible. Protein "d" was composed of 8 well separated 
isoforms in both gels A and B and these were of similar relative intensity. The 
reproducibility between these replicates confirmed the efficiency of the solubilisation 
buffer and showed the capacity of the 2D system to reproducibly separate low 
abundance protein isoforms with high resolution. 
Area 2 (Figure 4.11) is located at pH 5.5-6, MW 45-60 kDa and represented 
three high abundance proteins between 50 and 60 kDa. Figure 4.11 shows a zoom view 
of area 2 from the two replicates A and B, the three proteins were reproducibly 
separated, the intensity of the staining was also very similar between A and B although 
the lower MW protein showed a slight decrease in intensity in replicate B. These three 
proteins are high abundance proteins and their migration pattern on 2-DE was 
reproducible across both replicates. 
Area 3 (Figure 4.11) is located at pH 7.5-8, MW 30-35 kDa and contained four 
medium abundance proteins of size less than 37 kDa, the protein spots were found in 
both replicates with a similar relative intensity. 
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1- AREA 1 (MW 100-250 kDa; pH 5.5-7) 
a 
A000 c ti 
ac 
2- AREA 2 (MW 45-60 kDa; pH 5.5-6) 
3- AREA 3 (MW 35-40 kDa; pH 7.5-8) 
Figure 4.11: Zoom view of area 1,2 and 3 in replicates A and B of HT29 membrane-enriched proteins. 
Region 1 is located from pH 5.5 to 7 and MW from 100 to 250 kDa. Four trails of protein are highlighted 
and named "a", "b", "c" and "d". Those four low abundance proteins comprised many isoforms and were 
reproducible in both replicates A and B. Protein "c" seemed to sustain a significant variation in quantity 
indicated with the red arrow. The eight isoforms of the protein d were reproducibly found in both 
replicates (blue arrow). Region 2 is located at pH 5.5-6, MW 45-60 kDa and contained three high 
abundance proteins. The 2-DE migration pattern of these three proteins is similar in the two replicates A 
and B with a slight decrease in abundance of the lower MW protein in gel B. The four proteins of the 
region 3 are located at pH 7.5-8, MW 30-35 kDa and show similar pattern of migration in replicates A 
and B. 
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The analysis of the three characteristic regions of the two replicates of the same 
sample showed that we have developed a sensitive, reproducible and robust 
methodology to separate CRC membrane-enriched proteins by 2-DE. 
4.5.2 Comparison of HT29/SW480 membrane-enriched 
proteins using a 2-DE system 
HT29 and SW480 both originate from colorectal adenocarcinomas and would 
therefore be expected to contain similar structural proteins, these might be used as 
reference proteins. We analysed the protein profile of the two cell lines separated by 2- 
DE. In this experiment 90 µg of membrane-enriched proteins from either HT29 or 
SW480 were loaded on two gels, separated and stained with Sypro Ruby. The general 
pattern of migration of the proteins from HT29 and SW480 appeared very similar with 
some variations of protein expression (Figure 4.12). Two regions were evaluated in 
more detail. The first region contained structural proteins (tubulin cc and (3) that were 
expressed in near same proportions in both of the cell types, the second region was 




























Figure 4.12: Comparison of HT29 and SW480 membrane-enriched proteins separated by 2-DE. 90 µg of 
proteins from HT29 (A) and SW480 (B) were separated on a pH3-10 
IPG strip, then on a 12% SDS- 
PAGE before fluorescent staining with Sypro Ruby. The two regions that were investigated 
further are 
framed and numbered 1 and 2 in both gels. 
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A zoom view and a mountain plot from region 1 of Figure 4.12 contained three 




Figure 4.13: Zoom and 3D view of area 1 (MW 45-60 kDa, pH 5.5-6) from Figure 4.12. 
The three proteins contained in this box are identically separated on HT29 (panel A) and SW480 (panel 
B). Their patterns of migration are also very similar. 
The framed-zone 2 from Figure 4.12 was similarly analysed and an enlarged 
view is shown in Figure 4.14. This showed similar protein patterns with discrete 
changes in the amounts of some of the proteins. In the 3D view of Figure 4.14 the blue 
and red arrows indicate proteins present in greater amounts in HT29 and SW480 
respectively. Two proteins (circled in Figure 4.14) have similar intensities in both of the 
two cell lines, this taken with the observation regarding similar quantity of structural 
proteins rules out the possibility of a variation due to protein loading. The 
reproducibility of the 2-DE system therefore offered potential to study the level of 
expression of HPA-binding proteins in these to cell lines. 
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Figure 4.14: Zoomed and 3D view of area 2 (MW 30-35 kDa, pH 9-10) from Figure 4.12 
The proteins of this area are identically separated but variations in their expression are noted. The two 
circled proteins are expressed in similar quantity but the arrows show protein spots sustaining increase in 
protein expression in HT29 (blue) and in SW480 (red). 
4.6 Discussion 
In this chapter we first evaluated the compatibility of the chemicals used in 
solubilisation buffers with several protein assay methods and we established that the 
Bradford assay was the most suitable and reliable to determine the protein content when 
a complex mixture of chemicals containing up to 7M urea, 4% CHAPS, 1% DTT and 
2% ampholytes was used. 
There have only been a few studies investigating cancer-derived HPA binding 
proteins and even fewer investigating the HPA-binding partner of membrane-enriched 
proteins from CRC cells. It seems that high speed centrifugation is the preferred 
approach to study such proteins (De Albuquerque Garcia Redondo et al., 2004) 
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although detergent-based approaches are also available to prepare membrane-enriched 
proteins. De Albuquerque Garcia Redondo et al. (2004) were the first group to 
investigate the membrane proteins recognised by lectins such as HPA and WGA of the 
surface of CRC cell lines (HCT116 and CaCo2). The methods to prepare membrane 
proteins in our study are slightly different with respect to the buffers used but the key 
step is the use of high speed centrifugation and this was a common feature in both 
studies. A comparison of the membrane-enriched protein content of HT29 (our study) 
and HCT 116 (De Albuquerque Garcia Redondo's group) showed that we solubilised, in 
higher quantity, the same 8 proteins bands ranging from 20 kDa to 97 kDa that they 
identified in the membrane-enriched fractions of HCT 116 but we also identified several 
other proteins. In addition, we also showed that the membrane-enriched fraction of 
HT29 contained the majority of the total HPA-binding proteins of HT29. We concluded 
that our approach enabled us to prepare a protein fraction enriched in membrane 
components and that this constitutes an ideal model for studying HPA-binding proteins 
in CRC. 
The analysis of membrane proteins remains a major challenge for 2-DE based 
proteomics. For a long time membrane proteins could not be solubilised under the 
condition required for IEF (Wikins et al., 1998). However the use of thiourea, urea and 
the introduction of zwitterionic detergents has enabled the analysis of some membrane 
proteins by 2-DE (Rabilloud et al., 1997; Chevallet et al., 1998; Rabilloud et al., 1999). 
We evaluated the efficiency of several solubilisation buffers by comparing the 
separation of the proteins by 2-DE and found that the U7M/T2 buffer allowed efficient 
solubilisation of membrane-enriched proteins and compatibility with the Bradford assay 
and that this system was the solubilisation buffer of choice. However there are not ideal 
solutions to the problem of solubilisation of hydrophobic proteins and it is well accepted 
that various membrane proteins will not be solubilised with a single non 
ionic/switterionic detergent such as CHAPS. This is detrimental as some important 
HPA-binding proteins may be lost when studied by 2-DE. The solubilisation of 
membrane proteins has been studied by several research groups contributing 
to a great 
improvement of their analysis by 2-DE or by other methods. In particular the use of 
non-ionic and/or zwitterionic detergents with 
higher "solubilising power" such as 
dodecyl maltoside, decaethylene glycol monohexadecyl ether, triton 
X 100 or ASB14 
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has been shown to improve the solubilisation of integral membrane proteins (Luche et 
al., 2003). The composition of the solubilisation buffers has to be empirically adapted to 
reach the best solubilisation rate for the proteins of interest. New techniques have also 
been developed to study the highly hydrophobic proteins such as proteolytic digestion 
prior to chromatographic separation (RP LC) and identification by MS (Rabilloud, 2003; 
Wu et al., 2003). Also the labelling of cell surface proteins (e. g. with biotin) followed 
by affinity purification and identification of tryptic peptides by MS greatly improve the 
analysis of membrane proteins (Sabarth et al., 2002; Clifton et al., 2007; Zhang et al., 
2003). Although in our case the 2-DE with U7M/T2 buffer appeared well suited to 
analyse the HPA-binding proteins of HT29, the use of another detergent or other 
techniques could enhance our analysis. 
Finally we evaluated the robustness of the separation method, 2-DE. We 
assessed the reproducibility between two analytical replicates and we established that 
the method can be used to detect changes in protein expression in HT29 and SW480 
cells. The protein map of the membrane-enriched proteins from HT29 separated using 
2-DE with pH3-10 IPG strips was comparable to the 2D map generated for the same 
cell line by Tan et al. (2002). Several high abundance proteins of MW ranging from 40 
kDa to 70 kDa were found to be present in both experiments although different samples 
were used, total lysate (Tan et al. ) and membrane preparation (our group). For example 
the three high abundance proteins that we analysed (Figure 4.12, Area 2, MW 45-60 
kDa, pH 5.5-6) were common to both our system and that of Tan et al.. We also 
observed high MW proteins (Figure 4.12, Area 1, MW 100-250 kDa; pH 5.5-7) that 
were not identified in the 2D map of Tan et al. This may be because these proteins are 
membrane proteins which were enriched in the high speed ultracentrifugation step. 
More over the resolution obtained in our experiment using 7 cm strips was as good as 
the 2D map obtained using 17 cm strips by Tan et al. This suggests that our method for 
solubilisation and separation generates high quality 2D maps. From this work we 
concluded that the 2-D system is ideally suited to allow the analysis of protein 
levels 
and the HPA binding proteins with a high probability that many of these are 
found on 
the surface of HT29 cells. 
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CHAPTER FIVE: 
Identification of HPA 
binding glycoproteins 




Many studies have described the ability of the lectin HPA to bind poor prognosis 
cancer cells and cell lines with metastatic potential such as HT29. We confirmed those 
findings using the cell lines HT29, SW480 and SW620 in conjunction with 
fluorescently labelled lectin and using both confocal microscopy and microtitre assay. 
Our previous experiments with HT29 showed mainly membrane localisation of 
the binding (Figure 4.4). The utility of HPA as a prognostic tool would be expected to 
come from its ability to bind to membrane glycoproteins as HPA binding ligands from 
cancer cells have been linked to the metastatic spread of colorectal cancer cells in vivo 
(Schumacher et al., 1994) and has also been shown to be implicated in adhesion to 
endothelial cells (reviewed by Dwek and Brooks, 2004). The investigation of the HPA 
binding proteins of the cell surface of a metastatic cell line HT29 was therefore used as 
an approach to assist in the discovery of glycoproteins involved in the metastatic 
process. De Albuquerque Garcia Redondo et al. (2004) was the first group to study the 
HPA binding proteins of colorectal cancer cell lines using isolated cell membranes and 
they described glycoproteins that are common to all the cell lines as well as differences 
in the composition of the HPA binding proteins, for this HCT116, Caco-2 and IEC-6 
cell lines were used. Observations were made using 1-DE and lectin blotting but in this 
study De Albuquerque Garcia Redondo et al. did not identify the HPA binding 
glycoproteins. In 2001, Brooks et al. studied the HPA binding proteins in various breast 
cancer cell lines and highlighted 11 major protein bands ranging from 20 to 200 kDa but 
the proteins were simply evaluated with reference to their molecular weight. Previously 
Schumacher et al. (1995) and Mitchell et al. (1995) reported 4 and 7 HPA binding 
bands ranging from 20 to 90 kDa including bands at 69 kDa and 90 kDa identified as an 
N-acetylgalactosaminylated form of albumin and the transferrin receptor. 
We used HT29, SW480 and SW620 as cell lines models of metastasis. HT29 
and SW480 are HPA positive and HPA negative as described earlier. A proteomic 
approach was undertaken this was based on I DE and 2DE separation of membrane- 
enriched proteins followed by lectin binding. HPA affinity chromatography combined 
with 2-dimensional electrophoresis (2-DE) and mass spectrometry allowed us to 
discern 
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and identify the HPA binding proteins in the cell line bearing the metastatic phenotype 
(HT29). 
5.2 Overview of the HPA binding proteins of HT29, 
SW620, SW480 by SDS-PAGE and lectin blotting. 
SDS-PAGE analysis followed by HPA-western blotting of the enriched plasma 
membrane fractions from HT29, SW620, and SW480 was performed in three separate 
experiments. A typical lectin blotting is shown in this sections (Figure 5.1) and 
highighted similarities in HPA-binding but also allowed identification of differences 
between the cell lines. HT29 contained 17 glycoproteins recognised by HPA ranging 
from 24 kDa to 135 kDa. SW480 and SW620 both contained 18 proteins bands ranging 
from '- 24 to 130 kDa and -25 to 130 kDa respectively, the exhaustive list of proteins 
bands detected in each cell line as well as their relative abundance and molecular 
weights are reported in the Appendix 5. Figure 5.1 shows the results of the western blot 
analysis, the bands which showed varied expression across the cell lines (bands 1,2) 
and also the major protein bands common to the three cell lines (bands 3,4,6,7,8 and 
9). The MW of proteins 1-8 for each cell line are shown in Table 5.1. In the HPA 
positive cell lines HT29 and SW620, two proteins of high intensity (bands 1 and 2 were 
the predominant HPA binding sites. Protein bands 1 and 2 were subject to variations in 
intensity across the 3 cell lines. Band 1 (GP 130) was a very intense HPA-binding 
polypeptide in HT29, less intense in SW620 and almost non-detectable in SW480. 
Similarly band 2, (GP80) showed decreased intensity of HPA-binding across the cell 
lines from intense in HT29 to moderate in SW620 and non-detectable in SW480. When 
comparing all the three cell lines at the 1-DE level it became obvious that most of the 
proteins recognised by HPA in SW480 (3-8) were also recognised in HT29 and SW620, 
therefore we classified these glycoproteins recognised by HPA as "non specific" 
binding. Two major glycoproteins GP130 and GP80 attracted our interest as they were 
the most intense HPA binding species in the HPA positive HT29 and SW620 whereas 
they were almost non-detectable in SW480. 
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Figure 5.1: HPA lectin blotting after separation by 1DE. 20 µg of proteins of the three cell lines were 
separated on a 12% SDS-PAGE , probed with HPA and detected with DAB/H202. The proteins 1 and 2 
are recognised by HPA in HT29 and SW620 and constitute the main HPA binding sites. The protein 3 is 
consistently found in the three cell lines and constitute the background of signal due to streptavin binding. 
The proteins 4-8 are recognised by HPA in the Three cell lines. 
Band number Molecular Weight (kDa) 
HT29 SW620 SW480 
1 135 130 130 
2 87 85 N/D 
3 74 71 73 
4 45 44 44 
5 33 32 32 
6 31 31 31 
7 30 30 30 
8 29 29 29 
Table 5.1: Proteins recognised by HPA in HT29, SW620 and SW480 and their relative molecular weight. 
N/D=not detectable 
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5.3 Binding of a blood group A antibody to Western 
blots of HT29, SW620 and SW480 proteins 
In this experiment we aimed to determine whether HPA simply recognises the 
blood group A epitope in the three cell lines, HT29, SW480 and SW620 (all derived 
from blood group A individuals). We used a murine monoclonal antibody directed 
against the blood group A antigen to probe the proteins of the three cell lines separated 
by 1-DE, the aim of this step was to determine whether the glycoproteins recognised by 
HPA are blood group antigen expression or if they are glycans with a different 
composition. HT29, SW480 and SW620 showed 12,11 and 13 protein species 
respectively that were recognised by the blood group A antibody, these ranged from 
-20-80 kDa (Figure 5.2) 
Similarities in the overall pattern of proteins carrying blood group epitopes are 
observed between the three cell lines of our model however interesting variations are 
observed in particular between SW480 and SW620, the two cell lines with different 
metastatic capabilities derived from the same blood group A patient. Indeed changes in 
the composition of proteins as well as the intensity of the signal suggest that the cells 
with a metastatic potential (SW620) undergo modification in their glycan repertoire. In 
particular the reduction of the blood group A epitopes as detected by the blood group A 
monoclonal antibody seem to be part of the changes leading to a metastatic phenotype 
as previously suggested by Ichikawa et al. (1998). 
The blood group A antibody bound most intensely to proteins between 20 kDa 
and 85 kDa (shown by asterisks on Figure 5.2) these bands were also recognised by 
HPA in HT29, SW480 and SW620. Two of these proteins appeared to be common to 
all of the cell lines (shown by red asterisks on Figure 5.2). The proteins described in 
section 5.2 as "non specific" with respect to HPA binding also appeared to be the major 
bands that bound the anti-blood group A antibody although GP 80 seems to be 
composed of two HPA-binding bands and only one of these carried the blood group A 
antigen. This suggests that some of the epitopes recognised by HPA contain glycans 
bearing the blood group A antigen. However the blood group A epitope was not 
detected on all of the HPA binding glycoproteins, for example, GP 130 and several other 
proteins that bound HPA in a less intense manner. This suggested that the 
binding of 
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HPA to the metastatic cell lines was by recognition of epitopes bearing glycosylation 
motifs distinct from the blood group A antigen potentially encompassing part of the 








































Figure 5.2: HT29, SW480 and SW620 membrane-enriched proteins separated by 1-DE and Western 
blotting. 
Detection of blood group A antigen using a monoclonal antibody directed against human blood group A 
epitope. The equivalent Western blot probed with HPA is shown as a reference blot. 
The anti-blood group A antibody detected 12,11 and 13 protein bands respectively in HT29, SW480 and 
SW620 in a range of sizes from -20 to 80 kDa. 7,7 and 8 proteins (shown by asterisks) were detected by 
HPA and the anti-blood group A antibody in HT29, SW480 and SW620 respectively. Amongst these, 2 
protein bands were commonly found in every cell line and are shown by red asterisks. GP80 was 
recognised by HPA and the anti-blood group A antibody suggesting that its HPA binding sites contain the 
blood group A residues. In contrast, GP130 was only detected by HPA and did not bind the anti-blood 








5.4 Inhibition study of HPA binding to membrane- 
enriched proteins from HT29 at the protein level 
Membrane-enriched proteins from HT29 were separated by 1-DE and blotted 
onto nitrocellulose membranes. In order to determine that HPA was binding the 
glycoproteins via a glycan-lectin interaction and also to determine the monosaccharide 
specificities we pre-incubated the lectin for 30 min in a buffer containing GaINAc, 
G1cNAc or SA before probing the Western blot. These experiments were repeated three 
times and were undertaken using monosaccharides in the range 50 to 250 mM, and the 
typical data for 250 mM solutions are shown. G1cNAc, Ga1NAc and SA all inhibited the 
binding of HPA to the predominant HPA binding polypeptide of 130 kDa (GP 130) as 
well as to the 80 kDa species (GP80) (Figure 5.3). Ga1NAc was a slightly more 
effective inhibitor of HPA binding to the lower molecular weight proteins than GlcNAc 
supporting the data that showed these proteins contain the blood group A epitope 
(Figure 5.2). Incubation with SA at this concentration abrogated the majority of HPA- 
binding to HT29 proteins, including the lower molecular weight species of 25,31 and 
45 kDa. The results illustrate that the interaction between biotinylated HPA and the 
cancer glycoproteins is via a lectin-mediated interaction that may be inhibited using 
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Figure 5.3: Inhibition of the HPA binding to HT29 proteins. 20 µg of proteins from HT29 were separated 
on a 12% SDS-PAGE and incubated with HPA-biotin; pre-incubated for 30 min with 250 mM Ga1NAc, 
G1cNAc or SA. Inhibition of GP130 and GP80 was observed with all three sugars. The negative control 
where HPA was omitted showed a non-specific band of 75 kDa present in every experiment. 
5.5 HPA binding: 2-DE and lectin blotting analysis 
The membrane-enriched proteins from HT29 and SW480, were separated by 2- 
DE, transferred to nitrocellulose and probed with HPA. We used the resolving power of 
2-DE to investigate in detail the individual polypeptides recognised by the lectin HPA 
in three separate occasions and typical results are shown in this section. The 
observations were similar to those made on 1 -DE with several common proteins of MW 












Figure 5.4: Comparison of HPA binding proteins of HT29 (panel A) and SW480 (panel B) by 2-DE and 
lectin blotting with HPA. 90 tg of HT29 and SW480 membrane-enriched proteins were separated by 2- 
DE, transferred to nitrocellulose by Western blotting and probed with HPA. A wide range of proteins 
were recognised below 80 kDa including the streptavidin binding protein (shown with an arrow) and a 
large number of proteins weakly bound by HPA in both cell lines. In the HPA positive cell line HT29, 
HPA bound strongly to GP 130 (framed in red) and a group of several glycoproteins badly separated of 80 
kDa (black box), whereas HPA did not bind to proteins in the same region in SW480. 
In this experiment some of the "non specific" binding was seen to be due to 
endogenous biotin as represented by the streptavidin binding protein of MW 80 kDa 
(Figure 5.4, shown by the black arrow). GP80 was detected only in HT29 as a wide, 
diffuse trail of proteins (black box, Figure 5.4). The intensity of the HPA-binding to 
GP80 was intense but its protein components were not individually separated. GP130 
was separated and the intensity of HPA binding confirmed that it was one of the 
principal HPA binding sites in the metastatic cell line HT29. This experiment confirmed 
that higher molecular weight acidic proteins comprising GP130 are the major proteins 
recognised by HPA in HT29 (red box, Figure 5.4), these proteins were not recognised in 
SW480. Moreover 2-DE enabled the separation of individual polypeptides hidden 
within, for example, the GP 130 protein band perhaps representing differentially 
glycosylated forms of the same polypeptide sequence. 
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5.6 Inhibition of the HPA binding to GP130 in HT29 
The monosaccharide specificity of HPA was tested after separation of the 
proteins by 2-DE. We used the previous results obtained in the 1-DE to design this 
experiment as we have shown previously that HPA binding to GP 130 could be inhibited 
using GaINAc, GlcNAc and SA. We chose the region of the gel containing GP130 
proteins and evaluated the inhibition of binding of HPA using G1cNAc and SA. In 
Figure 5.5 panel A, HPA alone was used and the various components of GP 130 (black 
box) as well as the non specific streptavidin binding (dotted box) were observed. The 
streptavidin binding signal was used as a landmark to locate GP130 in each subsequent 
experiment. Preincubation of HPA with GlcNAc at 250 mM (Figure 5.5, panel B) or SA 
at 250 mM (Figure 5.5, panel C) inhibited the binding of HPA to all of the components 
of GP 130, confirming that HPA binds GP 130 via glycan epitopes containing GlcNAc or 
SA. 
A: HPA .............................. 
B: HPA + G1cNAc ....... 
ý 
................. 
C: HPA + SA .............................: 
D: Streptavidin control .......................... 
Figure 5.5: Inhibition of HPA binding to GP 130 in HT29.90 µg of HT29 membrane-enriched proteins 
were separated on pH 3-10 2-DE and probed with HPA (panel A), HPA preincubated with 250 mM 
G1cNAc (panel B), HPA preincubated with 250 mM SA (panel Q. In the last experiment (panel D) HPA 
was omitted and highlighted the presence of streptavidin binding proteins in HT29 (dotted 
box). The 
binding of HPA to GP130, shown in the black boxes, was totally inhibited by G1cNAc and SA. The, 
negative control where HPA was omitted highlighted the presence of streptavidin 
binding proteins in 
HT29. 
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5.7 Analysis of GP130 
The data obtained in the 1-DE and 2-DE experiments have shown a range of 
proteins that bind HPA in HT29. Of these, GP 130 was recognised by HPA in both the 
metastatic cell lines HT29 and SW620. We aimed to analyse this protein further, to this 
end, the same conditions were used to run three 2-DE experiments using a range of pH 
gradients to improve the separation of the GP130 material (Figure 5.6). The zoom view of 
the region containing GP130 shown in Figure 5.6 confirmed that several proteins species 
comprise GP130. Using the pH3-10 strip the separation was not sufficient to establish a 
clear map of the polypeptide composition (Figure 5.6, panel A). Using pH 5-8 strip the 
separation was improved (Figure 5.6, panel B) whilst the pH 4-7 strip afforded the 
greatest improvement in separation. In this final zoom strip GP130 was found to comprise 
four clear trails of proteins ranging from pH 5 to 6.5 (numbered 1-4 in Figure 5.6 Panel C). 
Protein 1 contained approximately 13 faint protein spots each probably representing an 
isoform of the same protein. The protein 2 contained approximately 10 to 12 spots, the 
variations between 0.05 and 0.1 pH unit suggest this protein may be modified post- 
translationally, for example by phosphorylation but there was also a slight variation in the 
MW which might result from differences in glycosylation. Proteins 3 and 4 contained, 
respectively, 4 and 10 isoforms. We can also speculate on the affinity of the HPA binding 
as it seems that HPA binds preferentially to components 2 and 4 of GP 130. This series of 
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Figure 5.6: Separation of GP 130 using a zoom 2-D gel strategy. 
IPG strips with various pH gradient were used to separate GP130. The quality of the separation gradually 
improved by altering the pH gradient from pH 3-10 (panel A), pH 5-8 (panel B) to pH 4-7 (panel Q. 
Each panel shows a zoom view of the region between pH 5-6.5 containing GP130. In panel C we 
numbered 1,2,3,4 the polypeptides that comprise GP130. 
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5.8 Purification of the HPA binding proteins of HT29 
In the previous section we established the basis of the recognition of membrane- 
emriched glycoproteins by HPA by probing Western blots with the lectin. In the next 
step we purified the HPA-binding proteins by HPA affinity chromatography in an 
attempt to enrich and identify them. The procedure briefly utilised an HPA 
chromatography column prepared using 1 mg of purified lectin attached to Sepharose 
beads. Total cell lysate was prepared in 150 mM KCl and 500 µg of proteins were 
loaded onto the column. Throughout this section each experiment was performed 
several times (at least three times) and typical results are shown. Figure 5.7 shows the 
chromatogram obtained with HT29, SW620 and SW480 proteins and the corresponding 
Coomassie stained 1D gel separation of proteins that bound HPA. The overall pattern of 
the three separations was in accordance with the previous findings on the Western blots. 
In HT29, approximately 11 % of the protein loaded bound to the column and these 
appeared to be composed of 8 main protein species ranging from -25kDa to 150 kDa, 
these proteins included GP130. In the non-metastatic cell line SW480 approximately 
1.2% of the protein loaded bound to the column. Three proteins ranging from -25 kDa 
to 55 kDa were visualised after separation on a 1D gel. For the cell line SW620 
approximately 3% of the proteins bound to the HPA column. The analysis of the three 
chromatograms is presented in Appendix 6. The increasing amount of HPA-binding 
proteins purified from SW480, SW620 and HT29 correlates with the metastatic 
potential of each of the cell lines and appeared to confirm the importance of GP130 in 
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Figure 5.7: Affinity purification of HPA binding proteins. Cell lysate was prepared in 150 mM KCl for 
HT29, SW620, SW480 and 500 tg were loaded onto the HPA affinity column. The HPA binding proteins 
were eluted with a gradient of G1cNAc from 0-1M. The unbound proteins and the proteins which were 
eluted by competition with G1cNAc (bound) are shown with black arrows. The proteins contained in the 
eluted fraction were separated on 1D gel and stained with Coomassie Brilliant Blue. 
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5.9 Improvement to the HPA affinity chromatography 
purification of HT29 proteins 
Although sufficient proteins were obtained in the previous experiment to allow 
1D analysis, there was not enough material to allow proteomic analysis of the HPA 
binding proteins. 
An improved method in which membrane-enriched proteins were prepared and 
solubilised in lectin buffer supplemented with 0.1% of CHAPS was developed. This 
method allowed us to load the column with a sample enriched in HPA binding proteins. 
To further improve the amount of HPA binding material collected, the column was 
prepared with 5 mg of purified HPA (instead of 1 mg in the previous experiment) 
coupled to the column. Figure 5.8 panel A shows the result of an experiment in which 
500 µg of HT29 membrane-enriched proteins were loaded onto the column. The HPA 
binding proteins were eluted from the column with a step gradient of 250 mM G1cNAc. 
Analysis showed that 28% of the protein loaded onto the column bound HPA (2.5 times 
more protein than in the previous experiment). This enabled the separation of HPA 
binding glycoproteins on 2-DE with Coomassie Brilliant Blue staining prior to mass 
spectrometry analysis of the protein spots (Figure 5.8 panel B). 















Figure 5.8: Affinity purification of HT29 proteins using an HPA-Sepharose column. 500 µg of proteins 
from HT29 membrane-enriched preparation solubilised in lectin buffer supplemented with 0.1% of 
CHAPS. 
Two peaks are observed (shown with arrows in panel A), these correspond to the flow through and the 
bound glycoproteins eluted from the column using 250 mM G1cNAc (panel A). Panel B shows the 2-DE 
separation of the HPA binding glycoproteins after purification by HPA lectin affinity chromatography, 
the proteins were visualised using Coomassie Blue. 
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The membrane-enriched proteins purified by HPA affinity chromatography 
described above were identified using MALDI-MS and MS-MS. The exhaustive list of 
proteins identified is presented in Table 5.2, the MALDI-TOF mass spectra as well as 
the sequence coverage of the peptides identified are shown in Appendix 7. The protein 
spots that were analysed by MALDI-MS and MS-MS are annotated in Figure 5.9. 
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Figure 5.9: Proteomic analysis of the affinity purified HPA binding proteins of HT29. 
2-DE separation of HT29 membrane proteins pre-fractionated by HPA affinity chromatography was 
achieved on a pH 3-10 IPG strip followed by SDS-PAGE. Two out of four protein components of GP130 
were recovered and identified by mass spectrometry as integrin a6 and aV. 13 other proteins were 
submitted to mass spectrometry and their identity are presented on the gel. 
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Protein names Accession 
number 
Mascot mass kDa 
score 
calculated pI sequence 
coverage 
Integrin Alpha 6 giJ5726563 389 120.6 6.44 19% 
Integrin Alpha 6 gi15726563 599 120.6 6.35 25% 
Cytokeratin 8 gi1181573 758 53.3 5.5 45% 
Cytokeratin 8 giJ 181573 758 53.3 5.5 43% 
Integrin Alpha V giJ4504763 431 117 5.45 14% 
Tumor rejection antigen gi14507677 166 92.7 4.76 9% 
gp 96 
90 kDa Heat shock giJ306891 348 83.5 4.97 20% 
protein 
Cytokeratin 18 gi130311 127 47.3 5.27 19% 
Cytokeratin 18 giJ30311 127 47.3 5.27 15% 
Annexin A2 isoform 2 giJ4757756 1010 38.8 7.57 62% 
Guanine nucleotide- gi120357529 470 38 5.6 36% 
binding protein Beta 2 
subunit 
heat shock protein 8 gi15729877344 344 71 5.37 
14% 
isoform 1 
Alpha tubulin gi1340021662 662 50.8 4.94 30% 
Tubulin Beta 2 giJ20809886419 419 50.2 4.76 22% 
Beta Actin giJ4501885 511 42 5.29 
26% 
Annexin A4 gib 1703319 563 36 5.9 
32% 
Table 5.2: Identification of the HPA binding protein of HT29. The protein spot analysis was compiled 
in 
this table and provides protein identities, Mascot score and sequence coverage. 
5.10 Anti integrin a6 antibody binding to HT29, 
SW620 and SW480 proteins 
Purification of HPA binding proteins combined with mass spectrometry analysis 
identified integrin a6 as an important component of GP 130 and this suggests 
that both 
the integrin a6 protein and/or its altered glycovariant may play a 
role in the metastatic 
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process. Two experiments were performed and typical results are shown in Figure 5.10. 
We used an anti-integrin a6 antibody (anti-CD49f) to compare the level of integrin a6 
in the three cell lines HT29, SW620 and SW480 and we observed that the binding of 
HPA to the three cell lines HT29, SW620 and SW480 correlated with the binding of the 
mAb anti-CD49f (Figure 5.10), although the HPA binding band (GP 130) was 
consistently more diffuse and therefore presumably comprises a wider range of epitopes 
including integrin a6. It is important to note that the changes of expression as detected 
by the mAb anti-CD49f may partly explain the binding of HPA to the metastatic cell 
lines HT29 and SW620 however it seems that the expression of glycoforms of the 
integrin a6 carrying changes in their glycans repertoire is more important for the 
metastatic phenotype than the level of expression of the "normal" integrin a6 itself. 
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Figure 5.10: Integrin a6 antibody and HPA binding to Western blots of HT29, SW620 and SW480 
proteins. 20 µg of membrane proteins from SW480 and HT29 cell lines were separated on a 
12% SDS- 
PAGE, transferred to nitrocellulose membrane and incubated with either 5 µg/ml of biotinylated-HPA 
(panel A), or 4µg/ml of mAb anti integrin a6 (panel B), before incubation with 2 µg/ml of streptavidin- 
HRP and detection. GP130 is detected with the lectin only on HT29 and 
SW620, similarly, integrin a6 
is detected on HT29 and SW620 but not on SW480. 
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5.11 Protein expression analysis of HT29 and SW480 
As a further evaluation of the metastatic and non-metastatic cell line models, the 
overall protein expression was compared using a 2-DE based proteomics approach. This 
experiment aimed to determine whether the HPA-binding glycoproteins detected in 
HT29 are ubiquitous proteins showing changes in glycosylation, or if they are 
glycoproteins found at different levels under particular conditions such as 
transformation leading to a metastatic phenotype. We prepared two reproducible gels 
per cell line and we analysed two typical gels, one from HT29 and one from SW480 
using membrane proteins separated on an IPG strip of pH 3-10 followed by SDS-PAGE, 
stained with Sypro Ruby and used a software-assisted approach to compare and match 
the proteins from SW480 and HT29. 
Figure 5.11 shows the region between pH 5-7 and MW 50-150 kDa of HT29 and 
SW480 2-DE gels (Figure 5.11, panel A and B). The proteins framed in box 1 
comprising GP130 are expressed only in HT29. The separation and the intensity of each 
component of GP 130 is illustrated in panel C. Several others proteins (circled in Figure 
5.11, panels A and B) are also differentially expressed in HT29 but these were not 
recognised by HPA on 2-DE. There are also proteins expressed in near identical 
quantity in HT29 and SW480 as shown on the example (Box 2, Figure 5.11, panel D 
and E). 
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Figure 5.11: Comparison of the proteins from HT29 and SW480.90 gg of protein from HT29 and 
SW480 were separated by 2DE and stained with Sypro ruby. The region between pH5 and 7 and MW 
from 50 to 150 is presented as it contained a protein of interest, GP130 (panel A and B). Some proteins 
were found in equivalent quantities in HT29 and SW480 and the 3D view of the region 2 (panel D and 
E) illustrates this observation. GP130 sustained changes in expression (red box 1) and was expressed in 
HT29 but not in SW480. 
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The software package Phoretix Evolution, from Nonlinear Dynamics was used 
to overlay the proteins maps of HT29 and SW480 (Figure 5.12). 1096 proteins spots 
were detected on the SW480 gel and 1125 on the HT29 of which 827 were matched to 
SW480. In HT29,298 spots were not matched to SW480, including the GP 130 
material. This suggests a difference in the regulation of the expression of the GP 130 
proteins and the other proteins in HT29. The GP130 proteins appeared to be of major 
importance for the binding of HPA. The findings using the Phoretix software reinforce 
the hypothesis that GP 130 is a key element in the binding of HPA and probably in the 




























Figure 5.12: Overlay of 2-DE separation from HT29 and SW480.2-DE was performed with 90 µg of 
proteins from HT29 and SW480: the first dimension was undertaken using a pH 3-10 IPG strip and a 
zoom in the pH range 5-8 is shown, the second dimension was performed on a 10% SDS-PAGE. The 
software Phoretix Evolution (Nonlinear Dynamics) was used to analyse the gels. Spots were detected 
automatically, filter applied and gel matching was performed. SW480 is shown in green and was set as 
the master gel, HT29 is shown in purple and was matched to SW480.1096 spots were 
detected in SW480 
and 1125 in HT29.827 spots were matched and appear in black on the 
image. Purple spots, including 
GP 130 are shown in the boxed area at the top of the gel and represent proteins spots 
found exclusively in 




In this study we used a well characterized model of human colorectal cancer cell 
lines with defined in vivo behaviours and lectin binding properties to discern the 
glycoproteins bound by the lectin HPA. Using 1-DE we found 17,18 and 18 protein 
bands were recognised by HPA in HT29, SW620 and SW480 respectively. Many of the 
proteins of MW <80 kDa were found in all three cell lines and were the weaker bands 
in terms of intensity of lectin binding. A non specific signal due to biotinylated proteins 
which bound to streptavidin-HRP was observed in each cell line and had MW between 
71 and 74 kDa. The comparative analysis also showed there were considerable 
differences between the HPA binding protein species in the three cell lines, HT29, 
SW620 and SW480. Two major HPA binding partners of high molecular weight (MW: 
130 kDa and MW: 80 kDa) were identified by lectin blotting of membrane proteins 
separated by I DE in the metastatic cells HT29 and SW620. Interestingly these two 
protein bands were most strongly detected in HT29 and SW620 (GP 130 being stronger 
than GP80) but were not detected in the non-metastatic cell line SW480. Brooks et al. 
(2001) identified 11 major protein bands recognised by HPA in a variety of breast 
cancer cell lines and they noticed changes in the intensity of HPA binding to some 
bands but did not identify the proteins. Previous experiments by Schumacher et al. 
(1995) and Mitchell et al. (1998) identified 4 and 7 protein bands recognised by HPA 
and two of these were identified as an N-acetylgalactosaminylated form of albumin and 
the transferrin receptor. De Albuquerque Garcia Redondo et al. (2004) were the first 
group to evaluate the HPA binding proteins of membrane fractions of three colorectal 
cancer cell lines. They observed variations in the composition of HPA binding protein 
of three cell lines (IEC-6, CaCo2, and HCT 116). The protein bands observed ranged 
from 14-60 kDa but they did not establish a clear difference between the cell lines 
Inhibition experiments 
Inhibition experiments showed that the interaction between HPA and the two 
predominant protein bands was via a lectin-like interaction that could be inhibited with 
both GaINAc and G1cNAc and, somewhat surprisingly, SA. Analysis using an anti 
blood group A antibody has shown that the glycan epitopes that are recognized by HPA 
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include the blood group A antigens but there was also a range of other protein species 
that were not recognised by the blood group A antibody and that, presumably, exhibit 
different glycosylation (Hakomori, 1999). The experiments showed that GP130 did not 
bear the blood group A antigen but competitive inhibition experiments allowed us to 
conclude that this protein did contain G1cNAc and SialAc motifs. A proteomic 
approach was developed to analyse GP 130. We demonstrated that GP 130 is composed 
of four glycoproteins which undergo variations in their expression and that 
differentially bind HPA, a strong correlation was noted between expression of GP 130 
and binding of HPA. 
MS analysis of proteins binding HPA 
The proteins of GP 130 and other HPA binding proteins are known to be present 
in small quantities which did not enable identification by mass spectrometry MALDI- 
TOF therefore we used a strategy comprising pre-fractionation by HPA-affinity 
chromatography to unravel the glycoproteins recognized by HPA in the metastatic 
HT29 cancer cells. This experiment did not allow a complete recovery of all the four 
members of GP130 protein band but two of the proteins (number 2 and 4) were 
identified as integrin a6 and aV. Thirteen other HPA binding proteins were also 
identified. The proteins that eluted in the HPA binding affinity chromatography fraction 
included molecules involved in cell adhesion and migration (integrin a6, integrin (xV, 
annexins) re-modeling (filament proteins including (X tubulin, f tubulin, cytokeratins, 
actin) and anti-apoptotic pathways (Hsp-70, Hsp-90, Hsp-96 and TNFR-1) (Juliano and 
Varner, 1983; Prasad et al., 1999; Ciocca and Calderwood, 2005). Some of the proteins 
are present because they bind directly with HPA and others are found as complexes 
with HPA binding proteins. Whilst many of these proteins have previously been 
described in cancer we are not aware of any reagent - other than HPA - which will bind 
these proteins simultaneously. HPA may recognize these proteins by virtue of changes 
in the normal glycan repertoire and the data obtained using the anti blood group A 
antibody supports this hypothesis. It is important to note that the MASCOT search 
program which compared the resulting peptide mass fingerprint of a sample analysed to 
the theoretical peptide fingerprint generated in silico by the search program, and 
produces a statistically based Mowse score that evaluates the significance of the 
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matches (Pappin et al., 1993). In our experiment proteins were identified with Mowse 
scores >163 (with the exception of the TNFR-1) which confers a high degree of 
confidence to our results. 
Integrins 
The results obtained in this study showed that the binding of HPA to HT29 and 
SW620 is via the recognition of epitopes carried by several proteins including integrin 
a6 and integrin uV. There are many reports of altered integrin expression in carcinoma 
as compared to their "normal" counterpart, but some of them are conflicting and are 
reviewed in Gilcrease, 2007. The best studied integrins in cancers include the laminin 
receptors a2ß1, a3(31, a6pl and a604 which all showed altered expression in 
cancerous tissues of the colon as compared to their healthy counterpart (Chao et al., 
1996). The presence/abscence of integrins and in particular a6(34 appear to be a 
common feature in invasive CRC. Indeed a6ß4 is highly involved in several stage of 
cancerous progression and its expression during metastasis is no longer localised in 
hemidesmosmes but at the invasive front and in cell protusions (Rabinovitz et al., 1999; 
Rabinovitz and Mercurio, 1997). a6ß4 is also involved in the enzyme-mediated 
degradation of the ECM. In migrating cancerous cells a6ß4 triggers the production of 
ECM degradative proteases (Ivaska and Heino, 2000). Not only does the level of 
expression of integrins and in particular a6134 seem to be important in metastasis, but 
changes in their properties and localisation appear essential which could be explained 
by changes in their glycan repertoire as detected by HPA. Also aV integrins binds to 
vitronectin, a constituent of platelets (Hynes, 1987), and its presence in the metastatic 
CRC cell lines may explain how CRC cells invade and spread to distant organs by 
attaching to platelets. HPA binds to glycoproteins which play a central role in invasion 
but more importanly it seems that the glycosylation changes detected by the lectin may 
be of importance to understand the mechanism of metastasis. Work in our laboratory is 
being undertaken to study the glycoconjugates of the HPA-binding glycoproteins. 
The results obtained in this chapter enabled us to determine the binding specificity 
of HPA. Also the proteins that bind to HPA were identified and this showed that the 
lectin recognises a diverse range of proteins with a range of 
different roles in cell 
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adhesion, movement, signalling and apoptosis. However, these results were obtained 
using cell line models and we sought to determine whether the HPA binding 
glycoproteins of the cell lines were also the same in human tissue samples collected 
from patients with CRC. 
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CHAPTER SIX: 




We have previously investigated the basis for the recognition of colorectal 
cancer cells by HPA using three cell lines, chosen for their biological differences in 
order to construct an in vitro model of metastasis. Next we extended our analysis to 
tissue samples from patients with colorectal cancer. Frozen tissues were kindly provided 
by Dr Juliette Smith-Ravin (Universite de Guadeloupe). The tissues were collected after 
informed consent under the auspices of the University Hospital Martinique Ethics 
Committee as described in the materials and methods section. Prior to selection a range 
of the samples were taken, 5µm frozen sections cut using a cryostat and the presence of 
cancer cells confirmed by staining with haematoxylin and eosin and viewing under the 
light microscope. Samples containing >60% cancer cells and free of bloody infiltrate 
were selected for the proteomic study. The clinical features of the samples selected are 
presented in Table 6.1. 
We grouped the tissue samples into four categories, "low stage" colorectal 
cancer (Cl), corresponding healthy tissue taken away from the tumour tissue (NI), 
"advanced" colorectal cancer (C2) and corresponding healthy tissue (N2) these 
represented pools of four tissue samples per category. The proteins of each sample were 
solubilised individually in U7M/T2 buffer and the protein concentration was determined. 
The four pools were made by mixing 100 µg of each of the cancer/normal proteins of 
the four appropriate samples. We investigated the HPA-binding glycoproteins in each 
group of samples and verified if the proteins found in the cell lines that bound HPA 
were also present in the tissue samples and to what extent. In this study several 
replicates of each experiment were reproducibly performed (at leat two replicates) and 
typical results are presented in this section. 
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Categories Tissue samples 
TNM status Gender Age 
T2NO Female 44 
ci T2NO Female 62 
T2NO Female 54 
T3NO Male 70 
Ni Healthy tissues from each patients used in C1 
C2 T4N 1 Female 64 
T4N2 Male 70 
T3N2 Female 49 
T3N2 Female 57 
N2 Healthy tissues from each patients used in C1 
Table 6.1: Description of the pooled tissue samples Cl, Ni, C2 and N2. An identical amount of proteins 
(100 µg) solubilised from four patients were used to prepare each pooled samples Cl, Ni, C2 and N2. 
The TNM status, the gender and the age of each patients are compiled in this table. 
6.2 Separation of tissue sample proteins by 1-DE 
The proteins of C 1, Ni, C2 and N2 solubilised in U7M/T2 buffer were separated 
by 1-DE. In this separation the protein composition did not appear to differ significantly 
across the different pooled samples whether from cancerous colon or normal tissues. 
Eight proteins were consistently detected in all four samples and these ranged from 30 
kDa to 130 kDa (Shown by asterisks in Figure 6.1), the protein expression was slightly 
altered in the proteins of 30 kDa, 40 kDa and 50 kDa which showed intense staining in 
C1 and lower staining in the three other samples. Proteins of 250 kDa and 190 kDa were 
found in C1 and not detected in any other of the three samples. The proteins of sample 
C2 appeared to have "sticky edges", this may be attributed to the glycosylation of the 
proteins although further work would be required to substantiate this hypothesis. 
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Figure 6.1: Protein composition of Cl, Ni, C2 and N2 analysed by SDS-PAGE. 20µg of proteins of Cl, 
Ni, C2, N2 were separated on a 10% SDS-PAGE gel and stained with Coomassie Brilliant Blue. Eight 
proteins are consistently detected in each sample and are shown by asterixes. 
6.3 HPA binding glycoproteins 
The four samples used in the 1-DE experiments were separated as before, 
blotted onto nitrocellulose and probed with HPA (Figure 6.2). In this analysis proteins 
were recognised by HPA in each of the samples, cancerous and normal. The protein 
bands were diffuse and this is consistent with extensive glycosylation of the proteins as 
heterogeneity in glycosylation gives subtle differences in MW that are not resolved by 
1-DE. 
HPA recognised epitopes across the molecular weight range from 20-200 kDa. 
In samples C 1, Ni and N2 the intensity of HPA binding was consistently weak whereas 
in the metastatic cancer tissues the binding was more intense. This observation of HPA 
binding to cancer pool C2 supports the hypothesis that metastatic cancer is associated 
with glycoproteins carrying altered glycan epitopes recognised by the lectin. A band of 
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130 kDa, similar to GP 130 that we identified in CRC cell lines, was observed in every 
pooled tissue sample (arrows on Figure 6.2) and was the main HPA-binding protein 
band of all four samples. In C2 this band was very intense and broad and seemingly 
composed of several diffuse protein bands, a further protein band of 60 kDa in C2 was 
absent in Cl, NI and faint in N2. In C1 the poor resolution did not enable the 
visualisation of other minor HPA binding proteins. HPA bound to minor proteins of 170 
kDa and 75 kDa in N1, C2 and N2. In C2 and N2 a diffuse band of 25 kDa was also 
detected. 
The preliminary results concurred with the observations that we made using the 
cell lines as the higher MW proteins were found to bind HPA more in the metastatic 
cancer tissue pool as compared to low stage cancer pool. 
HPA 











Figure 6.2: Lectin blotting to pools of colorectal cancer proteins Cl, C2 and corresponding "normal" 
tissue Ni and N2.20 µg of proteins from Cl, Ni, C2, N2 were separated 
by SDS-PAGE and submitted to 
detection by HPA-biotin. Streptavidin-HRP was then added and colorimetric detection with DAB/H202 
was performed. This enabled visualisation of the HPA-binding partners 
in each of the samples, these are 




6.4 Reactivity of CRC tissue samples with antibody 
directed against the blood group A antigen 
This experiment was designed to visualise the proteins recognised by HPA that 
carry the blood group A antigen. 20 µg of pooled proteins of C 1, N 1, C2, and N2 were 
loaded on a 10% SDS-PAGE, transferred to nitrocellulose by Western blotting and 
probed with an antibody directed against blood group A antigen as before. 
The tissue samples consistently showed four major glycoprotein bands carrying 
the blood group A epitope. These four glycoproteins were 75 kDa, 50 kDa, 40 kDa and 
15 kDa and are indicated with red asterisks on Figure 6.3. 
Two other weaker binding glycoprotein bands (27 kDa, 30 kDa), were detected in Cl, 
C2, Ni but not in N2. These two proteins were shown by black asterisks in Figure 6.3. 
Compared with the HPA blot we observed that the higher MW proteins that are 
recognised by the lectin in the tissue samples (Figure 6.2) do not carry the blood group 
A antigen. Equally the protein band of 60 kDa detected by HPA in C2, N2 and the band 
of 170 kDa found in Ni, C2 and N2 do not exhibit the blood group A determinant. 
However the relatively weak HPA binding protein of 70 kDa found in N1, C2 and N2 
(Figure 6.2) as well as the 30 kDa protein band detected in Cl and Ni both bound to the 
antibody against the blood group A antigen (Figure 6.3). 
The results obtained in this experiment indicated that some, but not all, of the 
HPA binding glycoproteins from the tissue samples carry the blood group A antigen. 
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Figure 6.3: Reactivity of CRC tissue samples with blood group A antibody. 20 µg of proteins from Cl, 
NI, C2, N2 were separated on 10% SDS-PAGE, transferred to nitrocellulose and probed with a 
monoclonal anti-blood group A antibody. Four proteins recognised by the anti-blood A antibody (marked 
with red asterisks) were common to all of the pooled tissue samples four samples and two others (marked 
by black asterisks) were only present in Cl and N 1. 
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6.5 HPA binding glycoproteins: 2-DE and lectin 
blotting analysis 
6.5.1 Separation of tissue sample proteins by 2-DE 
The proteins from the pooled tissue samples were separated by 2-DE on a pH 5- 
8 IPG strip and a 10% SDS-PAGE, and were stained with Coomassie Brilliant Blue. 
The migration of the proteins is similar in the four gels as shown in Figure 6.4. 






































Figure 6.4: Separation by 2-DE of pooled proteins from normal (N) or cancerous (C) tissue samples of 
CRC patients with high stage (C2 and N2) and low stage (C 1 and N 1) disease. The gel was stained with 
Coomassie blue. The areas shown by the black boxes represent serum proteins whilst the areas shown by 
the red boxes indicate proteins showing differential protein levels in the cancer or high stage samples. 
There are proteins present in large quantities, reproducibly found in all the four 
gels and shown in the black boxes numbered 1-4. By comparison with 2-D gels loaded 
with serum proteins we deduced that these proteins may be serotransferrin (1), albumin 
(2), haptoglobin (3) and apolipoprotein (4) (Steel et al., 2003) and presumably these are 
present in the samples from blood infiltrate. Although the serum proteins are present 
in 
137 
relatively large quantities we were also able to observe several differences in the low 
abundance proteins (shown in the red boxes of Figure 6.4 labelled A-D) which are 
further analysed in 3D views (Figure 6.5). 
The 3D view for each of the boxes shown in Figure 6.4 was generated to help 
assess the expression levels in all the four samples (Figure 6.5). In Figure 6.5, region A 
showed a range of protein spots (black arrow) consistently observed in all four samples. 
A second range of protein spots, shown with a red arrow was observed only in the 
normal tissues Ni and N2 and these were not observed in the cancerous samples Cl and 
C2. In region B, there were two proteins consistently found in all the four samples 
(black arrow) but interestingly two proteins (circled) were only expressed in the 
metastatic sample. In region C two proteins were detected consistently across all the 
four samples in slightly varying quantities. In region D three proteins were consistently 
detected in the normal tissues (NI and N2) whereas all three proteins in C1 and one of 
the three proteins in C2 showed reduced expression levels. Finally in region E, two 
proteins were detected in all four samples (black arrows) with a variation in the levels of 
the lower MW protein and one of the proteins (circled) was expressed only in cancerous 
samples Cl and C2. 
The separation of the proteins by 2-DE enabled us to observe several proteins 
only detectable in the cancerous samples. Two proteins observed in region B were 




















Figure 6.5: 3D view of proteins showing altered expression levels by 2-DE in Cl, N1, C2 and N2. In 
panel A the black arrows show a group of proteins consistently expressed in the four samples whereas the 
red arrows show proteins detected only in N1 and N2. In panel B two proteins are expressed in the four 
samples (black arrows) and two proteins (circled in red) are present only in the metastatic sample C2. In 
panel C two proteins are detected in each sample. In the region shown in panel D three proteins are 
detected in N1 and N2 in similar quantities whereas all three in C1 and one (lowest MW) in C2 showed a 
reduced expression (black arrows). In panel E two proteins are detected in all four samples with slight 
variations (black arrows) and one protein circled in red is detected only in Cl and C2. 
6.5.2 Analysis of the HPA binding proteins separated by 2-DE 
The data obtained when the tissue samples were separated by 1-DE showed that 
there were several proteins that bound to HPA, although these were poorly resolved. 
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Next we aimed to examine in depth, using 2-DE and lectin blotting, the HPA binding 
proteins in the pooled samples Cl, N1, C2, N2 with a particular focus on the GP 13 0 
proteins identified in the cell lines. Samples C1 and C2 contained many glycoproteins 
strongly recognised by HPA whereas in their healthy counterparts NI and N2 only 7 
proteins spots were consistently detected, (Figure 6.6). It appears that HPA 
preferentially binds to glycoproteins of the cancerous cells and in the metastatic cancer 
pool C2 there was more intense binding of the lectin. There were five main HPA 
binding areas when Western blots of the pooled proteins from Cl and C2 were probed 
with the lectin. These included a range of proteins spots of 130 kDa believed to be the 
GP130 proteins observed in cell lines. The five main HPA binding regions on the 2-D 
gel were further analysed using the Melanie 6 software. 
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Figure 6.6: Detection of the HPA-binding proteins of Cl, Ni, C2 and N2 after separation of protein 
by 2- 
DE. The area labelled 1,2,3,4,5 contain the HPA binding protein of the samples 
Cl and C2 and were 
investigated further. The boxed area represent the non specific signal due to streptavidin binding. 
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Figure 6.7 shows the 3D view of the five HPA binding regions from the pooled 
tissue-derived proteins. Region 1 comprises one glycoprotein that strongly bound to 
HPA in C1 and C2 and is viewed as a sharp peak. Cl contains one other glycoprotein 
that was a less intense HPA binding protein and is represented as a poorly resolved peak 
in the 3D view (Figure 6.7 red arrow), this acidic glycoprotein bound by HPA was 
absent in the C2 material. The HPA binding glycoproteins shown by arrows 2 and 3 in 
Figure 6.6 showed a similar pattern of migration in Cl and C2 but the intensity of the 
binding was increased in C2 as illustrated by the 3D view (Figure 6.7, panels 2 and 3), 
The MW and pI of these proteins allowed us to correlate these with the GP 130 proteins 
found on the metastatic cell line HT29 (Chapter 5). Two components of GP 130 that we 
identified as integrin alpha V and integrin alpha 6 in cell lines were detectable in 
regions 2 and 3 of Cl and C2, these proteins strongly bound HPA in the metastatic pool, 
C2. Region 4 and 5 also contained proteins more strongly recognised in C2 as compared 
to C 1. In region 4a sharp peak is detected in Cl whereas the same peak appeared more 
diffuse in C2 (shown by black arrows). In Cl this region also comprises a trail of 
diffuse proteins weakly bound by HPA (shown by a red arrow). In C2 these proteins are 
more strongly recognised by HPA and appeared as 6 successive protein spots of similar 
MW. Finally in region 5 HPA recognised three proteins in Cl and five of higher 
















Figure 6.7: 3D view of HPA-binding proteins of the region 1,2,3,4,5 of C1 and C2 indicated by the red 
arrows on Figure 6.6. In panel 1 one glycoprotein is recognisd by HPA in Cl and C2 (black arrows) and 
one protein shown by red arrows is bound in Cl only. In panel 2a similar pattern of HPA binding protein 
is observed although the intensity is higher in C2. In panel 3 there is one common protein in Cl and C2 
(black arrows) and a series of glycoprotein isoforms appear to be present only in C2 (red arrows). In panel 
4 one protein peak appear more diffuse in C2 (black arrows) and a trail of protein isoforms is present in 
higher intensity in C2 (red arrows). The proteins of panel 5 are more intense in C2. 
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The results of the 2-DE separation showed that the binding of HPA was stronger 
in the cancerous tissue than in the normal tissue counterpart, but this analysis also 
showed that HPA bound significantly more strongly to proteins derived from the high 
stage cancers (C2) as compared with the pooled proteins from the low stage cancers 
(Cl). We observed five main regions on the 2-DE blot from the two cancerous samples 
C1 and C2 for which there were differences with respect to HPA binding. Two of the 
areas on the blots (zones 2 and 3) may represent components of GP 130 and these were 
elevated in the pooled protein from the high stage cancers (C2). Based on the MW, pI 
and protein migration pattern we hypothesised that the proteins of region 2 and region 3 
may be integrin aV and integrin a6 respectively. In the next part of the work we used 
an antibody directed against integrin a6 to test this hypothesis. 
6.5.3 Integrin a6 
Proteins from Cl, N 1, C2, N2 were separated by 1-DE, transferred to 
nitrocellulose membrane by Western blotting and probed with an antibody against 
integrin a6 (Figure 6.8). The results obtained showed there was a reduction in the level 
of integrin a6 in the cancerous sample and in particular in the metastatic sample C2 
compared with the normal counterpart and the expression of integrin a6 did not 
correlate with the binding of HPA as the latter was increased in the metastatic sample. 
Anti alpha 6 
GP130 
C1 Ni C2 N2 
Figure 6.8 Anti-integrin a6 antibody probing of Western blots of cancer and normal tissue proteins. 
20 . tg of proteins Cl, Ni, C2, N2, separated on 10% SDS-PAGE were probed with either HPA or 
antibody anti-integrin a6. The profile of the binding intensity was created. Integrin a6 seemed to 
be 
present in higher quantity in normal tissue as compared to their cancerous counterpart. 
Again integrin a6 
sustained a dramatic decrease in C2. 
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6.6 Discussion 
In this chapter we used human tissue samples to compare the overall 2-DE 
protein map and the HPA binding glycoproteins with those obtained from the CRC cell 
lines. We used 16 human colorectal tissues samples divided in four sub-categories 
according to their TNM status: C1 (early stage cancer), C2 (advanced cancer), NI and 
N2 were chosen as control samples; therefore in each category there were four tissue 
samples. Our previous findings in cell lines (SW480, SW620 and HT29) of varying 
metastatic phenotype from non metastatic to highly metastatic, enabled us to determine 
that the lectin HPA recognised several glycoproteins including GP130 in the metastatic 
cell lines. Two of the GP 130 components were identified as integrin a6 and integrin aV. 
It has been shown that the binding of HPA to cell lines and human tissues correlates 
with a metastatic phenotype. Our observations on the cell lines suggested that the main 
HPA binding partner was GP 130 and we concluded that the expression of GP 130 could 
be an important feature towards the acquisition of the metastatic phenotype in cell lines. 
These findings are supported by various studies which attribute a role for integrin a6, in 
its dimeric form a6131, a6(34, in progression and metastasis, this has been observed in 
tumours originating from the colon, breast, prostate, lung and melanoma (Chao et al., 
1996; Shaw et al., 1996; Rabinovitz et al., 1995; Yamamoto et al., 1996; Kuphal et al., 
2005). 
The present chapter investigated the glycoprotein partners of HPA in the tissue 
samples. The 1-DE/lectin blot showed that glycoproteins of the cancer samples were 
very heavily glycosylated with HPA binding glycans. The multitude of proteins bearing 
the HPA binding epitopes did not allow clear evaluation of all the HPA binding partners 
present in the samples, although the binding of HPA was observed to be stronger in the 
proteins pooled from the metastatic samples. The same analysis using proteins separated 
by 2-DE gave a better resolution enabling a more detailed analysis. Five groups of 
HPA-binding proteins were consistently observed in the CI and C2 protein pools and 
the intensity of the binding varied between the two pools, with several proteins more 
intensely recognised by HPA in the metastatic pool, C2. These 
included a high 
molecular weight protein which was of MW consistent with 
GP 130. The Western 
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blotting experiment with an antibody directed against integrin a6, however failed to 
confirm the presence of this protein in the metastatic cancer sample. 
HPA binds proteins that exhibit altered glycosylation in metastatic cancer. In the 
cell line model GP 130 was one of the main HPA-binding components but this was not 
the case in the tissue samples. There are several possible reasons for this apparent 
discrepancy in results, for example, cancer tissue samples are a heterogeneous mixture 
of cells, some will possess a metastatic phenotype whilst other will not, also pooled 
samples were used in this analysis and in some of the samples GP 130 may be of 
relevance with respect to HPA binding whilst in other samples it may not. Finally we 
compared GP 130 levels in both normal and cancerous tissue, the integrin a6 antibody 
bound to both of these tissues but this does not presuppose that the glycosylation of this 
epitope is the same in normal and cancer tissue. Indeed, it may be the case that whilst 
the GP 130 material was the main HPA binding band in the cancer samples the protein 
level was less than in the normal samples, perhaps indicating a "hyper-glycosylated" 
form of this protein in the cancer samples. Further analysis at the protein and glycan 
level will be required before the similarity between the cell line model and tissue 
samples can be determined at the molecular level. Other approaches could have been 
used to investigate the importance of integrin a6 and its glycosylation in tissue samples. 
Indeed the double blotting of 1-DE separated proteins with anti-integrin a6 antibody 
followed by HPA could confirm that HPA recognise the abnormal glycosylation carried 
by integrin a6 rather than the protein itself. Also in oder to verify our hypothesis the 
removal of the contaminating serum proteins and an improvement of the solubilisation 
of proteins could decrease the complexity of the pooled samples. The use of pooled 
samples constituted an easy way to evaluate our observations made in cell lines, 
however the complexity and heterogeneity of the tissue samples appeared to limit our 
analysis. Lectin staining of the tissues and selection of cells using laser capture 
microdissection technology prior to protein analysis of the proteins composition and 
glycosylation by MS-based approaches could be a way forward to evaluate the 
importance of the glycosylation changes carried by integrin a6 and other membrane 
glycoproteins in cancer progression. 
In this analysis HPA has proved to be an interesting tool to detect proteins 
potentially involved in metastasis and further work needs to 
be carried out in order to 
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identify these tissue derived proteins and their glycosylation. The prognostic value of 
HPA was confirmed on tissue samples but it seemed that HPA binding does not rely 






7.1 HPA as a tool for cancer prognostication 
Over the past 30 years many studies have demonstrated the ability of the lectin 
HPA to bind to poor prognosis primary tumours, including those of the colon. 
Although the precise nature of the HPA-binding glycans involved in cancer cell 
metastasis have yet to be discovered, variations in the expression of a range of 
glycoconjugates on the surface of epithelial cancers have been shown to occur during 
malignant transformation and to play an important role in the metastatic process. The 
value of HPA as a prognostic marker has been demonstrated in retrospective studies of 
resected primary tumour tissues, cell lines and in SCID mice (Ikeda et al., 1994; 
Schumacher et al., 1994 a, b). The lectin HPA which has a nominal monosaccharide 
binding specificity for a-linked Ga1NAc and G1cNAc (Hammarstrom and Kabat, 1969) 
detects changes in glycosylation associated with tumour progression and is thought to 
recognise glycan epitopes that are involved in cell adhesion either locally in the primary 
tumour or on endothelial cells at sites of metastases (Springer and Lasky, 1991). 
Although changes in the glycan composition of cancer cells have been observed, little is 
known about the cancer specific HPA binding partners (Lescar et al, 2007, Brooks, 
2000). In the current study our aim was to characterise the glycoprotein binding 
partners of the lectin HPA. We examined HPA binding to CRC cell lines and evaluated 
the intensity of the binding; we assessed the effect of preincubating the lectin with a 
range of monosaccharides at different concentrations. Next we used a proteomic 
approach to isolate and identify the HPA binding proteins present in the cell membrane 
of the metastatic cell line HT29, finally we tested our findings on CRC tissue samples. 
7.2 The binding of HPA to CRC cells 
The localisation of HPA binding to the CRC cell lines HT29 and SW480 was 
investigated at the level of confocal microscopy (chapter 3). Direct observations as well 
as 2D and 3D reconstructions enabled us to localise the binding to the surface of the 
metastatic cell line HT29 with some granular intracellular staining consistent with the 
Golgi labelling (Brooks, 2000). We measured the binding intensity and the effect of 
competitive inhibition by relevant (Ga1NAc, GlcNAc, SA) and irrelevant sugars (Man) 
on a large population of cells using a microtitre plate assay developed in our laboratory. 
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We found that Ga1NAc, G1cNAc and SA almost completely inhibit the binding of HPA 
at a concentration of 50 mM. Although it seems that Ga1NAc, the nominally specific 
sugar for HPA was the most suitable monosaccharide for inhibiting the binding at both 
the cellular and Western blotting level, only limited differences were observed between 
the three sugars suggesting a more complex binding specificity. The interaction 
between the cancer-cell derived glyconjugates and HPA could be more fully 
investigated in studies utilising surface plasmon resonance (BiaCore system) or 
isothermal titration calorimetry and such an approach would allow the affinity and 
avidity of the HPA interaction to be mapped in the presence / absence of a range of 
competing sugars. 
Somewhat surprisingly (as discussed above) we observed that HPA binding to 
HT29 membrane glycoproteins can be inhibited by SA. This constitutes a new binding 
specificity for the lectin in CRC. Other reports have suggested that the HPA binding 
glycans from breast cancer tissues contain charged residues (Chen et al., 1995; Dwek et 
al., 2001) and that HPA binding to breast cancer tissue sections can be abrogated by 
pretreatment with neuraminidase (Fenlon et al., 1987). In further support of this 
observation a glycan microarray experiment has shown that HPA can bind to sialyl-T 
antigen (Sanchez et al, 2006). Reports describing the SA composition of colorectal 
tumours are rather contradictory; a recent study reported a decrease in sialylation 
(Kovno et al., 2002) whilst another study reported an increase in sialylation in CRC (De 
Albuquerque Garcia Redondo et al., 2004), and this may be attributed to increased 
sialyltransferase activity (Dall'Olio et al., 1989; Akamatsu et al., 1996). The idea that 
HPA interacts with metastatic cancer cells via recognition of SA residues is supported 
by the results in this study and also by unpublished observations from our laboratory 
showing that one of the polypeptide components of HPA has 54% sequence similarity 
with a SA binding lectin from the garden snail Cepea hortensis (Markiv unpublished 
data). The presence of isolectins and other components in the lectin preparation might 
explain the differences observed in the pattern of HPA-binding to cancer tissues 
compared with that of other Ga1NAc binding lectins, for example the 
lectins from Helix 
aspersa (HAA) and Dolichos biflorus (DBA). 
It seems likely that HPA recognises a range of oligosaccharide structures 
including the blood group A antigen, the Cad antigen, the Forssman 
determinant (Baker 
149 
et al. 1983), sialyl-T, STn and / or Tn antigen (Springer 1989). It has been suggested 
that HPA simply recognises the Tn antigen that is often elevated in solid tumours 
(Springer 1988,1989) but histochemical studies with breast cancer tissues and the anti- 
Tn antibodies BRICIII and BRIC66 have shown that HPA binds to different cells within 
breast tumour tissue, thereby supporting the idea that HPA binding encompasses a 
wider range of glycans epitopes (Brooks and Leathern, 1995). It is likely that other 
factors such as the presence of other monosaccharides within the complex 
oligosaccharide structure, the availability of divalent cations (Ca2+, Mgt+) and the 
conformation of the protein backbone of the glycoproteins harbouring the HPA binding 
glycans may all be required for the binding of HPA (Brooks et al., 1997 b). Also, HPA 
is a glycoprotein and it is possible that the interaction between the lectin and cancer 
cells is via cancer cell proteins binding to the glycans of HPA (which are likely to 
include N-linked structures with xylose / fucose residues, van Kuik et al., 1985) Studies 
with recombinant or non-glycosylated lectin would be required to either support or 
refute this hypothesis. 
Our findings have illustrated the complexity of HPA recognition of cancer cells. 
The exposure of terminal GaINAc often described as the main HPA binding partner, is 
unusual in normal cells and is a commonly found alteration in cancer cells either due to 
up-regulation of GaINAc transferases (Brockhausen, 2005) or down-regulation of sialyl 
transferases (Shang et al., 1999). The inhibition of HPA binding with SA is an 
interesting feature of this study and we hypothesise that HPA may recognise the STn 
antigen which is an indicator of poor prognosis CRC. The data appears contradictory as, 
on the one hand, HPA recognises glycan epitopes that may be uncovered by a decrease 
in sialylation and, on the other hand, HPA appears to recognise sialylated epitopes. One 
potential explanation for this apparent dichotomy may be that HPA can bind to core 
Ga1NAc / Tn and another lectin or an isolectin of HPA binds to sialic acid. Further 
work would be required to determine if this is the case preferably in conjunction with 
experiments to measure the glycosyltransferase activity (perhaps using a microarray 
methodology such as the one that is currently being piloted by the Consortium for 
Functional Glycomics http"//w-vvw fLinction. alglycomics. org). The mechanism by which 
HPA interacts with the cancer glycans also needs further characterisation and, as 
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mentioned above, it may be the case that the presence of isolectins in the HPA 
preparation enables the recognition of a range of different glycosylated structures. 
7.3 HPA-binding glycoproteins in CRC cell lines 
Proteomic analysis of HT29 cell membrane proteins revealed that the basis for 
HPA recognition is via its ability to bind to a range of glycoproteins with diverse 
functions in cancer biology (chapter 5). The analysis of the proteins separated by SDS- 
PAGE and following lectin blotting showed that HT29, SW620 and SW480 expressed 
different levels of HPA binding proteins with a large number of the protein species of 
varying size and intensity recognised in the three cell lines. The proteins included 
several species that bound the lectin only weakly (MW<75 kDa), these were sometimes 
recognised by the anti-blood group A antibody and were not essential for the specific 
recognition of the metastatic cells by HPA. Quantitative differences in levels of higher 
MW protein species for example GP130 and GP80 were also noted. The GP130 and 
GP80 glycoproteins were present in higher amount in the metastatic cell lines HT29 and 
SW620 compared with SW480. Preliminary results on the cell lines suggested that 
GP130 and GP80 (to a lesser extent) is a metastasis-specific HPA-binding 
glycoconjugate containing G1cNAc, GaINAc and SA. GP80 was recognised by HPA 
and the blood group A antibody, whilst GP130 did not appear to contain the blood 
group A epitope. A table was constructed (Appendix 8) that gives an overview of the 
results of the 1-DE and Western blotting experiments. From the cell line work it seems 
likely that the binding of HPA to metastatic cell lines was, in part, due to recognition of 
GP 130 and GP80 as their intensity across the cell lines was correlated with the general 
HPA binding intensity. GP 130 was shown to comprise a mixture of four glycoproteins 
and the 2-DE work suggested that each of the GP 130 polypeptide species contains 
several differentially glycosylated / phosphorylated isoforms. A comparison of the 
levels of this group of proteins in HT29 and SW480 showed that GP130 is expressed 
in 
the metastatic cell line alone. Inhibition of HPA binding to GP 130 on Western 
blots 
showed that the nominal specificity of HPA, Ga1NAc, is too restrictive to explain 
HPA 
binding to this group of proteins and probably does not clearly describe the 
interaction 
between HPA and the surface of metastatic CRC cells. Further inhibition work and 
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glycan release / mapping would be needed to characterise the glycans involved in HPA 
binding to GP 130 and the other proteins found to bind HPA in this study. One of the 
main components of GP 130 was integrin a6, this protein has previously been correlated 
with aggressive cancer and has been shown to facilitate invasion of cancer cells through 
the ECM (Chao et al., 1996). The discovery that some members of the integrin family 
are amongst the proteins most recognised by HPA in aggressive cancer cells is not 
surprising as such proteins (e. g. a2ß1, a3ß1, a6131, a6ß4) have previously been 
described to be associated with aggressive phenotype in colorectal cancer cell lines 
(Chao et al., 1996). For example integrin a6134 expressed in CRC cell lines promote cell 
invasion on matrigel and its redistribution from hemidesmosome to cell protrusion 
suggest a role in cancer cell invasion by regulating cell movement (Chao et al., 1996; 
Rabinovitz et al., 1999; Rabinovitz and Mercurio, 1997). Also integrins have been 
involved in other aspect of cancer progression such as cell growth, survival and ECM 
degradation (reviewed by Mercurio and Rabinovitz, 2001). However we suggested that 
not only the expression of integrins play a role in cancer but also changes in their glycan 
composition as detected by HPA. Previous studied have found that the a6134 expressed 
in cancer cells do not form hemidesmosome suggesting that glycovariant of the integrin 
could be expressed in cancer cells and this could be correlated to our findings. 
Moreover Ichikawa et al. (1998) described how changes of blood group A determinant 
carried by members of the integrin family (a3, a6, j31) modulate motility and 
proliferation. The presence of HPA-binding glycans on integrin a6, may modulate its 
function in HT29 cells and the role of this protein in the invasion of HT29 cells in our in 
vitro model will be the subject of future studies using the matrigel technology. Also 
unravelling the glycan composition of the integrins and other proteins recognised by 
HPA using a MS-based approach may provide new insights into the understanding of 
cancer progression and invasion. 
In this study we have established that the variation in HPA binding in cell lines 
relies on the presence of several proteins including GP130 and GP80. Our findings 
partly correlate with the observations made by Prokopishyn et al. (1999) who used a 
different approach based on 3A7 antibody binding to HT29 cells. The 3A7 antibody 
detects oncodevelopmental changes and a3ß1 integrin was identified as a component of 
a protein entity (GP140), which appeared to be the major carrier of oncodevelopmental 
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carbohydrates in HT29. The Prokopishyn study and our own used different approaches 
but the results were very similar suggesting that members of the integrin family, 
possessing abnormal glycosylation, may play a role in the metastastic process. 
The HPA binding glycoproteins that have been studied in breast (Brooks et al., 
2001) and CRC (De Albuquerque Garcia Redondo et al., 2004) cell lines were poorly 
characterised. We pre-fractionated the HT29 and SW480 cell membrane proteome by 
affinity-purification on an HPA-Sepharose column and we analysed the proteins by 2- 
DE (chapter 5). The proteins that were eluted in the HPA binding fraction were present 
either by virtue of their ability to bind directly to HPA or as protein complexes with 
HPA binding partners. Identification of the HPA binding proteins by MALDI-MS / MS- 
MS showed that all of the proteins had previously been described as altered in cancer 
and the binding of HPA to the metastatic cancer cells could not be explained by the 
presence or absence of a single HPA-binding glycoprotein. HPA binding to the cancer 
cells was explained by the lectin binding to a range of glycoproteins with varying 
expression levels and / or glycosylation states. 
7.4 HPA-binding glycoproteins in CRC tissue samples 
The analysis of the colorectal tissue sample proteins (cancerous and normal) by 
both 1-DE and 2-DE highlighted differences in the levels of several proteins (chapter 6). 
The 2-DE and lectin blotting approach enabled us to isolate several HPA binding 
partners found exclusively in the cancerous samples. Some of these proteins are present 
in higher levels in the protein pool from the metastatic tissue samples as compared to 
the non metastatic tissue sample pool. The comparative analysis showed that one of the 
HPA binding proteins might be GP 130 but immunodetection using an antibody directed 
against integrin a6 failed to establish a relationship between the integrin a6 level and 
the intensity of HPA binding. This brings to light the limitations of cell line models and 
the difficulty of transposing findings from an in vitro model to cancer tissue samples. 
Our approach allowed us to separate five groups of proteins recognised by HPA 
in the 
proteins from the cancer tissue samples. The levels of the proteins were compared using 
the protein pools each containing proteins derived from four different tissue samples. 
Clearly the variation in the level of the proteins in the individual tumour samples would 
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need to be established. A higher throughput approach to evaluate the use of the protein 
as a biomarker of metastasis in low stage cancer, perhaps using an antibody directed 
against the proteins or glycopeptides would also be useful for testing larger numbers of 
CRC tissue samples. 
The proteins recognised by HPA could play a role in the metastatic process and 
their identification is needed to complement the findings that were made with the cell 
line model. The identification of these proteins and their glycosylation might also 
increase our understanding of the metastatic process and may be of interest as cancer 
biomarkers. 
7.5 Conclusions and future directions 
The work presented in this thesis confirmed that HPA is a useful tool for 
identification of proteins in metastatic cancer. The proteomic analysis showed that the 
value of HPA relies in its recognition of complex carbohydrates carried by specific 
proteins differentially expressed in metastatic cells. More work is required to confirm 
and extend our findings to determine if the HPA binding glycoproteins observed in 
CRC are the same as those found in other epithelial tumours and also to characterise the 
glycans involved. 
One of the main reasons that HPA has not been used for diagnostic purposes is 
the variability in the methodology for HPA histopathology (Brooks et al., 1996). Other 
important factors that might render the HPA material useful in clinical decision making 
include the need for recombinant lectin (for use in diagnostic kits), lack of clarity 
regarding the cancer-associated HPA-binding glycans and limited knowledge of the 
structural basis for HPA-binding to metastatic cancer cells. Recombinant HPA lectin 
would be of considerable value in driving forward method development efforts and 
would allow multi-centre trials to be conducted to evaluate the lectin in a diagnostic 
setting. A detailed knowledge of either the cancer or lectin biology would open avenues 
based around targeting the HPA binding epitopes in solid tumours. The data that we 
have obtained has enabled us to make significant inferences regarding the basis for HPA 




APPENDIX 1: TNM staging 
T describes the extent of the cancer spread through the colon wall. The wall of the colon 
is formed of several layers described in the section "anatomy of the colon" of this thesis. 
These layers are the following from the inner to the outer, mucosa, muscularis mucosa, 
submucosa, muscularis propria, subserosa and serosa. 
Tx: description impossible 
Tis: the cancer is named "in situ" and is confined in the mucosa. It has not invaded 
beyond the muscularis mucosa. 
T l: The cancer has invaded through the muscularis mucosa and extent to the submucosa 
T2: The cancer has invaded through the submucosa and extent to the muscularis propria 
T3: The cancer has invaded through the muscularis propria and subserosa without 
affecting any nearby organs or tissues. 
T4: The cancer has spread through the wall of the colon into the nearby tissues. 
N indicates the degree of involvement of the regional lymph node 
Nx: no description possible 
NO: No lymph node involvement is found 
Ni: Cancer cells found in 1-3 neighbouring lymph node 
N2: Cancer cells found in 4 or more nearby lymph node 
M indicates whether or not the cancer has spread to distant organs. 
Mx: no description possible 
MO: no distant spread 
Ml: distant spread observed 
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APPENDIX 2: Protein assays 
Bradford protein assay 
50 µl of BSA standard solution prepared in buffers 1 to 4 (table 3) or appropriate 
dilution of sample in a final volume of 50 µl, were incubated for 5 min at room 
temperature with 1.5 ml of ready to use Bradford reagent (Sigma), consisting of 
Brilliant blue G in methanol and phosphoric acid. The absorbance was measured at 595 
nm on a spectrophotometer. 
DC protein assay: 
50 µl of BSA standard solution prepared in buffers 1 to 4 (table 3) were 
incubated with 200 µl of reagent A, consisting in alkaline copper tartrate solution 
supplemented with SDS solution, and 2 ml of Folin reagent (reagent B) for 15 min 
before the absorbance was read at 750 nm in spectrophotometer. 
RCDC protein assay: 
25 µl of BSA standard solution prepared in buffers 1 to 4 (table 2.5) were 
incubated for 1 min at room temperature with 125 µl of RC reagent 1 before 125 µl of 
RC reagent 2 was added and the mixture centrifuged at 15000 g for 5 min. 127 µl of DC 
reagent A (alkaline copper tartrate supplemented with SDS) was added to the pellet and 
incubated for a further 5 min before being incubated for 15 min with 1 ml of Folin 
reagent. The absorbance was then read at 750 nm. 
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APPENDIX 3: Recipes for buffers used in 1-DE and 2- 
DE experiments. 
Resolving gel Buffer (1M Tris-HC1 pH 8.8) 
Tris (FW 121.1) 1M 
dH2O 150 ml 
HCl to pH 8.8 
dH2O to 200 ml 
Stacking gel Buffer (0.5M Tris-HC1 pH 6.8) 
Tris (FW 121.1) 0.5M 
dH2O 150 ml 
HC1 to pH 6.8 
dH2O to 200 ml 
Water-saturated n-butanol 
N-butanol 50 ml 
dH2O 50 ml 
15 % Ammonium persulfate 
Ammonium persulfate (FW 228.2) 15% w/v 
dH2O 1 ml 
10%SDS 
SDS (FW 288.38) 10% 
dH2O to 100 ml 
Running buffer 
Tris (FW 121.1) 0.025 M 
Glycine (FW 75.07) 0.192 M 
SDS (FW 288.38) 0.1% w/v 
dH2O to IL 
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Stacking gel (2.5 ml per minigel) 4% 
Acrylamide/bisacrylamide 40% 0.25 ml 
Stacking buffer 0.63 ml 
dH2O 1.5 ml 
10% SDS 25 µl 
15% APS 12.5 µl 
TEMED 2.5 µl 
Resolving gel (5 ml per minigel) 10% 12% 
Acrylamide/bisacrylamide 40% 1.25 mll. 5 ml 
Resolving buffer 1.9 ml 1.9 ml 
dH2O 1.8 ml 1.55 ml 
10%SDS 50µl 50µl 
15% APS 25 µl 25 µl 
TEMED 2.5 µl 2.5 µl 
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APPENDIX 4: Microtitre plate assay 
HT29 SW620 SW480 
Fluorescence/ Mean Standard Fluorescence/ Mean Standard Fluorescence/ Mean Standard 
100000 cells 
deviation 100000 cells 
deviation 100000 cells 
deviation 
(Au) (Au) (Au) 
1 6699 4816 1337 
2 6862 5204 1001 
3 7524 7014 539 5281 4985 233 1181 1216 132 
4 7048 4772 1199 
5 6265 4755 1376 
6 7688 5080 1202 
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APPENDIX 5: List of HPA-binding proteins in HT29, 






























HPA binding protein bands 
HT29 SW620 SW480 
Band MW Band MW Band MW 
number number number 
1 135 1 130 1 130 
2 94 2 113 2 73 
3 87 3 105 3 67 
4 74 4 92 4 60 
5 45 5 85 5 44 
6 43 6 71 6 41 
7 38 7 55 7 38 
8 33 8 52 8 37 
9 31 9 50 9 32 
10 30 10 44 10 31 
11 29 11 40 11 30 
12 28 12 37 12 29 
13 27 13 32 13 28 
14 26 14 31 14 27 
15 25.5 15 30 15 26 
16 25 16 29 16 25.5 
17 24 17 26 17 25 
18 25 18 24 
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APPENDIX 6: Affinity chromatography analysis 
Cell lines Area of the 
unbound 
fraction 
Area of the 
bound fraction 
% of bound 
proteins 
HT29 2999 388 11 
SW480 1963 25 1.2 
SW620 2799 107 3 
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MAAAGQLCLL YLSAGLLSRL GAAFNLDTRE DNVIRKYGDP GSLFGFSLAM 
HWQLQPEDKR LLLVGAPRAE ALPLQRANRT GGLYSCDITA RGPCTRIEFD 
NDADPTSESK EDQWMGVTVQ SQGPGGKWT CAHRYEKRQH VNTKQESRDI 
FGRCYVLSQN LRIEDDMDGG DWSFCDGRLR GHEKFGSCQQ GVAATFTKDF 
HYIVFGAPGT YNWKGIVRVE QKNNTFFDMN IFEDGPYEVG GETEHDESLV 
PVPANSYLGF SLDSGKGIVS KDEITFVSGA PRANHSGAW LLKRDMKSAH 
LLPEHIFDGE GLASSFGYDV AWDLNKDGW QDIVIGAPQY FDRDGEVGGA 
VYVYMNQQGR WNNVKPIRLN GTKDSMFGIA VKNIGDINQD GYPDIAVGAP 
YDDLGKVFIY HGSANGINTK PTQVLKGISP YFGYSIAGNM DLDRNSYPDV 
AVGSLSDSVT IFRSRPVINI QKTITVTPNR IDLRQKTACG APSGICLQVK 
SCFEYTANPA GYNPSISIVG TLEAEKERRK SGLSSRVQFR NQGSEPKYTT 
ELTLKRQKQK VCMEETLWLQ DNIRDKLRPI PITASVEIQE PSSRRRVNSL 
PEVLPILNSD EPKTAHIDVH FLKEGCGDDN VCNSNLKLEY KFCTREGNQD 
KFSYLPIQKG VPELVLKDQK DIALEITVTN SPSNPRNPTK DGDDAHEAKL 
IATFPDTLTY SAYRELRAFP EKQLSCVANQ NGSQADCELG NPFKRNSNVT 
FYLVLSTTEV TFDTPYLDIN LKLETTSNQD NLAPITAKAK WIELLLSVS 
GVAKPSQVYF GGTVVGEQAM KSEDEVGSLI EYEFRVINLG KPLTNLGTAT 
LNIQWPKEIS NGKWLLYLVK VESKGLEKVT CEPQKEINSL NLTESHNSRK 
KREITEKQID DNRKFSLFAE RKYQTLNCSV NVNCVNIRCP LRGLDSKASL 
ILRSRLWNST FLEEYSKLNY LDILMRAFID VTAAAENIRL PNAGTQVRVT 
VFPSKTVAQY SGVPWWIILV AILAGILMLA LLVFILWKCG FFKRNKKDHY 
DATYHKAEIH AQPSDKERLT SDA 
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Integrin Alpha 6 
Integrin alpha V 
Cl) c 




MAFPPRRRLR LGPRGLPLLL SGLLCRA FNLDVDSPAE YSGPEGSYFGFAVDFFVPSA 
SSRMFLLVGA PKANTTQPGI VEGGQVLKCD WSSTRRCQPIEFDATGNRDY AKDDPLEFKS 
HQWFGASVRS KQDKILACAP LYHWRTEMKQEREPVGTCFL QDGTKTVEYA 
PCRSQDIDAD GQGFCQGGFS IDFTKADRVL LGGPGSFYWQ GQLISDQVAE IVSKYDPNVY 
SIKYNNQLAT RTAQAIFDDSYLGYSVAVGD FNGDGIDDFV SGVPRAARTL GMVYIYDGKN 
MSSLYNFTGEQMAAYFGFSV AATDINGDDY ADVFIGAPLF MDRGSDGKL . EVGQVSVSLQ RASGDFQTTK LNGFEVFARF GSAIAPLGDL DQDGFNDIAI AAPYGGEDKK 
GIVYIFNGRS TGLNAVPSQI LEGQWAARSM PPSFGYSMKG ATDIDKNGYP DLIVGAFGVD 
RAILYRARPV ITVNAGLEVY PSILNQDNKT CSLPGTALKV SCFNVRFCLK ADGKGVLPRK 
LNFQVELLLD KLKQKGAIRR ALFLYSRSPSHSKNMTISRG GLMQCEELIA YLRDESEFRD 
KLTPITIFME YRLDYRTAAD TTGLQPILNQ FTPANISRQA HILLDCGEDN VCKPKLEVSV 
DSDQKKIYIGDDNPLTLIVK AQNQGEGAYE AELIVSIPLQ ADFIGWRNN 
EALARLSCAFKTENQTRQW CDLGNPMKAG TQLLAGLRFS VHQQSEMDTS 
VKFDLQIQSNLFDKVSPW SHKVDLAVLA AVEIRGVSSP DHIFLPIPNW EHKENPETEE 
DVGPWQHIY ELRNNGPSSF SKAMLHLQWP YKYNNNTLLY ILHYDIDGPM NCTSDMEINP 
LRIKISSLQT TEKNDTVAGQ GERDHLITKR DLALSEGDIH TLGCGVAQCL KIVCQVGRLD 
RGKSAILYVK SLLWTETFMN KENQNHSYSLKSSASFNVIE FPYKNLPIED ITNSTLVTTN 










STFSTNYRSL GSVQAPSYGA RPVSSAASVY AGAGGSGSRI SVSRSTSFRG 
GMGSGGLATG IAGGLAGMGG IQNEKETMQS LNDRLASYLD RVRSLETENR 
RLESKIREHL EKKGPQVRDW SHYFKIIEDL RAQIFANTVD NARIVLQIDN 
ARLAADDFRV KYETELAMRQ SVENDIHGLR KVIDDTNITR LQLETEIEAL 
KEELLFMKKN HEEEVKGLQA QIASSGLTVE VDAPKSQDLA KIMADIRAQY 
DELARKNREE LDKYWSQQIE ESTTVVTTQS AEVGAAETTL TELRRTVQSL 
EIDLDSMRNL KASLENSLRE VEARYALQME QLNGILLHLE SELAQTRAEG 
QRQAQEYEAL LNIKVKLEAE IATYRRLLED GEDFNLGDAL DSSNSMQTIQ 







MRECISIHVG QAGVQIGNAC WELYCLEHGI QPDGQMPSDK TIGGGDDSFN 
TFFSETGAGK HVPRAVFVDL EPTVIDEVRT GTYRQLFHPE QLITGKEDAANNYARGHYTI 
GKEIIDLVLD RIRKLADQCT RLQGFLVFHS FGGGTGSGFT SLLMERLSVD YGKKSKLEFS 
IYPAPQVSTA WEPYNSILT THTTLEHSDC AFMVDNEAIY DICRRNLDIE RPTYTNLNRL 
ISQIVSSITA SLRFDGALNVDLTEFQTNLV PYPRIHFPLA TYAPVISAEK AYHEQLSVAD 
ITNACFEPAN QMVKCDPGHG KYMACCLLYR GDWPKDVNA AIATIKTKRT 
IQFVDWCPTGFKVGINYQPP TWPGGDLAK VQRAVCMLSN TTAIAEAWAR 











MSIRVTQKSY KVSTSGPRAF SSRSYTSGPG SRISSSSFSR VGSSNFRGGL 
GGGYGGASGM GGITAVTVNQ SLLSPLVLEV DPNIQAVRTQ EKEQIKTLNN 
KFASFIDKVR FLEQQNKMLE TKWSLLQQQK TARSNMDNMF ESYINNLRRQ 
LETLGQEKLK LEAELGNMQG LVEDFKNKYE DEINKRTEME NEFVLIKKDV 
DEAYMNKVEL ESRLEGLTDE INFLRQLYEE EIRELQSQIS DTSWLSMDN 
SRSLDMDSII AEVKAQYEDI ANRSRAEAES MYQIKYEELQ SLAGKHGDDL 
RRTKTEISEM NRNISRLQAE IEGLKGQRAS LEAAIADAEQ RGELAIKDAN 
AKLSELEAAL QRAKQDMARQ LREYQELMNV KLALDIEIAT YRKLLEGEES 
RLESGMQNMS IHTKTTGGYA GGLSSAYGGS QAGLSYSLGS SFGSGAGSSS 
FSRTSSSRAV WKKIETRDG KLVSESSDVL PK 








MSELEQLRQE AEQLRNQIRD ARKACGDSTL TQITAGLDPV 
GRIQMRTRRTLRGHLAKIYA MHWGTDSRLL VSASQDGKLI IWDSYTTNKV 
HAIPLRSSWVMTCAYAPSGN FVACGGLDNI CSIYSLKTRE GNVRVSRELP 
GHTGYLSCCR FLDDNQIITS SGDTTCALWD IETGQQTVGF AGHSGDVMSL 
SLAPDGRTFVSGACDASIKL WDVRDSMCRQ TFIGHESDIN AVAFFPNGYA 
FTTGSDDATCRLFDLRADQE LLMYSHDNII CGITSVAFSR SGRLLLAGYD 










MSKGPAVGID LGTTYSCVGV FQHGKVEIIA NDQGNRTTPS YVAFTDTERL 
IGDAAKNQVA MNPTNTVFDA KRLIGRRFDD AWQSDMKHW 
PFMWNDAGRPKVQVEYKGE TKSFYPEEVS SMVLTKMKEI AEAYLGKTVT 
NAVVTVPAYFNDSQRQATKD AGTIAGLNVL RIINEPTAAA IAYGLDKKVG 
AERNVLIFDL GGGTFDVSIL TIEDGIFEVK STAGDTHLGG EDFDNRMVNH 
FIAEFKRKHK KDISENKRAV RRLRTACERA KRTLSSSTQA SIEIDSLYEG 
IDFYTSITRA RFEELNADLF RGTLDPVEKA LRDAKLDKSQ IHDIVLVGGS 
TRIPKIQKLL QDFFNGKELN KSINPDEAVA YGAAVQAAIL SGDKSENVQD 
LLLLDVTPLS LGIETAGGVM TVLIKRNTTI PTKQTQTFTT YSDNQPGVLI 
QVYEGERAMT KDNNLLGKFE LTGIPPAPRG VPQIEVTFDI DANGILNVSA 
VDKSTGKENK ITITNDKGRL SKEDIERMVQ EAEKYKAEDE KQRDKVSSKN 
SLESYAFNMKATVEDEKLQG KINDEDKQKI LDKCNEIINW LDKNQTAEKE 







MREIVHLQAG QCGNQIGAKF WEVISDEHGI DPTGTYHGDS 
DLQLERINVYYNEATGGKYV PRAVLVDLEP GTMDSVRSGP FGQIFRPDNF 
VFGQSGAGNN WAKGHYTEGA ELVDSVLDW RKEAESCDCL QGFQLTHSLG 
GGTGSGMGTL LISKIREEYP DRIMNTFSW PSPKVSDTW EPYNATLSVH 
QLVENTDETY CIDNEALYDI CFRTLKLTTP TYGDLNNLVS ATMSGVTTCL 
RFPGQLNADLRKLAVNMVPF PRLHFFMPGF APLTSRGSQQ YRALTVPELT 
QQMFDAKNMM AACDPRHGRY LTVAAVFRGR MSMKEVDEQM LNVQNKNSSY 
FVEWIPNNVK TAVCDIPPRG LKMSATFIGN STAIQELFKR ISEQFTAMFR 











MDDDIAALW DNGSGMCKAG FAGDDAPRAV FPSIVGRPRH 
QGVMVGMGQK DSYVGDEAQS KRGILTLKYP IEHGIVTNWD DMEKIWHHTF 
YNELRVAPEEHPVLLTEAPL NPKANREKMT QIMFETFNTP AMYVAIQAVL 
SLYASGRTTGVMDSGDGVT HTVPIYEGYA LPHAILRLDL AGRDLTDYLM 
KILTERGYSFTTTAEREIVR DIKEKLCYVA LDFEQEMATA ASSSSLEKSY 
ELPDGQVITIGNERFRCPEA LFQPSFLGME SCGIHETTFN SIMKCDVDIR 
KDLYANTVLSGGTTMYPGIA DRMQKEITAL APSTMKIKII APPERKYSVW 

















MAMATKGGTV KAASGFNAME DAQTLRKAMK GLGTDEDAII 
SVLAYRNTAQ RQEIRTAYKS TIGRDLIDDL KSELSGNFEQ VIVGMMTPTV 
LYDVQELRRA MKGAGTDEGC LIEILASRTP EEIRRISQTY QQQYGRSLED 
DIRSDTSFMFQRVLVSLSAG GRDEGNYLDD ALVRQDAQDL 
YEAGEKKWGT DEVKFLTVLCSRNRNHLLHV FDEYKRISQK DIEQSIKSET 
SGSFEDALLA IVKCMRNKSA YFAEKLYKSM KGLGTDDNTL IRVMVSRAEI 
DMLDIRAHFK RLYGKSLYSFIKGDTSGDYR KVLLVLCGGD D 
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MRALWVLGLC CVLLTFGSVR ADVDGT VEEDLGKSRE 
GSRTDDEWQREEEAIQLDG LNASQIRELR EKSEKFAFQA EVNRMMKLII 
NSLYKNKEIFLRELISNASD ALDKIRLISL TDENALSGNE ELTVKIKCDK 
EKNLLHVTDTGVGMTREELV KNLGTIAKSG TSEFLNKMTE AQEDGQSTSE 
LIGQFGVGFY SAFLVADKVI VTSKHNNDTQ HIWESDSNEF SVIADPRGNT 
LGRGTTITLV LKEEASDYLE LDTIKNLVKK YSQFINFPIY VWSSKTETVE 
EPMEEEEAAK EEKEESDDEA AVEEEEEEKK PKTKKVEKTV WDWELMNDIK 
PIWQRPSKEVEEDEYKAFYK SFSKESDDPM AYIHFTAEGE VTFKSILFVP 
TSAPRGLFDE YGSKKSDYIK LYVRRVFITD DFHDMMPKYL NFVKGVVDSD 
DLPLNVSRETLQQHKLLKVI RKKLVRKTLD MIKKIADDKY NDTFWKEFGT 
NIKLGVIEDHSNRTRLAKLL RFQSSHHPTD ITSLDQYVER MKEKQDKIYF 
MAGSSRKEAE SSPFVERLLK KGYEVIYLTE PVDEYCIQAL PEFDGKRFQN 
VAKEGVKFDE SEKTKESREA VEKEFEPLLN WMKDKALKDK IEKAVVSQRL 
TESPCALVASQYGWSGNMER IMKAQAYQTG KDISTNYYAS QKKTFEINPR 
HPLIRDMLRR IKEDEDDKTV LDLAWLFET ATLRSGYLLP DTKAYGDRIE 










MSTVHEILCK LSLEGDHSTP PSAYGSVKAY TNFDAERDAL NIETAIKTKG 
VDEVTIVNIL TNRSNAQRQD IAFAYQRRTK KELASALKSA LSGHLETVIL 
GLLKTPAQYD ASELKASMKG LGTDEDSLIE IICSRTNQEL QEINRVYKEM 
YKTDLEKDII SDTSGDFRKL MVALAKGRRA EDGSVIDYEL IDQDARDLYD 
AGVKRKGTDV PKWISIMTER SVPHLQKVFD RYKSYSPYDM LESIRKEVKG 
DLENAFLNLV QCIQNKPLYF ADRLYDSMKG KGTRDKVLIR IMVSRSEVDM 









MPEEVHHGEE EVETFAFQAE IALIIN TFYSNKEIFL RELISNASDA 
LDKIRYESLT DPSKLDSGKE LKIDIIPNPQ ERTLTLVDTG IGMTKADLIN 
NLGTIAKSGT KAFMEALQAG ADISMIGQFG VGFYSAYLVA EKVVVIRKHN 
DDEQYAWESS AGGSFTVRAD HGEPIGMGTK VILHLKEDQT 
EYLEERRVKE VVKKHSQFIG YPITLYLEKE REKEISDDEA EEEKGEKEEE 
DKDDEEKPKI EDVGSDEEDD SGKDKKKKTK KIKEKYIDQE ELNKTKPIWT 
RNPDDITQEEYGEFYKSLTN DWEDHLAVKH FSVEGQLEFR 
ALLFIPRRAP FDLFENKKKK NNIKLYVRRV FIMDSCDELI PEYLNFIRGV 
VDSEDLPLNI SREMLQQSKI LKVIRKNIVK KCLELFSELA EDKENYKKFY 
EAFSKNLKLG IHEDSTNRRRLSELLRYHTS QSGDEMTSLS 
EYVSRMKETQ KSIYYITGES KEQVANSAFV ERVRKRGFEV VYMTEPIDEY 
CVQQLKEFDG KSLVSVTKEG LELPEDEEEK KKMEESKAKF ENLCKLMKEI 
LDKKVEKVTI SNRLVSSPCC IVTSTYGWTA NMERIMKAQA 
LRDNSTMGYM MAKKHLEINP DHPIVETLRQ KAEADKNDKA VKDLVVLLFE 
TALLSSGFSL EDPQTHSNRI YRMIKLGLGI DEDEVAAEEPNAAVPDEIPP 
LEGDEDASRM EEVD 
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APPENDIX 8: Relative intensity and molecular weight 
of protein species identified by SDS-PAGE and 
Western blot analysis. 
Relative RF SDS-PAGE HPA SDS-PAGE Blood 
MW value analysis of HPA Western blot analysis of Group A 
(kDa) affinity HT29 cells HT29 antibody 
chromatography membrane 
proteins 
HT29 SW480 HPA 250mM 250mM 250mM HT29 SW480 
alone GaINAc G1cNAc sialic acid 
141 0.04 8.64 4.29 4.29 1.67 
133 0.06 12.24 3.60 
108 0.08 12.90 0.53 0.53 2.97 
89 0.13 2.26 0.53 0.53 5.33 7.26 
78 0.18 4.18 6.78 6.22 1.33 6.78 2.81 2.92 
77 0.20 1.15 
73 0.24 16.07 1.70 11.51 16.07 2.55 7.59 7.24 
68 0.27 2.54 1.36 2.27 2.54 
67 0.28 4.75 0.35 0.29 0.56 0.35 4.01 
62 0.31 0.11 0.16 0.28 0.11 4.04 
62 0.34 2.85 2.50 1.70 2.85 
62 0.35 0.94 
62 0.36 6.28 2.13 
59 0.39 2.60 
58 0.41 2.00 17.63 18.67 1.20 11.40 8.31 
58 0.44 8.29 15.78 
57 0.46 16.11 5.13 3.44 5.13 
2.14 
55 0.48 6.50 8.46 3.90 8.46 4.65 
49 0.53 13.67 1.65 26.88 1.37 
6.13 7.90 
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48 0.56 3.51 27.85 13.00 18.63 0.98 3.06 1.91 
47 0.57 5.68 4.98 
43 0.63 5.67 5.72 10.25 4.63 
40 0.66 11.40 
40 0.67 0.67 12.25 5.84 
39 0.70 4.82 2.11 16.46 
36 0.76 24.55 13.24 19.16 27.85 13.24 22.28 8.61 2.99 
35 0.77 11.18 41.72 
35 0.78 2.44 
34 0.80 
33 0.82 5.29 10.04 5.30 11.68 
32 0.84 10.41 0.66 
31 0.86 0.62 33.47 6.48 0.62 
30 0.87 10.66 10.66 
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Proteome analysis of metastatic colorectal cancer cells 
recognized by the lectin Hefixpomatia agglutinin (HPA) 
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The lectin from Helix pomatia (H PA) binds to adenocarcinomas with a metastatic phenotype but 
the glycoconjugates of cancer cells that bind to the lectin have yet to be characterized in detail. We 
used a model of metastatic (HT29) and nonmetastatic (SW480) human colorectal cancer cells 
and a proteomic approach to identify HPA binding glycoproteins. Cell membrane proteins pu- 
rifiedby HPA affinity chromatography, were separated by 2-DE and analyzed by MS. Competitive 
inhibition experiments with N-acetylgalactosamine, N-acetylglucosamine, and sialic acid con- 
firmed that HPA binding was via a glycan-mediated interaction. Western blot analysis showed 
that HPA binds to proteins not recognized by an antibody against blood group A epitope. The 
proteomic study showed the main HPA binding partners include integrin (xv/oc6 and annexin 
A2/A4. These proteins were found complexed with microfilament proteins ot and P tubulin, 
actin, and cytokeratins 8 and 18. HPA also bound to Hsp70, Hsp90, TRAP-1, and tumor rejection 
factor 1. This study revealed that the prognostic utility of HPA lies in its ability to bind simulta- 
neously to many glycoproteins involved in cell migration and signaling, in addition, the proteins 
recognized by HPA are glycosylated with structures distinct from the blood group A epitope. 
Keywords: 
Cancer/ Glycoproteome / HPA/ Lectin /Metastatic 
1 Introduction 
Cancer mortality is a major problem in the West and a 
growing problem in developing nations. One of the main 
causes of patient mortality is an inability to identify and 
selectively target metastatic tumors. Although progress 
has been made in unraveling the molecular and cellular 
changes that occur during metastasis, there remains a 
need to identify cell membrane molecules as targets for 
drug discovery programs. Most biomarkers are glycopro- 
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teins and a vast body of evidence has chronicled that 
changes in protein glycosylation correlate with metastasis 
formation [1]. 
The carbohydrate binding protein (lectin) from the 
Roman snail Helix pomatia (HPA) was first reported to 
identify metastatic breast cancer two decades ago [2] and 
further studies have confirmed its utility for detecting meta- 
static solid tumors, including those of the colon, stomach, 
and esophagus [3]. Approximately 80% of metastatic tumors 
contain HPA binding epitopes [4] and an association be- 
tween H PA binding to cancer cells and metastasis in vivo has 
been described [5]. Despite the evidence of its utility HPA 
does not yet have a role in clinical decision-making for any 
tumor type, and the glycoproteins of HPA binding cancer 
cells have similarly never been defined. 
It was initially hypothesized that HPA simply detects 
cancer cells overexpressing blood group A substance but 
this was discounted [6]. Extraction of cancer-associated 
HPA-binding glycans revealed that they contain both N- 
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acetylgalactosamine (GalNAc) as well as sialic acid [71 and 
the predictive power of HPA was lost when cancer tissue 
sections were pretreated with neuraminidase [8]. A seem- 
ingly diverse range of glycan structures bind to HPA 
including GaINAcod-3GaINAc, GalNAca-Ser/Thr (Th anti- 
gen), and the Forsmann antigen [9,10]. With the exception 
of the Th antigen, the relevance to cancer of these antigens 
and the proteins to which they are attached has not been 
established. 
We set out to identify HPA binding glycoproteins in 
metastatic cancer. A proteomic approach using HPA affinity 
chromatography and 2-DE allowed us to discern the HPA 
binding proteins in a model of cancer metastasis. The data 
that we have obtained has enabled us to make significant 
inferences regarding the basis for HPA recognition of meta- 
static cancer cells. 
2 Experimental procedures 
2.1 Chemicals 
All chemicals were obtained from Sigma-Aldrich, Poole, 
UK, and Milh-Q grade water was used unless otherwise 
stated. 
2.2 HT29 and SW480 cell culture 
Human colorectal cancer cell lines SW480 and HT29 were 
maintained in DMEM supplemented with 10% v/v FCS and 
0.1% v/v gentamycin. The cells were grown to near con- 
fluence, washed twice in PBS and mechanically removed 
from the surface of the tissue culture flask using a sterile 
plastic cell scraper. The cells were lysed by sonication and 
used for protein extraction using the 'centrifugal protein 
extraction method' described by Lehner et al. [111. 
2.3 Confocal microscopy 
Cells were seeded into 12-well plates or 7.5 CM2 Petri dishes 
and maintained as above for 24 h until 80% confluent. The 
cells were processed using a modification of the HPA bind- 
ing protocol [12]: cells were fixed, trypsinized and blocked as 
described then incubated in the dark with HPA-TRITC 
(Sigma, UK) at 10 ýtg/rril for 60 min in lectin buffer. The cells 
were treated with 100 ýtg/ml, DNase-free ribonuclease A for 
20 min at 37'C and the nuclei counterstained using 1 ýA To- 
Pro-3 in PBS for 20 min (Invitrogen, UK). Images were 
acquired by sequential scanning using a Leica TCS SP2 con- 
focal microscope with a x63 ceramic dipping objective. 
Images were collected at 1024 x 1024 pixel resolution with a 
scanning speed of 400 Hz and line average of 2. For 3-D 
images z-stacks with increments of 1 vrn were scanned. A 
543 rim laser was used for the excitation of the HPA-TRITC 
(intensity 100%) and 633 nm laser for To-Pro-3 (intensity 
35%), emission was recorded over the bandwidth of 553- 
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630 nm, HPA-TRITC, and 650-720 nm for To-Pro-3. The 
specificity of lectin binding was investigated by preincubat- 
ing the lectin with GaINAc for 30 min at a concentrations of 
25-250 mM. 
2.4 HPA-affinity chromatography 
A1 mL HPA affinity chromatography column was pre- 
pared using a HiTrap NHS-activated Sepharose column 
according to the manufacturer's recommendations (GE 
Healthcare), 5 mg of HPA was coupled to the column. 
HT29 (0.5 mg) or SW480 membrane proteins were loaded 
onto the column in either 20 mM Tris, pH 7.4,0.5 M NaCl, 
(for the 1-DE analysis) or in lectin buffer containing 0.1% 
w/v CHAPS (for 2-DE analysis). The column was washed 
with five column volumes of loading buffer and HPA- 
binding proteins eluted using loading buffer containing 
250 mM GlcNAc. 
2.5 Experimental design/1-D and 2-DE 
Membrane proteins were prepared on at least three separate 
occasions from HT29 and SW480 cells according to the 
conditions shown above. Twenty micrograms of each mem- 
brane proteins preparation was separated by 1-D SDS- 
PAGE, again, on at least three separate occasions [13]. 
Either a 10 or 12% acrylamide gel and run at 150 V for 1h 
15 min. 
2-DE experiments for each cell line, HT29 or SW480, 
used 7 cm IPG strips of pH 3-10L according to [14] but 
modified as follows: 90 ýtg of membrane proteins were pre- 
pared in 7M urea, 2M thiourea, 4% w/v CHAPS, 2% v/v 
carrier ampholytes, 1% w/v DTT, the strip was rehydrated in 
this buffer at room temperature overnight and the IEF per- 
formed at 20'C with 300 V for 30 min; 600 V for 30 min fol- 
lowed by 3500 V for 2h 45 min. Focused strips were pro- 
cessed as described [14] and run in the second dimension. In 
all procedures proteins were visualized using either Sypro 
Ruby (Invitrogen) or by fixing the gel in 50% methanol, 10% 
acetic acid for 30 min and staining with 0.025% w/v Coo- 
massie Blue R-250 in 10% acetic acid for 1 h, followed by 
destaining in 10% acetic acid for 2 h. Two replicates of the 
cell membrane preparations from HT29 and SW480 were 
run on the 2-DE system. 
2.6 Analysis of 2-DE data 
The 2-DE gel images were obtained using either, for Sypro 
Ruby stained gels, a dual-laser Typhoon scanner (GE 
Healthcare) or, for Coomassie stained gels, transillumination 
with white light and UVP Biochemi Image Capture System. 
Images in. TIFF format were imported into Phoretix 2-D 
Advanced Software (Non-Linear Dynamics) and processed by 
background subtraction, spot detection, landmarking, and 
overlay analysis. 
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2.7 Western blotting 
Gels were transferred to NC membranes using a wet 
blotting system for 1.5 h at 100 V in transfer buffer 
(25mM Tris, 192mM glycine, 20% v/v methanol). The 
HPA blots were developed by blocking with 2% w/v BSA 
in TBS/Tween 0.05% v/v (TBS/T) at 4'C overnight, the 
membrane was incubated with 5 [ig/mL biotinylated HPA 
for 2h and 2 pg/mL HRP conjugated streptavidin (Pierce, 
UK) for 1 h. The detection system was diaminobenzidine 
(DAB) prepared in TBS/H202. A negative control, in 
which the lectin was omitted, was included in the analy- 
sis. For the antiblood group A analysis, gels and nitro- 
cellulose membranes were prepared as detailed above and 
incubated in antiblood group A antibody (Ortho-Reagent, 
Johnson and Johnson, 1 in 5 dilution) for 2 h, peroXidase 
labeled goat antimouse antibodies (I in 10000 dilution) 
for 2h and developed using the West Signal Dura reagent 
(Pierce). The chemilumine scent signal was captured onto 
X-ray film with an exposure time ranging from 30 s to 
2 min. 
2.8 Inhibition work 
The blots were prepared as above but the lectin was 
preincubated with GaINAc, GlcNAc, or sialic acid for a 
period of 30min prior to application on the blot. The 
monosaccharides were used in the range 50-250 mM. 
2.9 MS analysis for protein identification 
Protein identification was carried out by commercial 
arrangement with Dr. Jerry Thomas, Department of Bi- 
ology, University of York, using a MALDI-TOF/TOF 4700 
analyzer (Applied Biosystems). In brief, 2-DE protein 
spots stained with CBB were excised from the gel. The 
proteins were reduced using DTT and S-carbamido- 
methylation was performed using iodoacetamide prior to 
the tryptic digest. The gels pieces were washed three 
times in 50% v/v ACN/25 mM ammonium bicarbonate 
and air dried before rehydration in 10 ptL of 0.02 pg/pL 
s equencing- grade, modified porcine trypsin (Promega). 
Digestion was performed overnight at 37'C. A 0.5 pL 
aliquot of each tryptic digest and 0.5 [tL of a solution of 
CHCA (Sigma) in 50% aqueous (v/v) ACN containing 
0.1% TFA v/v, was applied to the MALDI target plate. 
Mass spectra were obtained in reflection mode with an 
accelerating voltage of 20 W The peptide mass finger- 
print generated was compared to the masses of all theo- 
retical tryptic peptides generated in silico by the MAS- 
COT search program [15]. CID MS/MS was also per- 
formed to corroborate the significant matches from the 
MALDI/MS. 
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3 Results 
3.1 HPA binding to HT29 and SW480 cells 
We used the human colorectal cell lines SW480 and HT29 
as an in vitro model of metastasis. These represent the 
extremes of HPA binding: SW480 is HPA negative and 
HT29 shows intense HPA binding. Subcutaneous implan- 
tation of SW480 and HT29 cell pellets between the sca- 
pulae of SCID mice shows SW480 to be nonmetastatic 
and HT29 to be metastatic [16]. Confocal microscopy con- 
firmed that the HPA binding pattern to these cell lines 
was the same as previously observed (Fig. 1), this analysis 
is particularly important as glycosylation changes can 
occur as a result of in vitro cell culture. The confocal 
analysis also enabled detailed localization of HPA binding; 
HPA bound weakly to SW480 with diffuse cytoplasmic 
staining pattern and no detectable cell membrane stain- 
ing, in contrast, HT29 showed intense membrane and 
granular cytoplasmic staining as described elsewhere [161. 
The lectin binding to the HT29 cells was almost entirely 
inhibited when HPA was preincubated with GaINAc (at 
concentrations of 50 mM or above) prior to probing the 
cancer cells (Fig. 1). 
SW480 HT29 HT29 3D vlew 
InhibItion of HPA: HT29 bind HPA 
ppk4 blot 
its 
Figure 1. Confocal images showing binding of TRITC-labeled 
HPA (red) to SW480 and HT29 cells. The nuclei were counter- 
stained with ToPro-3 (blue). HT29 showed intense lectin binding 
on the cell surface with some granular intracellular staining. 
There is almost no membrane or intracellular binding of HPA to 
SW480. The binding of HPA to HT29 cells was inhibited when the 
lectin was preincubated with GaINAc at concentrations of 50 mM 
or above. Inset panel shows HPA-Western blot analysis of 20 jig 
proteins prepared by ultracentrifugation. The pellet fraction of 
HT29 shows intense HPA binding confirming enrichment of 
membrane proteins using this system. 
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3.2 HPA interaction with HT29 and SW480 membrane 
proteins 
HPA binding membrane glycoprotems from HT29 and 
SW480 cells were obtained by HPA affinity chromatography 
and analyzed by SDS-PAGE. This approach revealed four 
weakly staining protein bands in SW480 and 16 discrete 
Coomassie staining protein bands in HT29 (Fig. 2, panel A). 
Some proteins were represented in both cell lines whereas 
others did not appear in SW480 and are assumed to be either 
specific to, or more highly represented in, HT29. The data 
supports the hypothesis that the development of a metastatic 
phenotype is accompanied by alterations in glycosylation on 
a range of proteins, in this case detected using the lectin 
HPA. 
3.3 Inhibition studies 
HT29 membrane proteins were separated by SDS-PAGE, 
blotted to nitrocellulose and probed with HPA-biotin. Again 
16 protein bands were observed (Fig. 2, panel B) although 
some of the protein bands only faintly visible in the CBB 
stained gel were the most dominant HPA binding proteins 
on the Western blot and we assume that these are heavily 
glycosylated proteins [17]. A negative control in which HPA- 
biotin was omitted was run and the results of this analysis 
concurred with previous reports of nonspecific binding of 
streptavidin to endogenous cellular proteins (Fig. 2, panel B) 
[181. 
To detennine the monosaccharide specificity of HPA we 
preincubated the lectin for 30 min in a buffer containing 
between 50 and 250 mM GaINAc, GlcNAc, or sialic acid 
before probing the Western blots, the data for the 250 mM 
solutions are shown (Fig. 2, panel B). GalNAc, GlcNAc, and 
sialic acid all inhibited binding of HPA to the predominant 
polypeptide of 130 kDa as well as to the 80 kDa species. 
GalNAc was a slightly more effective inhibitor than GlcNAc 
but, intriguingly, incubation with sialic acid at this con- 
AB 
14PA aMnlty 
chroffkltography HT29' HPA Westem blot 
SDS-PAGE with competitive inhibition 
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centration abrogated almost all HPA binding; as well as 
some of the nonspecific streptavidin-bindlng (Fig. 2, panel 
B). These results confirm that the interaction between HPA 
and the cancer ceE glycoproteins is via a lectin-mediated 
interaction that can be inhibited using GaINAc, GlcNAc, 
and/or sialic acid. 
3.4 Antiblood group A antibody 
SW480 and HT29 membrane proteins were separated by 
SDS-PAGE, blotted to nitrocellulose and probed with an 
ant1human blood group A antibody. The predominant 
130 kDa protein species observed to bind HPA in HT29 did 
not interact with the antibody (Fig. 2C). In contrast, a range 
of lower molecular weight protein species (from 26 to 
80 kDa) bound to the antibody in SW480 and HT29 but these 
proteins either did not, or only weakly, bound to HPA. In 
both HT29 and SW480 the same amount of protein (20 Vg) 
was loaded onto the gel and transferred to nitrocellulose, 
nevertheless, SW480 membrane proteins bound more 
intensely to the antiblood group A antibody compared with 
HT29 membrane proteins, suggesting that the H PA binding 
epitope in HT29 cells encompasses glycoconjugates con- 
taining glycans other than the blood group A antigen. 
The HPA binding proteins from SW480 and HT29 sepa- 
rated by 1-dimensional and 2-dimensional SDS-PAGE are 
shown in Table 1. 
3.5 Proteome analysis of HPA interaction with HT29 
To obtain an overview of the HPA binding proteins on HT29 
cells, membrane proteins were separated by 2-DE and 
stained with Sypro Ruby. A representative gel is shown in 
Fig. 3, panel A. The reproducibility of the system was inves- 
tigated using replicate gels as described in the materials and 
methods and the boxed areas shown in Fig. 3 (panel C, 1,11, 
and III) illustrate the robustness of the system for both the 
high and low abundance proteins. 
c 
Blood group A 
antibody 
Western blot 
. t: epl 
sos- mvv 






Figure 2.1-D SDS-PAGE separation of SW480 
and HT29 membrane glycoproteins (20 kg load- 
ing throughout). Panel A: affinity purified HPA 
binding proteins from SW480 and HT29 stained 
with CBB. Panel B: Western blot of total HT29 
membrane proteins incubated with HPA-biotin, 
visualized using streptavidin-HRP and DAB/H202- 
Competitive inhibition of HPA preincubated with 
250 mM GlcNAc, GaINAc, or sialic acid (SA), 
SDS-PAGE analysis of HT29 proteins stained 
with CBB. Panel C: Western blot of SW480 and 
HT29 membrane proteins probed with antiblood 
group A antibodies, visualized using West Signal 
Dura chemiluminescence system. 
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Table 1. Relative intensity and molecular weight of protein species identified by SDS-PAGE and Western blot analysis, shown in Fig. 2 
Relative RF SDS-PAGE analysis HPA Western blot HT29 cells SDS-PAGE Blood group A MW value of HPA affinity analysis antibody (kDa) chromatography of HT29 
HT29 SW480 HPA GaINAc GIcNAc Sialic acid 
membrane 
HT29 SW480 
alone (250 mM) (250 mM) (250 mM) 
proteins 
141 0.04 8.64 4.29 4.29 1.67 
133 0.06 12.24 3.60 
108 0.08 12.90 0.53 0.53 2.97 
89 0.13 2.26 0.53 0.53 5.33 7.26 
78 0.18 4.18 6.78 6.22 1.33 6.78 2.81 2.92 
77 0.20 1.15 
73 0.24 16.07 1.70 11.51 16.07 2.55 7.59 7.24 
68 0.27 2.54 1.36 2.27 2.54 
67 0.28 4.75 0.35 0.29 0.56 0.35 4.01 
62 0.31 0.11 0.16 0.28 0.11 4.04 
62 0.34 2.85 2.50 1.70 2.85 
62 0.35 0.94 
62 0.36 6.28 2.13 
59 0.39 2.60 
58 0.41 2.00 17.63 18.67 1.20 11.40 8.31 
58 0.44 8.29 15.78 
57 0.46 16.11 5.13 3.44 5.13 2.14 
55 0.48 6.50 8.46 3.90 8.46 4.65 
49 0.53 13.67 1.65 26.88 1.37 6.13 7.90 
48 0.56 3.51 27.85 13.00 18.63 0.98 3.06 1.91 
47 0.57 5.68 4.98 
43 0.63 5.67 5.72 10.25 4.63 
40 0.66 11.40 
40 0.67 0.67 12.25 5.84 
39 0.70 4.82 2.11 16.46 
36 0.76 24.55 13.24 19.16 27.85 13.24 22.28 8.61 2.99 
35 0.77 11.18 41.72 
35 0.78 2.44 
34 0.80 
33 0.82 5.29 10.04 5.30 11.68 
32 0.84 10.41 0.66 
31 0.86 0.62 33.47 6.48 0.62 
30 0.87 10.66 10.66 
29 0.89 4.10 10.78 1.14 3.36 
28 0.93 8.73 21.20 
27 0.97 8.64 7.44 
To investigate the HPA binding proteins of HT29 cells, 
the membrane proteins were purified by HPA affinity chro- 
matography in a buffer containing CHAPS and eluted by 
competition with 0.25 M GIcNAc. The eluted proteins were 
separated by 2-DE and stained with CBB to facilitate MS 
analysis (Fig. 3, panel B). The protein species that showed 
the highest abundance were subjected to MALDI-MS and 
MS-MS (Table 2). 
We identified the HPA binding proteins as integrin CX6, 
integrin ocV, annexin A2, and annexin A4. We also identified 
O-actin, a and Otubulin, cytokeratin 8, cytokeratin 18 in the 
HPA binding fraction and these cytoplasmic proteins are 
assumed to elute from the HPA-affinity chromatography 
column as protein complexes with the cell membrane pro- 
teins. The presence of Hsp96, Hsp90, and Hsp70 as well as 
TNFR-1 (although with a weaker MASCOT score) suggests 
that HPA also recognizes proteins involved in antiapoptotic 
pathways (Hsp70, Hsp90). 
Discussion 
in this studY we used a well characterized model of human 
colorectal cancer cell lines with defined in vivo behaviors and 
lectin binding properties to discern the glycoproteins that 
bind to the lectin HPA. In the first instance we found that 
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Figure 3.2-DE separation of HT29 membrane 
glycoproteins (90ýig). Panel A: HT29 membrane 
proteins stained with Sypro Ruby. Panel B: zoom 
on boxed areas indicated as 1,11, and 111, from 
panel A. Two replicates are shown for each area 
1,11, and III and illustrate the reproducibility of the 
2-DE separation system. Panel C: HT29 mem- 
brane proteins prefractionated by HPA-affinity 
chromatography, stained with CBB. The proteins 
identified by MS analysis are shown with arrows 
on the 2-DE gel. Panel D: Western blot of 2-DE 
separated membrane proteins from HT29 and 
SW480, the blots were probed with HPA. The 
area of the 2-DE Western blot corresponds to 
the boxed area indicated by the dashed line in 
panel A. 
Table 2. MS an aI ysis of HT29 mem bra ne p rote ins, prefractionated by HPAaffinitychromatogra ph y and separated 
by 2-DE 
Protein name Accession MASCOT Nominal Predicted Sequence 
number score mass (kDa) p/ coverage 
Integrin alpha 6 
Integrin alpha 6 
Cytokeratin 8 
Cytokeratin 8 
Integrin alpha V 
Tumor rejection antigen gp 96 
Heat shock (90 kDa) protein 
Cytokeratin 18 
Cytokeratin 18 
Annexin A2 isoform 2 
Guanine nucleotide-binding 
protein beta 2 subunit 
Heat shock protein 8 isoform 1 
Alpha tubulin 
Tubulin beta 2 
Beta actin 
Annexin A4 
giJ5726563 389 120.6 6.44 19 
giJ5726563 599 120.6 6.35 25 
giý181573 758 53.3 5.5 45 
giý181573 758 53.3 5.5 43 
giý4504763 431 117 5.45 14 
giJ4507677 166 92.7 4.76 9 
giJ306891 348 83.5 4.97 20 
giJ30311 127 47.3 5.27 19 
giJ30311 127 47.3 5.27 15 
gil4757756 1010 38.8 7.57 62 
giJ20357529 470 38 5.6 36 
gil5729877344 344 71 5.37 14 
giJ340021662 662 50.8 4.94 30 
giJ20809886419 419 50.2 4.76 22 
giý4501885 511 42 5.29 26 
giJ1703319 563 36 5.9 32 
The table shows the protein identity, accession number, MASCOT score, nominal mass, predicted pl, and 
sequence coverage following MS analysis. 
high-resolution confocal. microscopy in conjunction with 3-D 
modeling allowed location of the HPA binding epitopes to 
the surface of the metastatic cancer cell line (HT29). Mem- 
brane proteins were enriched by high-speed centrifugation 
followed by solubilization in the presence of CHAPs and 
subsequent affinity purification on an HPA affinity chroma- 
tography column. In this manner, sufficient HPA binding 
membrane proteins were obtained to allow analysis using 
1-D and 2-D SDS-PAGE. The comparative analysis showed 
considerable differences between the HPA binding protein 
species in the two cell lines. Inhibition experiments showed 
that the interaction between HPA and the proteins was 
@ 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www. proteomics-journal. com 
4088 J. Saint-Guirons et al. 
Leading edge: 
enzyme secretion 










hyaluronan larninin 4/5 
p rot 
HPA gCI q-R 
p33 GaINAc 
binding 
iectin 0 . ýtransduction 
adaptor signalling pathways a ap 
A eins 














. .... ....... .. 
ý ; 7ý 
survival 
DDA 














Figure 4. Schematic diagram showing HT29 HPA binding proteins. The proteins identified in this study are shown in the hatched boxes and 
the putative binding partners are shown in the solid boxes. 
indeed via a lectin-like interaction that could be inhibited 
with both GaINAc and GlcNAc. Somewhat surprisingly, sia- 
lic acid, also inhibited interaction of the lectin with the gly- 
coproteins and this supports thý idea that HPA recognizes a 
sialylated epitope [7,8]. Indeed, metastatic cancer cells which 
bind HPA adhere to activated endothelia, presumably via the 
sialic acid recognizing cell adhesion molecules Selectins [19]. 
Analysis using an antiblood group A antibody has shown 
that the glycan epitopes that are recognized by HPA includes 
the blood group antigens but also a range of other protein 
species, presumably exhibiting different glycosylation, the 
detailed analysis of these is being undertaken in our labora- 
tories. 
We used proteomic analysis to unravel the glycoproteins 
recognized by HPA in the metastatic HT29 cancer cells. The 
proteins that eluted in the HPA binding affinity chromatog- 
raphy fraction included molecules involved in cell adhesion 
and migration (integrin a6, integrin cxV, annexins) [20] 
remodeling (filament proteins including a tubulin, P tubu- 
lin, cytokeratins, actin) [21] and antiapoptotic pathways (Hsp- 
70, Hsp-90, Hsp-96, and TNFR-1) [22]. Some of the proteins 
are present because they bind directly with HPA and others 
are found as complexes with HPA binding proteins, residing 
in the cytoplasm and therefore nonglycosylated or glycosy- 
lated with O-GlcNAc. In other systems, Hsp-70, actin, and 
tubulin have been shown to be modified by the attachment of 
O-GlcNAc (refs. [23-25], respectively); this may be the case in 
HT29 and HPA may recognize these proteins by virtue of 0- 
GlcNAcylation but further work would be required to sup- 
port this hypothesis. To piece together the results of the pro- 
teomic analysis, the proteins identified in this study and 
their role(s) as described extensively in the literature in rela- 
tion to cancer metastasis, are shown schematically in Fig. 4. 
Whilst many of these proteins have previously been 
described in cancer [21,22,26] we are not aware of any 
reagent - other than HPA - which will bind these proteins 
simultaneously. HPA may recognize these proteins by virtue 
of changes in the normal glycan repertoire and the data 
obtained using the antiblood group A antibody supports this 
hypothesis. Further work is being undertaken to elucidate 
the way in which HPA interacts with the proteins identified 
in this study. 
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